LUPUS & KCR 2023

The 15th International Congress on Systemic Lupus Erythematosus and The 43rd KCR Annual Scientific Meeting & 17th International Symposium

May 17 (Wed) - 20 (Sat), 2023 | Coex, Seoul, Korea

Program Book

Hosted by
Korean Society of Systemic Lupus Erythematosus Research

Supported by
**Contents**

Welcome Address ................................................. 04
Program at a Glance ............................................. 08
LUPUS & KCR 2023 Highlight .................................. 12
Floor Plan .......................................................... 14
Invited Faculty ..................................................... 18
Scientific Program

**Day 1:** May 17 (Wed) ........................................... 28
**Day 2:** May 18 (Thu) ........................................... 34
**Day 3:** May 19 (Fri) ............................................ 50
**Day 4:** May 20 (Sat) ............................................ 68
Short Oral Presentation ........................................... 82
E-poster Presentation ............................................. 94
Organizing Committee .......................................... 118
Sponsorship ......................................................... 124
Welcome Address of Congress Chair

Dear colleagues and friends,

On behalf of the Organizing Committee, it is my great pleasure and honor to invite you to the 15th International Congress on Systemic Lupus Erythematosus and the 43rd Korean College of Rheumatology Annual Scientific Meeting & 17th International Symposium (LUPUS & KCR 2023). It will be held in Seoul, Korea from May 17th to 20th, 2023, co-hosted by Korean Society of Systemic Lupus Erythematosus Research (KSSR) and the Korean College of Rheumatology (KCR).

It is the first time that Korea has been given the honor of hosting this prestigious event and the fifth time the event has been hosted in the Asia-Pacific region after Singapore, Israel, China, and Australia.

"Stairway to the End of the War" is the theme of LUPUS & KCR 2023. It has multiple meanings, one of which is aiming to end the war on rheumatic diseases including SLE. We are hoping that it will also mean the end of war on COVID19 through which the participants could attend the meeting in person. It will gather a huge audience of more than 2,000 participants of rheumatologists from all over the world and world-renowned experts in rheumatic diseases on basic and clinical science.

KSSR is a professional membership organization composed of Korean rheumatologists who have a particular interest in SLE under the KCR. We have been managing most Korean SLE patients and actively performing both basic and clinical research. With over 1,000 members in Korea, KCR is an organization that represents health professionals and scientific societies related to the field of rheumatology. It has contributed to the advancement and promotion of rheumatology in Korea since 1981 and has successfully hosted the annual KCR international symposium since 2006 to strengthen collaboration on rheumatology both domestically and internationally.

This joint meeting of LUPUS & KCR 2023 will expand the scope of programs and topics encompassing and maximizing impacts and synergies. It will be the perfect meeting where you can present your products, discuss with world-renowned basic and clinical researchers specialized in rheumatic diseases so that you can connect and collaborate with experts.

I look forward to welcoming you in Seoul in 2023.

With warmest regards

Sang-Cheol Bae, MD, PhD, MPH
Congress Chair, LUPUS & KCR 2023
President, 15th International Congress on Systemic Lupus Erythematosus
President, Korean College of Rheumatology

Welcome Address of Chairman of the Board of Directors

Dear colleagues and friends,

On behalf of the Organizing Committee, it is my great honor to invite you to the 15th International Congress on Systemic Lupus Erythematosus and the 43rd Korean College of Rheumatology Annual Scientific Meeting & 17th International Symposium (LUPUS & KCR 2023).

Since 1981, members of KCR have been dedicated to the treatment and research of rheumatic diseases through clinical, basic, and translational research. In May of 2022, KCR successfully organized its annual congress in a hybrid format. Despite the unpredictable circumstances, 922 participants from 36 countries engaged and exchanged their knowledge and experience in KCR 2022.

As we host this joint congress with the International Congress on Systemic Lupus Erythematosus (SLE), which is the leading international meeting on SLE, we believe this collaboration could generate significant academic synergy.

We hope you actively engage in various sessions filled with valuable lectures by world-renowned speakers. Especially, we have organized a series of sessions: Plenary Session, Keynote Lectures, Joint Symposium, and International Symposium. I look forward to these sessions that will help you update knowledge and catch up with the latest trends in the field of rheumatology.

The organizing committee is filled with anticipation that we will hold the first in-person congress after an outbreak of a pandemic. As much as we are excited to see the speakers and audiences in person, we also promise to provide wholehearted support for organizing a safe and convenient congress.

I am looking forward to welcoming all of you face-to-face, in Seoul, in 2023.

My warmest regards,

Shin-Seok Lee, MD, PhD
Chairman of the Board of Directors,
Korean College of Rheumatology
Program at a Glance
# LUPUS & KCR 2023

## Program at a Glance

### DAY 1. | May 17 (Wed)

<table>
<thead>
<tr>
<th>Time</th>
<th>Auditorium (3F)</th>
<th>Grand Ballroom 101 (1F)</th>
<th>Grand Ballroom 102 (1F)</th>
<th>Grand Ballroom 103 (1F)</th>
<th>Grand Ballroom 104 (1F)</th>
<th>Conference Room 205 (2F)</th>
<th>Conference Room 209 (2F)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30 - 09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00 - 09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30 - 10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30 - 12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 - 12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30 - 13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00 - 13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30 - 14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00 - 14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30 - 15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00 - 15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30 - 16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 - 16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30 - 17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00 - 17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30 - 18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00 - 18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30 - 19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00 ~</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### DAY 2. | May 18 (Thu)

<table>
<thead>
<tr>
<th>Time</th>
<th>Auditorium (3F)</th>
<th>Grand Ballroom 101 (1F)</th>
<th>Grand Ballroom 102 (1F)</th>
<th>Grand Ballroom 103 (1F)</th>
<th>Grand Ballroom 104 (1F)</th>
<th>Conference Room 205 (2F)</th>
<th>Conference Room 209 (2F)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30 - 09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00 - 09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30 - 10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30 - 12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 - 12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30 - 13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00 - 13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30 - 14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00 - 14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30 - 15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00 - 15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30 - 16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 - 16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30 - 17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00 - 17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30 - 18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00 - 18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30 - 19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00 - 19:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30 - 20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00 - 20:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:30 - 21:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**LUPUS**

- **Opening Session & Key Note Lecture:** "The Field"
- **Asian Lupus Collaboration (APLC) Study Group Session**

**KCR**

- **Musculoskeletal US Workshop I - Advanced Course**
- **Musculoskeletal US Workshop I - Basic Course**

---

*(Marked session provides the ENG-KOR simultaneous interpretation)*
### Program at a Glance

#### DAY 3. | May 19 (Fri)

<table>
<thead>
<tr>
<th>Time</th>
<th>LUPUS</th>
<th>KCR</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:30</td>
<td>Breakfast Symposium 5</td>
<td>Breakfast Symposium 6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KCR Keynote Lecture 1 *</td>
</tr>
<tr>
<td>08:30 - 09:00</td>
<td>Meet the Professor 4 SLE and Infection</td>
<td>Free Paper Session 6</td>
</tr>
<tr>
<td>09:00 - 09:30</td>
<td>Meet the Professor 5 Precision Medicine</td>
<td>Free Paper Session 2 Vasculitis &amp; Metabolic Bone Disease</td>
</tr>
<tr>
<td>09:30 - 10:00</td>
<td>Meet the Professor 6 Managing Lupus Pregnancy</td>
<td>Free Paper Session 4 Epidemiology &amp; Health Service Research</td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>Plenary Session 3 Novel Treatments and Strategy</td>
<td>International Symposium 3 Rheumatoid Arthritis-Associated Interstitial Lung Disease</td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td>Special Lecture COVID-19 and LUPUS</td>
<td></td>
</tr>
<tr>
<td>12:00 - 12:30</td>
<td>Luncheon Symposium 6</td>
<td></td>
</tr>
<tr>
<td>12:30 - 13:00</td>
<td>Lunch &amp; Networking</td>
<td></td>
</tr>
<tr>
<td>13:00 - 13:30</td>
<td>Concurrent Session 5</td>
<td></td>
</tr>
<tr>
<td>13:30 - 14:00</td>
<td>Concurrent Session 6</td>
<td></td>
</tr>
<tr>
<td>14:00 - 14:30</td>
<td>Concurrent Session 7</td>
<td></td>
</tr>
<tr>
<td>14:30 - 15:00</td>
<td>Poster Viewing &amp; Coffee Break</td>
<td></td>
</tr>
<tr>
<td>15:00 - 15:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30 - 16:00</td>
<td>Plenary Session 4 Practical Treatment Issues</td>
<td></td>
</tr>
<tr>
<td>16:00 - 16:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30 - 17:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00 - 17:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30 - 18:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00 - 18:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30 - 19:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00 -</td>
<td>Gala Dinner</td>
<td></td>
</tr>
</tbody>
</table>

#### DAY 4. | May 20 (Sat)

<table>
<thead>
<tr>
<th>Time</th>
<th>LUPUS</th>
<th>KCR</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:30</td>
<td>Breakfast Symposium 9</td>
<td>Breakfast Symposium 10</td>
</tr>
<tr>
<td>08:30 - 09:00</td>
<td></td>
<td>Breakfast Symposium 11</td>
</tr>
<tr>
<td>09:00 - 09:30</td>
<td>Meet the Professor 7 Musculoskeletal Diseases in SLE</td>
<td>Meet the Professor 8 Lupus Nephritis</td>
</tr>
<tr>
<td>09:30 - 10:00</td>
<td>Meet the Professor 8 Lupus Nephritis</td>
<td>Meet the Professor 9 Pulmonary Hypertension</td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>Plenary Session 5 Clinical Challenges, Diagnosis and Outcome Measures</td>
<td>International Symposium 6 The Pathology of Fibromyalgia, Its Consequences, and Treatment</td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td></td>
<td>Free Paper Session 8 Metabolic Diseases and Inflammatory Disease</td>
</tr>
<tr>
<td>11:30 - 12:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 - 12:30</td>
<td>Luncheon Symposium 9</td>
<td></td>
</tr>
<tr>
<td>12:30 - 13:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00 - 13:30</td>
<td>Conjoint Session 9</td>
<td></td>
</tr>
<tr>
<td>13:30 - 14:00</td>
<td>Concurrent Session 10 Immune Cells</td>
<td></td>
</tr>
<tr>
<td>14:00 - 14:30</td>
<td>Targeting Organs</td>
<td></td>
</tr>
<tr>
<td>14:30 - 15:00</td>
<td>Posters Viewing &amp; Coffee Break</td>
<td></td>
</tr>
<tr>
<td>15:00 - 15:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30 - 16:00</td>
<td>Plenary Session 6 Sjögren’s Syndrome, Systemic Sclerosis &amp; Rheumatic Diseases</td>
<td></td>
</tr>
<tr>
<td>16:00 - 16:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30 - 17:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00 - 17:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30 - 18:00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Marked session provides the ENG-KOR simultaneous interpretation.
Scan Here!

Visit our official web platform to explore and connect with LUPUS & KCR 2023!

Scan the QR code and visit our official web platform where you can explore our program & speakers, search and like e-posters, and make connections!

You can log-in with the same ID and password information of our website.

Don't miss out on LUPUS & KCR 2023 official giveaways!

You may receive the conference bag and the USB card with the official artwork and the logo when you claim your name badge at the registration desk.

Get all stamps from our sponsors’ exhibition booths and get a special gift!

Visit all of our sponsors’ exhibition booths, located on the 1st floor lobby in front of the Grand Ballroom and the 2nd floor exhibition area, and gather the stamps!

When you complete the stamp tour, visit the Kit Desk on the 1st floor and a special gift is awaiting.

Visit E-poster Zone on the 2nd floor and push “Like” on your favorite one!

For the most liked E-posters, there will be a prize! Go on and check out LUPUS & KCR 2023 E-posters and “Like” your favorite ones.

You can also “Like” the E-posters on our official web platform.

평점관련 유의사항

1. LUPUS & KCR 2023은 대면 학술대회로, 현장에 참석하신 경우에만 평점이 인정됩니다.
2. 학술대회 평점은 최초 입장 시간과 최종 퇴장 시간을 기준으로산출됩니다.
   학술대회에 참석하지 않았던 경우 평점이 부여되지 않을 수 있습니다.
3. 휴식시간은 평점 이수시간 산출에 포함되지 않습니다.
4. 평점 확인은 학술대회 종료 후 결과보고가 완료되면 대한의사협회 연수교육 홈페이지(http://edu.kma.org)로 로그인 후 아이디에서 ‘연수교육 이수확인서’를 출력하실 수 있습니다.

학술대회 평점

<table>
<thead>
<tr>
<th></th>
<th>5월 17일(수)</th>
<th>5월 18일(목)</th>
<th>5월 19일(금)</th>
<th>5월 20일(토)</th>
</tr>
</thead>
<tbody>
<tr>
<td>대한의사협회 평점</td>
<td>2평점</td>
<td>6평점</td>
<td>6평점</td>
<td>6평점</td>
</tr>
<tr>
<td>전공의 평점</td>
<td>학술대회 기간동안 6시간 이수하면 2평점</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

관람초음파 인증

초음파 지도전문의 교육
- 대한내과학회 초음파지도전문의 연수 평점 3평점 부여
초음파 전공의 교육
- 대한내과학회 전공의 초음파 연수 15시간 인정

학술대회 평점 인정 기준

<table>
<thead>
<tr>
<th>연수교육 이수시간</th>
<th>인정 평점</th>
</tr>
</thead>
<tbody>
<tr>
<td>1시간 미만</td>
<td>평점 인정 불가</td>
</tr>
<tr>
<td>1시간 이상 2시간 미만</td>
<td>1평점 인정</td>
</tr>
<tr>
<td>2시간 이상 3시간 미만</td>
<td>2평점 인정</td>
</tr>
<tr>
<td>3시간 이상 4시간 미만</td>
<td>3평점 인정</td>
</tr>
<tr>
<td>4시간 이상 5시간 미만</td>
<td>4평점 인정</td>
</tr>
<tr>
<td>5시간 이상 6시간 미만</td>
<td>5평점 인정</td>
</tr>
<tr>
<td>6시간 이상</td>
<td>6평점 인정</td>
</tr>
</tbody>
</table>
Invited Faculty
**Invited Faculty**

**[Opening Session]**
- Sang-Cheol Bae  
  Hanyang Univ.  
  Korea
- Shin-Seok Lee  
  Chonnam Nat’l Univ.  
  Korea
- Seung Cheol Shim  
  Chonnam Nat’l Univ.  
  Korea
- Hyunjoon Yoo  
  Hyunjoon Yoo Architects  
  Korea
- Soo Hyun Ro  
  Lupus Patient & Singer  
  Korea
- Joewoo Yang  
  Pianist  
  Korea
- David McCann  
  Harvard Univ.  
  USA

**LUPUS 2023 Program**

**[LUPUS 2023 Congress Highlights]**
- Seung Cheol Shim  
  Chonnam Nat’l Univ.  
  Korea
- Sung Hwan Park  
  The Catholic Univ. of Korea  
  Korea

**[Plenary Session 1]**
- SLE: Year in Review
  - Mary Crow  
    Hosp. for Special Surgery  
    USA
  - Paul Fortin  
    Université Laval  
    Canada
  - Joe Craft  
    Yale Univ.  
    USA
  - George Tsokos  
    Harvard Medical School  
    USA

**[Plenary Session 2]**
- Disease Mechanism
  - Andrea Doria  
    Univ. of Padua  
    Italy
  - Brad Rovin  
    The Ohio State Univ.  
    USA
  - Chi-Chiu Mok  
    Tuen Mun Hosp.  
    Hong Kong
  - Ian Bruce  
    The Univ. of Manchester  
    UK

**[Plenary Session 3]**
- Novel Treatments and Strategies
  - Eric Morand  
    Monash Univ.  
    Australia
  - David Isenberg  
    Univ. College London  
    UK

**[Plenary Session 4]**
- Practical Treatment Issues

**[Plenary Session 5]**
- Clinical Challenges: Diagnosis and Outcome Measures
Scientific Program
DAY 01
Program
May 17 (Wed)
**LUPUS & KCR 2023**

**DAY 1. - May 17 (Wed)**

---

### Grand Ballroom 101

**Chinese SLE Treatment and Research Group (CSTAR) Study Group Session**

**Chairs**
- Xiaofeng Zeng (Peking Union Medical College, China)
- Mengtao Li (Peking Union Medical College Hospital, China)

**13:30-13:50**
- Treatment of neuropsychiatric systemic lupus erythematosus: Clinical challenges and future perspectives
  - Piping Yang (China Medical University, China)

**14:10-14:30**
- 2022 Chinese guideline for the management of pregnancy and reproduction in systemic lupus erythematosus
  - Zijian Zhao (Peking Union Medical College, China)

**14:30-15:00**
- Q & A

---

### Grand Ballroom 102

**The Systemic Lupus Erythematosus International Collaborating Clinics Group (SLICC) Study Group Session**

**Chair**
- Paul Fortin (Université Laval, Canada)

**13:30-13:50**
- HCQ issue
  - Nathalie Costedoat-Chalumeau (Cochin Hospital, France)

**13:50-14:10**
- Pregnancy
  - Evelyn Umet (McGill University Health Centre, Canada)

**14:10-14:30**
- NPSLE
  - Alexandra Legge (Dalhousie University, Canada)

**14:30-15:00**
- Q & A

---

### Grand Ballroom 105

**Asia Pacific Lupus Collaboration (APLC) Study Group Session**

**Chair**
- Chak-sing Lau (University of Hong Kong, Hong Kong)

**13:30-13:50**
- Establishment of the Asia Pacific Lupus Collaboration - Challenges and opportunities
  - Rangi Kandane-Rathnayake (Monash University, Australia)

**13:50-14:10**
- Scientific outcomes from the Asia Pacific Lupus Collaboration - From endpoint validation to survival factors
  - Eric Morand (Monash University, Australia)

**14:10-14:30**
- Treat to target studies in SLE - Using real world data to strengthen study design
  - Mandana Nikpour (The University of Melbourne, Australia)

**14:30-15:00**
- Q & A

---

**Grand Ballroom 103**

**[Pre-conference Workshop]**

**T2T: Defining LDA and Remission**

**Chair**
- Hye-Soon Lee (Hanyang University, Korea)

**15:00-15:12**
- Introduction: Infection in SLE
  - Chi-Chiu Mok (Tuen Mun Hospital, Hong Kong)

**15:12-15:24**
- Tuberculosis and non-tuberculosis mycobacterium in SLE
  - Lanyati Hampons (University of Padang, Indonesia)

**15:24-15:36**
- Pneumocystis pneumonia and rheumatology - Current understanding and approach to better practice
  - Kohei Sonomoto (University of Occupational and Environmental Health, Japan)

**15:36-15:48**
- Viral infections (except for COVID-19)
  - Kenji Oku (Kitasato University, Japan)

**15:48-16:00**
- COVID-19
  - Lai Shan Tam (The Chinese University of Hong Kong, Hong Kong)

**16:00-16:30**
- Q & A
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00-17:05</td>
<td>Welcome address&lt;br&gt;Sang-Cheol Bae (Hanyang Univ., Korea)</td>
</tr>
<tr>
<td>17:05-17:10</td>
<td>Congratulatory address&lt;br&gt;Shin-Seok Lee (Chonnam Nat’l Univ., Korea)</td>
</tr>
<tr>
<td>17:10-17:20</td>
<td>Overview of LUPUS &amp; KCR 2023&lt;br&gt;Sang-Cheol Bae (Hanyang Univ., Korea)</td>
</tr>
<tr>
<td>17:20-17:25</td>
<td>Congratulatory address&lt;br&gt;Se-hoon Oh (Mayor of Seoul)</td>
</tr>
<tr>
<td>17:25-17:30</td>
<td>Teaser of the FoUr&lt;br&gt;Saung Cheol Shim (Chungnam Nat’l Univ., Korea)</td>
</tr>
</tbody>
</table>

**Key Note lecture: The FoUr**

**Chairs**<br>Sang-Cheol Bae (Hanyang Univ., Korea)<br>Saung Cheol Shim (Chungnam Nat’l Univ., Korea)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30-17:40</td>
<td>The Light&lt;br&gt;Jeewoo Yang (Pianist, Korea)</td>
</tr>
<tr>
<td>17:40-18:00</td>
<td>The Words&lt;br&gt;David McCann (Harvard Univ., USA)</td>
</tr>
<tr>
<td>18:00-18:20</td>
<td>The Height&lt;br&gt;Hyunjoon Yoo (Hyunjoon Yoo Architects, Korea)</td>
</tr>
<tr>
<td>18:20-18:30</td>
<td>The Barrier&lt;br&gt;Soo Hyun Ro (Lupus Patient &amp; Singer, Korea)</td>
</tr>
<tr>
<td>18:30-21:00</td>
<td>Welcome Reception</td>
</tr>
</tbody>
</table>
DAY 02
Program
May 18 (Thu)
DA Y 2. - May 18 (Thu)

**Breakfast Symposium 1 - Celtrion**

**Biobetter: A New Therapeutic Option in Rheumatic Diseases**

- **Chair**: Dae Hyun Yoo (Hanyang Univ., Korea)
- **Time**: 08:00-09:00
- **Location**: Grand Ballroom 101-102

**Breakfast Symposium 2 - AbbVie**

**Optimizing Care to Resolve Issues in Rheumatoid Arthritis**

- **Chair**: Seung Cheol Shim (Chungnam Nat’l Univ., Korea)
- **Time**: 08:00-09:00
- **Location**: Grand Ballroom 103

**Breakfast Symposium 3 - Astellas**

**Rheumatoid Arthritis with Tacrolimus**

- **Chair**: Dae Hyun Yoo (Hanyang Univ., Korea)
- **Time**: 08:00-09:00
- **Location**: Grand Ballroom 104

**Breakfast Symposium 4 - Janssen**

**Redefine TNF-α in Rheumatoid Arthritis**

- **Chair**: Sang Heon Lee (Konkuk Univ., Korea)
- **Time**: 08:00-09:00
- **Location**: Grand Ballroom 105

**Special Lecture**

**Presidential Plenary Session**

- **Chair**: Shin-Seok Lee (Chonnam Nat’l Univ., Korea)
- **Time**: 09:00-10:00
- **Location**: Grand Ballroom 103+104+105

**Workshop**

**Musculoskeletal US Workshop 1 - Advanced Course**

- **Chairs**: Chong-Hyeon Yoon (The Catholic Univ. of Korea, Korea), Sang-Hoon Lee (Hanyang Univ., Korea)
- **Time**: 09:00-12:00
- **Location**: Room 209A&B

**Meet the Professor 1**

**B cell Therapy for Difficult Lupus Cases**

- **Facilitator**: Seung Ki Kwok (The Catholic Univ. of Korea, Korea)
- **Time**: 09:15-10:00
- **Location**: Grand Ballroom 101

**Meet the Professor 2**

**Cutaneous Lupus**

- **Facilitator**: Joo Yeon Ko (Hanyang Univ., Korea)
- **Time**: 09:15-10:00
- **Location**: Grand Ballroom 102

**Meet the Professor 3**

**Antiphospholipid Syndrome**

- **Facilitator**: Sang-Won Lee (Yonsei Univ., Korea)
- **Time**: 09:15-10:00
- **Location**: Room 209A&B
10:30-12:00  [Plenary Session 1]  LUPUS
SLE: Year in Review  
Auditorium

Chairs  Sang-Cheol Bae (Hanyang Univ., Korea)
        Shin-Heon Lee (Konkuk Univ., Korea)

10:30-11:00  Basic science
Mary Crow (Hosp. for Special Surgery, USA)

11:00-11:30  Clinical science
Paul Fortin (Unversité de Laval, Canada)

10:30-12:00  [Symposium]  KCR
Year in Review (Clinical)  
Grand Ballroom 103

Chairs  Chan-Hong Jeon (Soonchunhyang Univ., Korea)
        Sang-Heon Lee (Konkuk Univ., Korea)

10:30-11:00  Emerging new diagnostic and therapeutic options in systemic sclerosis
Hyun-Seok Kim (Soonchunhyang Univ., Korea)

11:00-11:30  Advances in therapeutic and diagnostic options for ANCA-associated vasculitis
Chun-Bum Choi (Soonchunhyang Univ., Korea)

11:30-12:00  Latest advances in the management of rheumatoid arthritis
Hae-Rim Kim (Konkuk Univ., Korea)

10:30-12:00  [Symposium]  LO-001  KCR
Year in Review (Basic)  
Grand Ballroom 104-105

Chairs  Dae Hyun Yoo (Soonchunhyang Univ., Korea)
        Jason Jungsk Song (Konkuk Univ., Korea)

10:30-11:00  Interaction between stromal cells and immune cells: Past, present, and future
Sang-K Lee (Soonchunhyang Univ., Korea)

11:00-11:30  Pain in musculoskeletal diseases, friend or foe
Hyun-Ah Kim (Hallym Univ., Korea)

11:30-12:00  Proteomics for the discovery of rheumatic diseases
Yang-Gil Kim (Univ. of Ulsan, Korea)

12:00-13:00  [Luncheon Symposium 2 - BMS]  Grand Ballroom 103
Impact of Autoantibodies in RA Treatment Outcomes and RA Associated Co-morbidities  

Chair  Won Park (Inha Univ., Korea)

12:00-12:40  Impact of autoantibodies in RA treatment outcomes and RA associated co-morbidities
Ronald van Vollenhoven (Amsterdam UMC, Netherlands)

12:00-13:00  [Luncheon Symposium 3 - Yuhan]  Grand Ballroom 104
Emerging Trends in Rheumatic Disease: The Changing Landscape of Biosimilars in Korea  

Chair  Jung-Yoon Choe (Seoul Catholic Univ., Korea)

12:00-13:00  Extension of rheumatic disease treatment area: Biosimilar’s role & position
Bon-San Koo (Yiye Univ., Korea)

12:00-13:30  [Luncheon Symposium 4 - Viatris]  Grand Ballroom 105
A Well-balanced NSAID for Rheumatoid Arthritis  

Chair  Seong-Ho Kim (Inje Univ., Korea)

12:00-13:00  The paradigm shift to selective COX-2 inhibitor: How PRECISION trial and sub-analysis impact on NSAIDs treatment
Min Won So (Pusan Nat’l Univ., Korea)

13:00-14:30  [Concurrent Session 1]  LUPUS
Global Challenges  
Auditorium

Chairs  Laurent Arnaud (Strasbourg Univ., France)
        Eun-Ha Kang (Seoul Nat’l Univ., Korea)

13:00-13:20  Global epidemiology of SLE: Do we need more than just counts?
Rosalind Ramsey-Goldman (Northwestern Univ., USA)

13:20-13:40  SLE disease burden from a patient perspective
Lai Shean Tam (The Chinese Univ. of Hong Kong, Hong Kong)

13:40-14:00  Access to health care
Sang-Cheol Bae (Soonchunhyang Univ., Korea)

LO-001  
Socioeconomic trends in outcomes of tertiary prevention among patients with systemic connective tissue disorders in Germany
Patrick Brozina (Witten/Herdecke Univ., Germany)

LO-002  
“Skin-Deep Resilience” in the black women’s experiences living with lupus (BeWELL) Study
Karla Chung (Tulane School of Public Health and Tropical Medicine, USA)

LO-003  
Prevalence of remission according to physician and patient and level of agreement in a real-world multicenter lupus registry
José María Pego reigosa (Hospital Mar del Plata, Spain)
### Alliance Session 1

**13:00-14:30**

**Improving Lupus Outcomes through Patient Education**

**Grand Ballroom 102**

**Chairs**

- Sandra Navarra (Univ. of Santo Tomas, Philippines)
- Seung Chul Shin (Chungnam Nat’l Univ., Korea)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00-13:20</td>
<td>Lupus education for physicians and patients in a resource-limited setting</td>
<td>Sandra Navarra (Univ. of Santo Tomas, Philippines)</td>
<td></td>
</tr>
<tr>
<td>13:40-14:00</td>
<td>Patient perspectives on education using digital resources</td>
<td>Seung Min Jung (The Catholic Univ. of Korea)</td>
<td></td>
</tr>
<tr>
<td>14:00-14:30</td>
<td>Panel Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

### Concurrent Session 2

**13:00-14:30**

**Biomarkers from Bench to Bedside**

**Grand Ballroom 101**

**Chairs**

- Yoshiya Tanaka (Univ. of Occupational and Environmental Health, Japan)
- Yong-Gil Kim (Univ. of Ulsan, Korea)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00-13:20</td>
<td>Immune phenotype and its therapeutic application in SLE</td>
<td>Yoshiya Tanaka (Univ. of Occupational and Environmental Health, Japan)</td>
<td></td>
</tr>
<tr>
<td>13:20-13:40</td>
<td>The quest for end organ focused biomarkers in SLE</td>
<td>Chandra Mohan (Univ. of Houston, USA)</td>
<td></td>
</tr>
<tr>
<td>13:40-14:00</td>
<td>Proteomics for urine biomarkers</td>
<td>Kyunggon Kim (Univ. of Ulsan, Korea)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Frequency and determinants of flare and persistently active disease</td>
<td>Yanjei Hsu (The Univ. of Melbourne, Australia)</td>
<td></td>
</tr>
<tr>
<td>LO-004</td>
<td>in a large multinational prospective lupus cohort</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Urinary L-selectin reflects clinical and histological renal disease</td>
<td>Huhua Ding (Shanghai Jiao Tong Univ., China)</td>
<td></td>
</tr>
<tr>
<td>LO-005</td>
<td>activity and treatment response in lupus nephritis across multiple</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ethnicities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LO-006</td>
<td>Change in urinary biomarkers at three months predicts 1-year</td>
<td>Andrew Fauci (Columbia Univ., USA)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>treatment response of lupus nephritis before proteinuria</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

### APLAR-KCR Joint Symposium

**13:00-14:30**

**Career Development of Young Rheumatologists in the APLAR Region**

**Grand Ballroom 103**

**Chairs**

- Debashish Danda (Christian Medical College Hosp, India)
- Shin-Seok Lee (Chonnam Nat’l Univ., Korea)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00-13:30</td>
<td>New initiatives of APLAR (APLAR Academy)</td>
<td>Debashish Danda (Christian Medical College Hosp, India)</td>
<td></td>
</tr>
<tr>
<td>13:30-14:00</td>
<td>Lessons learned from the Japan College of Rheumatology International</td>
<td>Tozumu Takeuchi (Kobe Univ., Japan)</td>
<td></td>
</tr>
<tr>
<td>14:00-14:30</td>
<td>KCR’s future directives for YRs</td>
<td>Kichul Shin (Seoul Nat’l Univ., Korea)</td>
<td></td>
</tr>
</tbody>
</table>

---

### Symposium

**13:00-14:30**

**COVID-19 in Health and Autoimmunity**

**Grand Ballroom 104**

**Chairs**

- Sung-Hwan Park (The Catholic Univ. of Korea, Korea)
- Young Mo Kang (Kyungpook Nat’l Univ, Korea)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00-13:30</td>
<td>Clinical Aspect of COVID-19 infection in patients with systemic</td>
<td>Su-Jin Moon (The Catholic Univ. of Korea)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>autoimmune diseases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30-14:00</td>
<td>Alliance of T and innate immune cells via cytokine receptors in</td>
<td>Insoo Kang (Yale Univ., USA)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>health and autoimmunity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00-14:30</td>
<td>T cell immune responses against SARS-CoV-2</td>
<td>Eui-Cheol Shin (KIST, Korea)</td>
<td></td>
</tr>
</tbody>
</table>

---

### KCR Research Foundation Session

**13:00-14:30**

**KCR Research Foundation Session**

**Grand Ballroom 105**

**Chairs**

- Jung-Yoon Choe (Seog-Catholic Univ., Korea)
- Won Tae Chung (Seog-A Univ., Korea)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00-13:20</td>
<td>Effect of complement factor H-related protein 5 in murine arthritis</td>
<td>Chang-Han Sun (Sung Shin Univ., Korea)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>models</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:20-13:40</td>
<td>The microbiome of the upper respiratory tract in rheumatoid arthritis</td>
<td>Young-Bin Ju (Yangpyung Univ., Korea)</td>
<td></td>
</tr>
<tr>
<td>13:40-14:00</td>
<td>Glucocorticoid and infectious complication in rheumatic disease</td>
<td>Jun Won Park (Seoul Nat’l Univ., Korea)</td>
<td></td>
</tr>
<tr>
<td>14:00-14:30</td>
<td>Korean diagnosis-related groups (DRGs) payment system in rheumatic</td>
<td>Byoung Yong Choi (Seoul Medical Center, Korea)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>and musculoskeletal diseases</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

### Meet the Mentor

**14:30-15:30**

**Meet the Mentor 1**

**Conference Room 205B**

**Facilitator**

- Seung-Ki Kwok (The Catholic Univ. of Korea, Korea)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30-15:30</td>
<td>Meet the Mentor</td>
<td>George Tsokos (Harvard Medical School, USA)</td>
<td></td>
</tr>
</tbody>
</table>
Korean Yoontae Lee
Type I interferon affects Th22 cell differentiation participated in the pathogenesis of lupus nephritis

Anti-TCP1 antibody is the potential biomarker of systemic lupus erythematosus

Decreased natural killer T-like cells correlated to disease activity in systemic lupus erythematosus

Chan Hong Jeon
Withdrawn

Intervention to improve medication adherence among patients with systemic lupus erythematosus

Trimeric oligonucleotides ameliorate disease in a mouse model of CLE-like inflammatory skin disease

Effects of progesterone-induced blocking factor 1 on the alleviation of lupus nephritis in MRL/lpr mice

cGAS deficiency enhances inflammasome activation in macrophages and inflammatory pathology in pristane-induced lupus

Type I interferon affects Th22 cell differentiation participated in the pathogenesis of lupus nephritis

Targeting pathogenic auto-reactive VH4-34 B cells with a rationally developed and highly specific anti-VH4-34 antibody offers a new therapeutic approach for VH4-34 autoimmune disorders

Trimeric oligonucleotides ameliorate disease in a mouse model of CLE-like inflammatory skin disease

Decreased natural killer T-like cells correlated to disease activity in systemic lupus erythematosus

LSO-001
Modulating T-bet-promoted energy metabolism in pathogenic age/autoimmune-associated B cells ameliorates lupus autoimmunity

Dei-Ox (Shanghai Jiaotong Univ., China)

LSO-002
The transcriptional factor Pax11 adjusts peripheral B cell homeostasis to constrain lupus autoimmunity

Dei-Ox (Shanghai Jiaotong Univ., China)

LSO-003
Effects of progesterone-induced blocking factor 1 on the alleviation of lupus nephritis in MRL/lpr mice

Young-Eun Kim (Univ. of Ulsan, Korea)

LSO-004
cGAS deficiency enhances inflammasome activation in macrophages and inflammatory pathology in pristane-induced lupus

Saneey Kumpunya (Center of Excellence in Systems Biology, Thailand)

LSO-005>Type I interferon affects Th22 cell differentiation participated in the pathogenesis of lupus nephritis

Hong-Xu Hu (Peking Union Medical College Hosp., China)

LSO-006
Targeting pathogenic auto-reactive VH4-34 B cells with a rationally developed and highly specific anti-VH4-34 antibody offers a new therapeutic approach for VH4-34 autoimmune disorders

Jerome Boyd-Kirkup (Hummingbird Bioscience, Singapore)

LSO-007
Trimeric oligonucleotides ameliorate disease in a mouse model of CLE-like inflammatory skin disease

Mary Spear (National Institute of Medical Research, Australia)

LSO-008
Decreased natural killer T-like cells correlated to disease activity in systemic lupus erythematosus

Ying Li (Peking Univ. People’s Hosp., China)

LSO-009
Modulating T-bet-promoted energy metabolism in pathogenic age/autoimmune-associated B cells ameliorates lupus autoimmunity

Chair: Yoontae Lee (Korea Univ. of Science and Technology, Korea)

LSO-010
Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibodies associated adverse pregnancy outcomes: a based on a 13-year longitudinal cohort study

Yin-Lung (Peking Union Medical College Hosp., Chinese Academy of Medical Sciences & Peking Union Medical C, China)

LSO-011
Withdrawn

LSO-012
Withdrawn

LSO-013
Metabolomics analysis identifies biomarkers for APS and suggests potential new pathway for APS pathogenesis

Yang-Ling (Peking Univ. People’s Hosp., China)

Chair: Hae-Rim Kim (Konkuk Univ., Korea)

LSO-014
Clinico-pathological association of serum CD44 level in lupus nephritis patients

Chair: Jason Jung Sik Song (Korea Univ., Korea)

LSO-015
Deuracavatibert reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 PASLEY study

Iain M. Caeless (Royal College of Surgeons, USA)

LSO-016
Activated leukocyte cell adhesion molecule, hemopexin, and peroxiredoxin 6 as a potential urinary biomarker for Korean patients with systemic lupus erythematosus

Ji-Won Kim (Aju Univ., Korea)

LSO-017
Anti-TCP1 antibody is the potential biomarker of systemic lupus erythematosus

Sung-Won Lee (Aju Univ., Korea)

LSO-018
iC3b/C3 ratios more strongly correlate with SLE disease activity in African-Americans compared with Whites

Alfred Kim (Washington Univ., USA)

LSO-019
The neutrophil-to-C3 ratio (NC3R) was an inflammatory marker in the assessment of lupus nephritis and ocular vessel density in systemic lupus erythematosus patients

Shuhan Yu (The Second Affiliated Hosp. of Guangzhou Medical Univ., China)

LSO-020
Effect of air pollutant exposure on disease activity of systemic lupus erythematosus : A prospective longitudinal study from Korea

Ji-Hyeon Kang (Chonnam Nat’l Univ., Korea)

LSO-021
Intervention to improve medication adherence among patients with systemic lupus erythematosus

Kai Sun (Duke Univ., USA)

LSO-022
Epidemiology and survival of SLE in the last decade: data from a large population-based study in northeastern Italy

Margherita Zen (Univ. of Padua, Italy)

LSO-023
Adverse childhood experiences and disease activity: The role of trauma in the black women’s experiences living with lupus (bewell) study

Kara W Chung (Tulane School of Public Health and Tropical Medicine, USA)

LSO-024
Clinical characteristics of SARS-CoV-2 infection in patients with systemic lupus erythematosus in Argentina: Data from the SAR-COVID national registry

Guilermo Pons-Estel (Centro Regional de Enfermedades Autoinmunes y Reumáticas, Argentina)

LSO-025
Comparison of clinical characteristics and outcomes in patients with systemic lupus erythematosus in a cross-national study

Sung Jun Lim (Ajou Univ., Korea)

Chair: Chan Hong Jeon (Soonchunhyang Univ., Korea)

LSO-026
Effect of air pollutant exposure on disease activity of systemic lupus erythematosus: A prospective longitudinal study from Korea

Ji-Hyeon Kang (Chonnam Nat’l Univ., Korea)

LSO-027
Intervention to improve medication adherence among patients with systemic lupus erythematosus

Kai Sun (Duke Univ., USA)

LSO-028
Epidemiology and survival of SLE in the last decade: data from a large population-based study in northeastern Italy

Margherita Zen (Univ. of Padua, Italy)

LSO-029
Adverse childhood experiences and disease activity: The role of trauma in the black women’s experiences living with lupus (bewell) study

Kara W Chung (Tulane School of Public Health and Tropical Medicine, USA)

LSO-030
Clinical characteristics of SARS-CoV-2 infection in patients with systemic lupus erythematosus in Argentina: Data from the SAR-COVID national registry

Guilermo Pons-Estel (Centro Regional de Enfermedades Autoinmunes y Reumáticas, Argentina)

LSO-031
Comparison of clinical characteristics and outcomes in patients with systemic lupus erythematosus in a cross-national study

Sung Jun Lim (Ajou Univ., Korea)
14:30-15:30 [Short Oral Presentation] Lupus Nephritis

Chair: Seung-Geun Lee (Pusan Natl. Univ., Korea, Korea)

LSO-025 Comparison between add-on pulse methylprednisolone versus medium to high dose glucocorticoids alone in Thai patients with proliferative lupus nephritis receiving monthly pulse intravenous cyclophosphamide

Pranit Tippawong (Prince of Songkla Univ., Thailand)

LSO-026 Sirolimus versus mycophenolate mofetil for the treatment of lupus nephritis: Results from a real-world CISTAR cohort study

WeeRao (Peking Union Medical College Hosp., China)

LSO-027 Predictors of long-term renal survival and mortality in patients with biopsy-proven lupus nephritis: A prospective cohort study

Jung-Min Shin (Eulji Univ., Korea)

LSO-028 Predictors of de novo renal flares in systemic lupus erythematosus – time to revisit belimumab dose for extra-renal disease? Results from five phase III clinical trials of belimumab

Joanna Fardelius (Karolinska Institute, Sweden)

LSO-029 Predictors of renal relapse in Korean patients with lupus nephritis: Over a 35-year period at a single center


LSO-030 Predictors of renal flares in systemic lupus erythematosus: A post-hoc analysis of four phase III clinical trials of belimumab

Aiko Gomaa (Karolinska Institute, Sweden)

LSO-100 Does early complete remission preclude adverse outcomes in lupus nephritis?

Dalha Gladman (Univ. of Toronto, Canada)

14:30-15:30 [Short Oral Presentation] SLE Diagnosis and Manifestations

Chair: Chang-Nam Son (Eulji Univ., Korea)

LSO-031 Association of serologic and clinical low disease activity states with outcomes in a large multi-national lupus cohort

Yanjie Hao (The Univ. of Melbourne, Australia)

LSO-032 Predictors of first hospitalizations due to disease activity and infections in systemic lupus erythematosus patients

Bernardo A. Pena-Estel (Regional Center for Autoimmune and Rheumatic Diseases, Argentina)

LSO-033 Comparison of the systemic lupus international collaborating clinics frailty index (SLICC-FF) and the FRAIL scale for identifying frailty among individuals with systemic lupus erythematosus

Alexandra Leggo (Doherty Institute, University of Melbourne, Australia)

LSO-034 Association of latent tuberculosis infection with clinical and serological parameters in systemic lupus erythematosus- a prospective observational study

Gayatri R. (Jawaharlal Institute of Postgraduate Medical Education and Research, India)

LSO-035 Withdrawn

LSO-036 Cluster analysis and subphenotype stratification in lupus erythematosus based on data from the Asia Pacific Lupus Collaboration cohort (APLC-CASTLE)

Shirley Chu Wei Chen (Univ. of Hong Kong, Hong Kong)
The Session with the icon provides English-Korean translation.

**Musculoskeletal US Workshop 2 - Basic Course**

**Chairs**
- Geun-Tae Kim (Kosin Univ., Korea)
- Hyun Ok Kim (Gujeongsang Natl Univ., Korea)

**15:30-18:30**
- **[Workshop]**
  - **MUSCULOSKELETAL US WORKSHOP 2 - BASIC COURSE**
  - **Room 209A+B**

**15:30-16:00**
- Ultrasound of the upper extremities
  - Kyung-Ann Lee (Seoul National Univ., Korea)

**16:00-16:30**
- Ultrasound of the low extremities
  - Jai Hyun Jung (Kosin Univ., Korea)

**16:30-17:30**
- Hands on courses of upper extremities - Shoulder
  - Boo Young Kim (Univ. of Ulster, Korea), Young Hee Koh (The Catholic Univ. of Korea, Korea)
- Hands on courses of upper extremities - Wrist, Elbow
  - Yune Jung (The Catholic Univ. of Korea, Korea), Soo Min Ahn (Univ. of Ulsan, Korea)

**17:30-18:30**
- Hands on courses of low extremities - Knee
  - Bora Nam (Hanyang Univ., Korea), Chang Hoon Lee (Wonkwang Univ., Korea)
- Hands on courses of low extremities - Ankle, Foot
  - Young Sun Suh (Gyeongsang Natl Univ., Korea), Jung Hee Koh (The Catholic Univ. of Korea, Korea)

**17:00-17:20**
- EULAR recommendations for management of SLE
  - Elisabet Svenungsson (Karolinska Institutet and Karolinska Univ. Hosp., Sweden)

**17:20-17:40**
- Treatment of SLE and lupus nephritis: Comparison of Asian and Western guidelines
  - Oliemide Akinwale (Lagos State Univ. Teaching Hosp., Nigeria)

**17:40-18:00**
- Cardiovascular disease risk management in SLE/APS
  - Thomas Dörner (Charité Universitätsmedizin Berlin and Deutsches, Germany)

**18:00-18:30**
- Panel Discussion

---

**Cytokines and Cell Signaling**

**Chairs**
- Marina Botto (Imperial College London, UK)
- Yong-wook Park (Chonnam Nat'l Univ., Korea)

**17:00-17:20**
- Deconvoluting JAK/STAT building blocks in development and disease
  - Lotta Henriksen-Hansen (Nat’l Institutes of Health, USA)

**17:20-17:40**
- Type I IFN and T cell metabolism in SLE
  - Marina Botto (Imperial College London, UK)

**17:40-18:00**
- Extracellular DNA and DNases in SLE
  - Bora Nam (Hanyang Univ., Korea), Chang Hoon Lee (Wonkwang Univ., Korea)

**17:00-17:20**
- The innate immune checkpoint NLRP12 represses IFN signatures and attenuates the progression of lupus nephritis.
  - Sau Ting Chen (Nat’l Yang Ming Chiao Tung Univ., Taiwan)

**17:20-17:40**
- Novel pathogenetic mechanisms mediated by dysregulation of TRIM21-STING-type I interferon axis in lupus
  - Young Hee Koh (The Catholic Univ. of Korea, Korea)

**17:40-18:00**
- Extracellular DNA and DNases in SLE
  - Bora Nam (Hanyang Univ., Korea), Chang Hoon Lee (Wonkwang Univ., Korea)

**18:00-18:30**
- Panel Discussion

---

**Rheumatic Diseases Around the World**

**Chairs**
- Bernardo A. Pons-Estel (Regional Center for Autoimmune and Rheumatic Diseases, Argentina)
- Yoon-Kyoung Sung (Hanyang Univ., Korea)

**17:00-17:20**
- Lupus in Africans - The past and the present
  - Olufemi Adelowo (Lagos State Univ. Teaching Hosp., Nigeria)

**17:20-17:40**
- Overcoming the challenges of rheumatic diseases in Asian Pacific region
  - Tsutomu Takeuchi (Keio Univ., Japan)

**17:40-18:00**
- Global collaborations on clinical trial, practice, and education in pediatric rheumatology
  - Angelo Ravelli (IRCCS Istituto Giannina Gaslini, Italy)

**18:00-18:30**
- Panel Discussion

---

**Best Practice in the Management of SLE**

**Chairs**
- Jisoo Lee (Ewha Womans Univ., Korea)
- Seonghoon Park (Seogwa Catholic Univ., Korea)

**17:00-17:20**
- Disease activity and treatment target in SLE
  - So-Young Bang (Hanyang Univ., Korea)

**17:20-17:40**
- Current therapies and changing perspective on managing lupus
  - Chang Hyo Sun (Ajou Univ., Korea)

**17:40-18:10**
- Discussion Forum

---

**Responsiveness of the CLASI to alopecia and mucous membrane involvement: A retrospective study of prospectively collected data**

**Authors**
- Victoria Werth (Univ. of Pennsylvania, USA)

**LO-012**
- The innate immune checkpoint NLRP12 represses IFN signatures and attenuates the progression of lupus nephritis.
  - Sau Ting Chen (Nat’l Yang Ming Chiao Tung Univ., Taiwan)

**LO-013**
- Novel pathogenetic mechanisms mediated by dysregulation of TRIM21-STING-type I interferon axis in lupus
  - Young Hee Koh (The Catholic Univ. of Korea, Korea)

**LO-014**
- Mechanistic interrogation of STAT1 gain-of-function syndrome provides new insights into human lupus pathogenesis
  - Shaun Jackson (Seattle Children’s Research Institute, USA)
DAY 2. - May 18 (Thu)

17:00-18:30  
[International Symposium 2]  
Management of Systemic Vasculitis  
Grand Ballroom 103  

Chairs  
Chan-Bum Choi  (Hanyang Univ., Korea)  
Sang-Won Lee  (Yonsei Univ., Korea)

17:00-17:30  
Recent advances in the treatment of ANCA-associated vasculitis  
Peter A. Merkel  (Univ. of Pennsylvania, USA)

17:30-18:00  
Application of the 2022 ACR/EULAR classification criteria for MPA, GPA, and EGPA to Korean patients with AAV  
Sung Su-Hee  (Yonsei Univ., Korea)

KIO-002  
Overlap syndrome of systemic sclerosis with antineutrophil cytoplasmic antibody-associated vasculitis according to the 2022 ACR/EULAR classification criteria  
Jangwoo Ha  (Severance Hosp., Korea)

18:10-18:25  
Metabolic syndrome in ANCA-associated vasculitis  
Pil Gyu Park  (Nat’l Health Insurance Service Ilsan Hosp., Korea)

17:00-17:30  
Meta-analysis for biomarker discovery  
Young Ho Lee  (Korea Univ., Korea)

17:30-18:00  
Statistical methods for biomarker discovery  
Seo Young Park  (Korea Nat’l Open Univ., Korea)

18:00-18:30  
EMR data for biomarker discovery  
Jonggi Choi  (Univ. of Ulsan, Korea)

18:30-19:30  
[Evening Symposium 2 - JW Pharmaceutical]  
Update on Treatment of Systemic Vasculitis  
Grand Ballroom 103  

Chair  
Chan-Bum Choi  (Hanyang Univ., Korea)

18:30-19:10  
Tocilizumab for the treatment of systemic vasculitis  
Sang-Won Lee  (Yonsei Univ., Korea)

19:00-21:00  
[Satellite Symposia - Samsung Bioepis]  
Samsung Bioepis Satellite Symposium  
InterContinental Seoul COEX Harmony Ballroom

Chair  
Josef S. Smolen  (Medical Univ. of Vienna, Austria)

19:00-20:00  
The economics of Anti-TNF biosimilar: Regulatory pathway to uptake and systemwide savings  
Adam H. Anis  (The Univ. of British Columbia, Canada)

20:00-21:00  
What rheumatology should know about biosimilar before prescription  
Jonathan Kay  (Urbana Chan Medical School, USA)

18:30-19:10  
A new chapter in lupus care: How can we improve long-term outcomes for patients?  
Masato Okada  (St. Luke’s Int’l Hosp., Japan)
The Session with the icon provides English-Korean translation. 통역 아이콘을 표시한 세션은 한-영 동시통역을 제공합니다.

**Day 3: May 19 (Fri)**

### Grand Ballroom 101+102

**08:00-09:00**

**[Breakfast Symposium 5 - Yuhan]**

**Exploring the Medical Strategies for Management of Rheumatic Disease in the USA**

**Chair:** Jae Joon Lee (Sungkyunkwan Univ., Korea)

- **08:00-08:40**
  - Current approach to treatment of rheumatoid arthritis and axial spondyloarthritis in the United States
    - Jonathan Kay (Emory Chan Medical School, USA)

### Grand Ballroom 103

**08:00-09:00**

**[Breakfast Symposium 6 - Eisai]**

**Introducing Jyseleca (Filgotinib): JAK1-preferential Inhibitor**

**Chair:** Chang Kwon Lee (Univ. of Ulsan, Korea)

- **08:00-08:40**
  - The efficacy and safety of Jyseleca in RA: Based on clinical trials and real world experience in Japan
    - Yuko Kawai (Keio Univ. Hosp., Japan)

### Grand Ballroom 104

**08:00-09:00**

**[Breakfast Symposium 7 - GSK]**

**Planning for Tomorrow Today: How Can We Improve Prognosis in SLE?**

**Chair:** Mandana Nikpour (The Univ. of Melbourne, Australia)

- **08:00-08:40**
  - Acting now to minimize the impacts of organ damage and infection in SLE
    - Yasuhiko Katsumata (Tokyo Women's Medical Univ., Japan)

### Grand Ballroom 105

**08:00-09:00**

**[Breakfast Symposium 8 - Pfizer]**

**Practical Review of RA Management with Etanercept**

**Chair:** Chang Hee Suh (Ajou Univ., Korea)

- **08:00-08:40**
  - Long-established clinical value of Enbrel in RA patients
    - Yune Jung Park (The Catholic Univ. of Korea, Korea)

### Grand Ballroom 101

**09:15-10:00**

**[Meet the Professor 4]**

**SLE and Infection**

**Facilitator:** Yeon-Ah Lee (Kyung Hee Univ., Korea)

- **09:15-09:45**
  - SLE and Infection
    - Masaofumi Hori (Tokyo Women's Medical Univ., Japan)

- **09:45-10:00**
  - Q&A

### Room 205A+B

**09:15-10:00**

**[Meet the Professor 6]**

**Managing Lupus Pregnancy**

**Facilitator:** Jisoo Lee (Ewha Womans Univ., Korea)

- **09:15-09:45**
  - Managing lupus pregnancy
    - Evelyn Vinet (McGill Univ. Health Centre, Canada)

- **09:45-10:00**
  - Q&A

### Auditorium

**10:30-12:00**

**[Plenary Session 3]**

**Novel Treatments and Strategies**

**Chairs:** Eric Morand (Monash Univ., Australia)

- **10:30-11:00**
  - Overview of new SLE treatments and defining the targets
    - Andrea Doria (Univ. of Padua, Italy)

- **11:00-11:30**
  - Calcineurin inhibitors: New & old
    - Brad Rovin (The Ohio State Univ., USA)

- **LO-015**
  - Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in a phase 2 trial in systemic lupus erythematosus (SLE): achievement of sustained SRI(4), BICLA, and dual responses over 48 weeks
    - Richard Furie (Northwell Health, USA)

- **LO-016**
  - The multifaceted immunomodulatory properties of cenerimod, a selective S1P1 receptor modulator, target three key aspects of SLE pathogenesis
    - Marianne M. Martinic (Idorsia Pharmaceuticals, Switzerland)

- **LO-017**
  - Zetorimizumab (KZR-616) demonstrates anti-inflammatory and immunomodulatory potential in patients with active lupus with or without lupus nephritis: Results from the open-label Phase 1b/2 MISSION study
    - Brad Rovin (The Ohio State Univ., USA)
COVID-19 and Lupus: Unraveling the mystery from real world data

Young Ho Lee
Seungwoo Han

Multi-target therapy in patients with lupus nephritis
Approach and management of rheumatoid arthritis with interstitial lung disease

Serum KL-6 levels in patients with rheumatoid arthritis-associated interstitial lung disease
Regional cardiovascular risk in gout patients: A nationwide cohort study in Korea

Association between trajectory of metabolic syndrome and knee pain over 11 years in middle-aged adults

Chairs
Seungwoo Han (Yonsei Univ., Korea)
Sang-II Lee (Seoul National Univ., Korea)

Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease
Approach and management of rheumatoid arthritis with interstitial lung disease
Shortened telomere length is associated with usual interstitial pneumonia in rheumatoid arthritis
Serum KL-6 levels in patients with rheumatoid arthritis-associated interstitial lung disease

Chairs
Young Il Seo (Seoul Nat’l Univ., Korea)
Chung Il Juang (Yonsei Univ., Korea)

Recovery and long-term renal outcome of patients with ANCA-associated vasculitis who are on dialysis at presentation
Application of the 2022 ACR/EULAR classification criteria for ANCA-associated vasculitis to patients with polymyositis and dermatomyositis presenting clinical manifestations suggestive of small- and medium-vessels vasculitis
Non-alcoholic fatty liver disease fibrosis score is a useful index for predicting all-cause mortality during the follow-up in patients with antineutrophil cytoplasmic antibody-associated vasculitis
Regional cardiovascular risk in gout patients: A nationwide cohort study in Korea
Comparative risk of retinal vascular complications in patients with gout initiating febuxostat versus allopurinol: A population-based cohort study

Chairs
Ji Hyeon Ju (The Catholic Univ. of Korea, Korea)
Hyun Sik Gong (Seoul Nat’l Univ., Korea)

Association of healthy lifestyles with all-cause and cause-specific mortality among individuals with osteoarthritis: A prospective cohort study of the UK Biobank
Association between trajectory of metabolic syndrome and knee pain over 11 years in middle-aged adults
The intervention of osteoarthritis and comorbid depressive disorder by a selective combination of pro/prebiotic treatment
Subchondral bone density distribution in elbows with early and advanced osteoarthritis in association with elbow alignment
Low serum adiponectin levels were associated with radiographic progression of hand osteoarthritis in a 6-year follow-up of the Dong-gu study
A single intraarticular injection of nanotechnology-based drug formulation as a safe osteoarthritis disease-modifying drug
Serial administration of recombinant human bone morphogenetic protein-2 and osteoprotegerin-Fc enhances the differentiation of osteoblasts
Osteoporesis gene therapy using non-viral minicircle vector inserted osteoprotegerin and PTHrP(1-34)+107-139 gene

Chairs
Nathalie Costedoat-Chaumeau (Cochin Hosp., France)
Han Joo Baek (Gachon Univ., Korea)

Autoimmunity, COVID-19, post-COVID-19, and SLE
COVID-19 and Lupus: Unraveling the mystery from real world data
Update in Treatment of LN with Tacrolimus

Chairs
Young Ho Lee (Korea Univ., Korea)

Multi-target therapy in patients with lupus nephritis

KO-009
KO-010
KO-011
KO-012
KO-013
KO-014
KO-015
KO-001
KO-002
KO-003
KO-004
KO-005
KO-006
KO-007
KO-008
12:00-13:00

**Lunch on Symposium 6 - Lilly**

**Grand Ballroom 103**

**Spotlight on JAKi to Making the Right Decision for Your Patients with RA**

**Chair**

Wan-Uk Kim (The Catholic Univ. of Korea, Korea)

12:00-12:40

Shared decision making for patients with RA based on the evidence of Baricitinib

Kei Ikeda (Dokkyo Medical Univ., Japan)

12:00-13:00

**Lunch on Symposium 7 - Novartis**

**Grand Ballroom 104**

**Luncheon Symposium 7**

**12:00-12:40**

**Spotlight on JAKi to Making the Right Decision for Your Patients with RA**

Kei Ikeda (Dokkyo Medical Univ., Japan)

**12:00-13:00**

**Lunch on Symposium 8 - AbbVie**

**Grand Ballroom 105**

**Optimizing Care to Improve Treatment Outcomes in Ankylosing Spondylitis**

**Chair**

Hoon-Suk Cha (Sungkyunkwan Univ., Korea)

12:00-12:40

Exploring a new treatment option for active ankylosing spondylitis

Sang-Hoon Lee (Kyung Hee Univ., Korea)

**13:00-14:30**

**[Concurrent Session 5]**

**Auditorium**

**Comorbidities**

**Chairs**

Dafna Gladman (Univ. of Toronto, Canada)

Hye-Soon Lee (Hanyang Univ., Korea)

13:00-13:20

Update in cardiovascular lupus

Michelle Petri (Johns Hopkins Univ., USA)

13:20-13:40

Malignancy in SLE

Stasha Sternecky (Research Institute of the Mt Sinai Univ. Health Centre, Canada)

13:40-14:00

Effect of COVID-19 infection on disease flares and herpes zoster reactivation in patients with SLE

: A case-control study

Chi-Chiu Mok (Tuen Mun Hosp., Hong Kong)

13:00-14:30

**[Concurrent Session 6]**

**Grand Ballroom 101**

**New Treatments**

**Chairs**

Richard Furie (Northwell Health, USA)

Hoon-Suk Cha (Sungkyunkwan Univ., Korea)

13:00-13:20

Precision medicine for lupus: Big problems but greater rewards

Joan Merrill (Oklahoma Medical Research Foundation, USA)

13:20-13:40

Type I interferon targeted therapy

Ronald Van Vollenhoven (Amsterdam UMC, Netherlands)

13:40-14:00

Targeting B cells/plasma cells in SLE

Richard Furie (Northwell Health, USA)

**LO-021**

Interim safety and efficacy of subcutaneous (s.c.) dose inaralumab (WAY736; anti-BAFF-R mAb) administered monthly over 28 weeks in patients with systemic lupus erythematosus (SLE)

Shin-Seok Lee (Chonnam Nat’l Univ., Korea)

**LO-022**

Modulation of inflammation in systemic lupus erythematosus utilizing mesenchymal stem cell-derived secretome

Sung Soo Ahn (Yonsei Univ., Korea)

**LO-043**

Single-cell RNA sequencing reveals the dynamics of circulating immune cells in SLE patients treated with Balmunab

Christine Suh-Yun Joh (Seoul Nat’l Univ., Korea)

**13:00-14:30**

**[Alliance Session 3]**

**Grand Ballroom 102**

**Global Collaboration to Overcome Health Care Disparities**

**Chairs**

Sung Sam Lim (Emory Univ., USA)

Chan-Bum Choi (Hanyang Univ., Korea)

13:00-13:20

Latin Americans: A population at risk of severe lupus

Guillermo Pons-Estel (Centro Regional de Enfermedades Autoinmunes y Reumáticas, Argentina)

13:20-13:40

Social determinants of health in lupus

Sung Sam Lim (Emory Univ., USA)

13:40-14:00

Strategies to end health disparities in SLE

Matthew H Liang (Harvard Medical School, USA)

14:00-14:30

Panel Discussion
13:00-14:30 | [International Symposium 4] | Grand Ballroom 103
Urate-Lowering Benefits and Risks on Comorbidities

Chairs: Hyo-Jin Choi (Gachon Univ., Korea)
        Jung Soo Song (Chung-Ang Univ., Korea)

13:00-13:30
Cardiovascular safety of urate lowering therapies
Eun Ha Kang (Seoul Nat’l Univ., Korea)

13:30-14:00
The role of hyperuricemia in the progression of chronic kidney disease
Daniel I. Feig (Univ. of Alabama, USA)

KO-006
Adherence to urate-lowering therapy affects the risk of cardiovascular events in patients with gout
Min Jung Kim (Seoul Nat’l Univ., Korea)

KO-007
Major adverse cardiovascular events with subclinical atherosclerosis in gouty arthritis patients
Yu Wang (First Hosp. of Peking Univ., China)

13:00-14:30 | [Free Paper Session 3] | Grand Ballroom 104
Spondyloarthritis

Chairs: Tae-Hwan Kim (Hanyang Univ., Korea)
        Myeong Su Lee (Wonsungang Univ., Korea)

KO-016
Dissociation of serum IL-23 and IL-17 levels in patients with spondyloarthritis according to radiographic stage
Jina Yeo (Gachon Univ., Korea)

KO-017
Clonorchis sinensis-excretory/secretory protein ameliorates inflammation in ankylosing spondylitis
Moon Ju Kim (Chonnam Nat’l Univ., Korea)

KO-018
The expression of alpha7 nicotinic acetylcholine receptor and the effect of smoking in curdlan-administered SKG Mice
Young Eun Kim (Univ. of Ulsan, Korea)

KO-019
Inferring metabolic pathway activity levels of bone formation from RNA-Seq data of TgA86 mouse model of Spondyloarthritis
Min S Kim (Kyung Hee Univ., Korea)

KO-020
The complement factor H-related protein-5 (FHR-5) exacerbates pathological bone formation of ankylosing spondylitis
Jiyoung Lee (Seoul Nat’l Univ., Korea)

KO-021
The emerging mechanism of IL-17A/WT1a/ROR2 axis in pathological bone formation of ankylosing spondylitis
Sungho Jo (Hanyang Univ., Korea)

KO-022
Microtrauma exacerbates arthritis and enthesitis in curdlan-administered SKG mice by inducing FGF16 expression
Seung Hoon Lee (Hanyang Univ., Korea)

13:00-14:30 | [Free Paper Session 4] | Grand Ballroom 105
Epidemiology & Health Service Research

Chairs: Soo-Kyung Cho (Hanyang Univ., Korea)
        Sung Won Lee (Seoul Nat’l Univ., Korea)

KO-023
Mortality-related health metrics in rheumatic and musculoskeletal diseases: an epidemiological analysis of a nationwide register-based cohort
Mucong Li (Peking Union Medical College Hosp., China)

KO-024
Risk of cancer, cardiovascular disease, thromboembolism, and mortality in rheumatoid arthritis with janus kinase inhibitors: Data from Korean health insurance data
Hong Ki Min (Konkuk Univ., Korea)

KO-025
Risk of major adverse cardiovascular events following targeted therapy according to cardiovascular disease history in patients with rheumatoid arthritis
Seung-Hun You (Chung-Ang Univ., Korea)

KO-026
Risk of infections between JAK inhibitors and TNF inhibitors among patients with rheumatoid arthritis
Se Rim Choi (Seoul Nat’l Univ., Korea)

KO-027
Risk-benefit analysis of primary prophylaxis against Pneumocystis jirovecii pneumonia in patients with rheumatic diseases receiving rituximab
Jun Won Park (Seoul Nat’l Univ., Korea)

14:30-15:30 | [Meet the Mentor] | Conference Room 209A
Meet the Mentor 2

Facilitator: Jason Jungsik Song (Yonsei Univ., Korea)

14:30-15:30 | [Meet the Mentor] | Conference Room 209B
Meet the Mentor 3

Facilitator: Jason Jung Sik Song (Yonsei Univ., Korea)

14:30-15:30 | [Meet the Mentor] | Conference Room 209B
Meet the Mentor 3

Facilitator: Jason Jung Sik Song (Yonsei Univ., Korea)

14:30-15:30 | [Meet the Mentor] | Conference Room 209B
Meet the Mentor 3

Facilitator: Jason Jung Sik Song (Yonsei Univ., Korea)
The treatment effect of STING inhibitor (ISD-017) on lupus phenotypes in the Fcgr2b-deficient mice

Greater social vulnerability associated with greater glucocorticoid use in patients with SLE

Genetic contributions to neuropsychiatric systemic lupus erythematosus

Multiple molecular biomarkers that predict response to treatment in lupus nephritis

A spatially-resolved single cell resolution atlas of pediatric lupus nephritis uncovers complex interactions between stromal and infiltrating immune cells.

Urinary neutrophil gelatinase-associated lipocalin (NGAL) as a mediator of the association between particulate matter exposure and disease activity in systemic lupus erythematosus

STING/TMEM173 mutation in systemic lupus erythematosus

Nrp12 deficiency mice present severer lupus nephritis in lupus prone model and pristane-induced lupus like model

Proteomic analysis of cutaneous lupus erythematosus and dermatomyositis dermal infiltrate reveals differentially expressed canonical pathways

Mitochondria promotes autoimmune plasmablasts generation in lupus

Loss-of-function NADPH oxidase variants promote lupus pathogenesis by modulating B cell-intrinsic TLR signals

The treatment effect of STING inhibitor (ISD-017) on lupus phenotypes in the Fcgr2b-deficient mice

A spatially-resolved single cell resolution atlas of pediatric lupus nephritis uncovers complex interactions between stromal and infiltrating immune cells.

Urinary neutrophil gelatinase-associated lipocalin (NGAL) as a mediator of the association between particulate matter exposure and disease activity in systemic lupus erythematosus

Sphingolipids are potential diagnostic biomarkers for Korean patients with systemic lupus erythematosus

Multiple molecular biomarkers that predict response to treatment in lupus nephritis

Metabolomic analysis for the unique profile and novel biomarkers of neuropsychiatric systemic lupus erythematosus

Utility of autoantibody against an UCH-L1 epitope as a serum diagnostic marker for neuropsychiatric systemic lupus erythematosus

The correlation between interleukin-6 (IL-6) and the development of systemic lupus erythematosus (SLE) in Universiti Sains Malaysia (USM)

The correlation between interleukin-6 (IL-6) and the development of systemic lupus erythematosus (SLE) in Universiti Sains Malaysia (USM)

Elevated expression of sa_circ_0000479 in neutrophils correlates with features of systemic lupus erythematosus

Genetic fine mapping of independent variants in MHC region associated with predisposition and clinical feature of systemic lupus erythematosus in Han Chinese population

Elevated expression of sa_circ_0000479 in neutrophils correlates with features of systemic lupus erythematosus

Genetic contributions to neuropsychiatric systemic lupus erythematosus

Impaired function of neutrophil cytotoxic factor 2 (NCF2) may participates in lupus from multiple pathways

Association between TNFSPA38 gene polymorphism and serum BAFF Levels with disease activity in SLE patients
**Conference Room 205A**

**14:30-15:30**

**[Short Oral Presentation]**

**SLE Outcomes and Prognosis**

**Chair**

Seung Min Jung (The Catholic Univ. of Korea, Korea)

**LSO-058**


Young Bin Jin (Yangyang Univ., Korea)

**LSO-059**

Systemic lupus erythematosus (SLE) patients in Auckland: Epidemiology and attainment of Lupus Low Disease Activity State (LLODAS)

Nabea Heather (Wellbeing-Oceania, New Zealand)

**LSO-060**

Self-efficacy is associated with a lower probability of damage accrual in patients with systemic lupus erythematosus.

Manuel Ugarte-gil (Universidad Cientifica del Sur, Peru)

**LSO-061**

Withdrawn

**LSO-062**

Worse outcomes linked to ethnicity for the early treatment of refractory SLE: Results from the BILAG-Br

Ian Bruce (The Univ. of Manchester, UK)

**LSO-063**

Prediction of mortality using clusters based on clinical and lab parameters: Data from 2072 patients from INSPIRE cohort

Chengappa Kavadiachanda (JIMPER, India)

**LSO-104**

Impact of time to remission, flares and exposure to immunosuppressives on the development of advanced chronic kidney disease (stage iv or worse) in lupus nephritis

Drina Godman (Univ. of Toronto, Canada)

**Conference Room 205B**

**14:30-15:30**

**[Short Oral Presentation]**

**SLE Treatment 1**

**Chair**

Su-Jin Moon (The Catholic Univ. of Korea, Korea)

**LSO-064**

Disease-modifying effect and long-term safety data of belimumab in patients with SLE: A single centre retrospective analysis

Takahiro Nakai (St. Luke’s Int’l Hosp., Japan)

**LSO-065**

Belimumab in combination with antimalarial agents prevent renal flares in patients with systemic lupus erythematosus and moderate-to-high extra-renal activity: Results from four randomised clinical trials

Alvaro Gomez (Karolinska Institutet, Sweden)

**LSO-066**

Spanish national registry of belimumab in patients with systemic lupus erythematosus

Vicente Aldasoro (Hosp. Universitario de Navarra, Spain)

**LSO-067**

Withdrawn

**LSO-068**

Association between organ-specific safety of estrogens in lupus erythematosus national assessment-systemic lupus erythematosus (SLE) disease activity index (SELENA-SLEDAI) response to belimumab and SF-36v2 and FACIT-Fatigue scores in patients with SLE

Wen Hung Chen (GSK, UK)

**LSO-069**

Satisfaction and effectiveness of switching from intravenous to subcutaneous belimumab treatment in daily clinical practice

Bastina Frede-Sosa (Hosp Clinic de Barcelona, Spain)

**LSO-105**

D-ALW nanoparticles ameliorate lupus nephritis in MRL/lpr mice

Yumei Xia (The Second Affiliated Hosp of Xiamen Jiaotong Univ., China)
15:30-16:30 [Free Paper Session 5] 
Grand Ballroom 104

**Rheumatoid Arthritis – Clinical Research 1**

**Chairs**
- Bin Yoo (Univ. of Ulsan, Korea)
- Jinseok Kim (Jeju Nat’l Univ., Korea)

**KO-029** Identification of a novel salivary diagnostic biomarker in rheumatoid arthritis
Mi Song Kim (Kyung Hee Univ., Korea)

**KO-031** Risk of acute myocardial infarction and stroke associated with anti-rheumatic drugs in patients with rheumatoid arthritis: A nationwide population-based study
Soo Min Ahn (Univ. of Ulsan, Korea)

**KO-032** Are disease-modifying anti-rheumatic drugs for rheumatoid arthritis associated with a lower risk of dementia? A systematic review with meta-analysis
Wenhui Xie (Peking Univ. First Hosp., China)

**KO-033** New-onset atrial fibrillation in seropositive rheumatoid arthritis: Association with disease-modifying anti-rheumatic drugs treatment
Sung Soo Ahn (Yonsei Univ., Korea)

**KO-034** Effect of rheumatoid arthritis on total knee arthroplasty

**KO-030** Salivary microbiome: As a diagnostic biomarker of seronegative rheumatoid arthritis
Hyesu Jo (Kyung Hee Univ., Korea)

15:30-17:00 [Symposium] 
Grand Ballroom 105

**Medical Humanities Program**

**Chairs**
- Sang-Hyon Kim (Kumsung Univ., Korea)
- Choong-Ki Lee (Kumsung Univ., Korea)

**KCR**

**15:30-16:30** Prevention is the best solution to medical disputes
Seung-Jae Hong (Kyung Hee Univ., Korea)

**16:30-17:00** Changes in the medical environment and ethics according to changes in Korea’s population
Hyunjung Won (Kumsung Univ., Korea)

16:30-17:30 [Free Paper Session 6] 
Grand Ballroom 104

**Rheumatoid Arthritis – Clinical Research 2**

**Chairs**
- Gwan Gyu Song (Korea Univ., Korea)
- Ki-Jo Kim (The Catholic Univ. of Korea, Korea)

**KO-035** Clinical characteristics and treatment outcomes of patients with difficult-to-treat rheumatoid arthritis: From the KOBIO registry
Hyoun-Ah Kim (Ajou Univ., Korea)

**KO-036** Identifying HLA-DRB1 haplotypes that predict better response to abatacept than to TNF inhibitors in patients with rheumatoid arthritis
Soojin Cha (Hanyang Univ., Korea)

**KO-066** Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: A post-hoc analysis of a randomised phase III trial
Hee Jin Seo (Yonsei Univ., Korea)

**KO-037** Effect of JAK1 inhibition on erosion repair in rheumatoid arthritis: A pilot HR-pQCT study

**KO-067** Real-world utilisation and switching between Janus kinase inhibitors in patients with rheumatoid arthritis in the Australian OPAL dataset
Young in Eom (Kyoto Univ., Japan)

17:00-18:30 [Concurrent Session 7] 
Auditorium

**Pregnancy and Reproductive Issues**

**Chairs**
- Angela Tincani (ASST-Spedali Civili and Univ. of Brescia, Italy)
- Jisoo Lee (Ewha Womans Univ., Korea)

**17:00-17:20** Use of SLE therapies in the pre-conceptual and pregnant SLE patient
Ian Bruce (The Univ. of Manchester, UK)

**17:20-17:40** Will my baby be healthy? The long term outcome of children from patients with SLE
Angela Tincani (ASST-Spedali Civili and Univ. of Brescia, Italy)

**17:40-18:00** Burden of SLE on women of childbearing age
Jisoo Lee (Ewha Womans Univ., Korea)

**LD-025** Increasing pre-eclampsia knowledge and higher prevalence of aspirin use in SLE with a specific educational tool: Interim analyses of a randomized controlled trial
Jo-Yong Lee (Esther) (Research Institute of McGill Univ. Health Centre, Canada)

**LD-026** Hydroxychloroquine use in pregnant women with systemic lupus erythematosus and major congenital malformations in the offspring
Viet Nguyen Nguyen (Karolinska Institute, Sweden)

**LD-027** COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus
Isaana Perakos (Karolinska Institute, Sweden)
### Concurrent Session 8

**Omnis and Breakthrough Technology**

**Grand Ballroom 101**

**Chairs**

Peter E. Lipsky (AMPEL, BioSolutions, USA)

Kwangwoo Kim (Kyung Hee Univ., Korea)

#### 17:00-17:20

**Lupus autoimmunity and Epstein-Barr virus informs other idiopathic diseases**

John Harley (Cincinnati Education and Research for Veterans Foundation, USA)

#### 17:20-17:40

**New insights into SLE from machine learning of transcriptomic data**

Peter E. Lipsky (AMPEL, BioSolutions, USA)

Betty Diamond (The Feinstein Institute for Medical Research, USA)

#### 17:40-18:00

**Neuromaging and single cell RNAseq**

Peter E. Lipsky (AMPEL, BioSolutions, USA)

**Functional dissection of dysregulated enhancers influencing SLE critical gene expression**

Guojun Hou (Shanghai Jiao Tong Univ., China)

**Longitudinal single-cell transcriptomic analysis of peripheral blood in lupus nephritis reveals different immune cell gene signatures depending on treatment response**

Woo-Joong Kim (KUST, Korea)

**Functional characterization of 2p22.3 locus identifies PARP-1 as an allele-specific interactor at rs13385731 which mechanistically regulates rasgrp3 expression in contributing SLE susceptibility**

Swapan Nath (Oklahoma Medical Research Foundation, USA)

### Alliance Session 4

**Grants and Funding for SLE Research**

**Grand Ballroom 102**

**Chairs**

George Tsokos (Harvard Medical School, USA)

Joe Craft (Yale Univ., USA)

#### 17:00-17:30

**Grants and funding-National Institute of Arthritis and Musculoskeletal and Skin Diseases**

Lindsey Crossley (Nat’I Institute of Health, USA)

**Grants and funding-Lupus Research Alliance**

Teodora Stawski (Lupus Research Alliance, USA)

#### 17:30-18:00

**Panel Discussion**

### Conroduction Session 8

**Omnis and Breakthrough Technology**

**Grand Ballroom 101**

**Chairs**

Peter E. Lipsky (AMPEL, BioSolutions, USA)

Kwangwoo Kim (Kyung Hee Univ., Korea)

#### 17:00-17:20

**Lupus autoimmunity and Epstein-Barr virus informs other idiopathic diseases**

John Harley (Cincinnati Education and Research for Veterans Foundation, USA)

#### 17:20-17:40

**New insights into SLE from machine learning of transcriptomic data**

Peter E. Lipsky (AMPEL, BioSolutions, USA)

Betty Diamond (The Feinstein Institute for Medical Research, USA)

#### 17:40-18:00

**Neuromaging and single cell RNAseq**

Peter E. Lipsky (AMPEL, BioSolutions, USA)

**Functional dissection of dysregulated enhancers influencing SLE critical gene expression**

Guojun Hou (Shanghai Jiao Tong Univ., China)

**Longitudinal single-cell transcriptomic analysis of peripheral blood in lupus nephritis reveals different immune cell gene signatures depending on treatment response**

Woo-Joong Kim (KUST, Korea)

**Functional characterization of 2p22.3 locus identifies PARP-1 as an allele-specific interactor at rs13385731 which mechanistically regulates rasgrp3 expression in contributing SLE susceptibility**

Swapan Nath (Oklahoma Medical Research Foundation, USA)

### Alliance Session 4

**Grants and Funding for SLE Research**

**Grand Ballroom 102**

**Chairs**

George Tsokos (Harvard Medical School, USA)

Joe Craft (Yale Univ., USA)

#### 17:00-17:30

**Grants and funding-National Institute of Arthritis and Musculoskeletal and Skin Diseases**

Lindsey Crossley (Nat’I Institute of Health, USA)

**Grants and funding-Lupus Research Alliance**

Teodora Stawski (Lupus Research Alliance, USA)

#### 17:30-18:00

**Panel Discussion**

### Patient Session 2

**Living and Coping with Lupus**

**Room 205A+B**

**Chairs**

Seung Chool Shim (Chungnam Nat’I Univ., Korea)

So-Young Bang (Hanyang Univ., Korea)

#### 17:00-17:20

**Living with lupus**

Jin Hye Kim (Korea Lupus Support Group, Korea)

**Coping with lupus**

Seonghun Park (Daegeu Catholic Univ., Korea)

#### 17:40-17:50

**KSSR introduction**

Seung Chool Shim (Chungnam Nat’I Univ., Korea)

**Korea Lupus Support Group introduction**

Jin Hye Kim (Korea Lupus Support Group, Korea)

#### 18:00-18:20

**Discussion Forum**

### Social Program

**Gala Dinner**

**InterContinental Seoul COEX Harmony Ballroom**

**Chairs**

Seung Chool Shim (Chungnam Nat’I Univ., Korea)

So-Young Bang (Hanyang Univ., Korea)

**LO-028**

Functional dissection of dysregulated enhancers influencing SLE critical gene expression

Guojun Hou (Shanghai Jiao Tong Univ., China)

**LO-029**

Longitudinal single-cell transcriptomic analysis of peripheral blood in lupus nephritis reveals different immune cell gene signatures depending on treatment response

Woo-Joong Kim (KUST, Korea)

**LO-030**

Functional characterization of 2p22.3 locus identifies PARP-1 as an allele-specific interactor at rs13385731 which mechanistically regulates rasgrp3 expression in contributing SLE susceptibility

Swapan Nath (Oklahoma Medical Research Foundation, USA)
DAY 04
Program
May 20 (Sat)
The Session with the icon provides English-Korean translation.

08:00-09:00
**Breakfast Symposium 9 - Amgen**

**Building Strong Bones for Life: Strategies for Long-Term Osteoporosis Treatment**

**Chair**
Jung Soo Song (Chung-Ang Univ., Korea)

08:00-08:40
Building strong bones for life: Strategies for long-term osteoporosis treatment
Kichul Shin (Seoul Nat’l Univ., Korea)

09:00-09:45
**Evolution of therapeutic B cell depletion in lupus**
Stephen Oliver (Novartis AG, Switzerland)

09:45-10:00
**Q&A**

09:00-09:45
**Lupus Nephritis**

**Facilitator**
Seokchan Hong (Univ. of Lins, Korea)

09:15-10:00
**Pulmonary Hypertension**

**Facilitator**
Hyun-Sook Kim (Soonchunhyang Univ., Korea)

09:15-09:45
**Pulmonary hypertension**
Mandana Nikpour (The Univ. of Melbourne, Australia)

09:45-10:00
**Q&A**

09:00-09:40
**Meet the Professor 8**

**Lupus Nephritis**

**Facilitator**
Eun Young Lee (Seoul Nat’l Univ., Korea)

09:15-10:00
**Meet the Professor 9**

**Pulmonary Hypertension**

**Facilitator**
Eun Young Lee (Seoul Nat’l Univ., Korea)

09:15-09:45
**Musculoskeletal Diseases in SLE**

**Facilitator**
Eun Young Lee (Seoul Nat’l Univ., Korea)

09:15-10:00
**Musculoskeletal Diseases in SLE**

**Facilitator**
Eun Young Lee (Seoul Nat’l Univ., Korea)

08:00-09:00
**Meet the Professor 7**

**Musculoskeletal Diseases in SLE**

**Facilitator**
Eun Young Lee (Seoul Nat’l Univ., Korea)

09:00-09:40
**Evolution of therapeutic B cell depletion in lupus**
Stephen Oliver (Novartis AG, Switzerland)

09:45-10:00
**Q&A**

10:30-12:00
**Plenary Session 5**

**Clinical Challenges: Diagnosis and Outcome Measures**

**Chairs**
Andrea Doria (Univ. of Padua, Italy)
Young Ho Lee (Korea Univ., Korea)

10:30-11:00
**Diagnostic challenges in SLE**
David Tansey (Univ. College London, UK)

11:00-11:30
**Challenges in measuring clinical outcomes in SLE**
Eric Morand (Monash Univ., Australia)

LO-031
**Working towards a core minimal dataset for systemic lupus erythematosus studies**
Ian Bruce (The Univ. of Manchester, UK)

LO-032
**LO-032**
**Increased IFITM gene-signatures in age-associated B and plasma cells define non-response to mycophenolate mofetil in systemic lupus erythematosus**
Daniele Toro-domínguez (Centre for Genomics and Oncological Research, Spain)

LO-033
**Towards a novel clinical outcome assessment for systemic lupus erythematosus trials - first outcomes of an international consensus process**
Eric Morand (Monash Univ., Australia)

08:00-09:00
**Breakfast Symposium 10 - Lilly**

**Improving Outcomes for the Patients with AxSpA**

**Chair**
Yong-Beom Park (Yonsei Univ., Korea)

08:00-08:40
Exploring the impact of ixekizumab in treatment for biologics-naive patients with Spondyloarthritis
Yun-Hong Dohn (Sungkyunkwan Univ., Seoul, Korea)

09:15-10:00
**Musculoskeletal Diseases in SLE**

**Facilitator**
Eun Young Lee (Seoul Nat’l Univ., Korea)

08:00-09:00
**Breakfast Symposium 11 - Lilly**

**Zetomipzomib: A Novel Approach in Lupus Nephritis**

**Chair**
Eric Morand (Monash Univ., Australia)

08:00-08:40
Selective immunoproteasome inhibition with Zetomipzomib for the treatment of lupus nephritis
Richard Furst (Northwell Health, USA)

09:00-09:40
**Improving Outcomes for the Patients with AxSpA**

**Chair**
Yong-Beom Park (Yonsei Univ., Korea)

08:00-08:40
Exploring the impact of ixekizumab in treatment for biologics-naive patients with Spondyloarthritis
Yun-Hong Dohn (Sungkyunkwan Univ., Seoul, Korea)

09:15-10:00
**Musculoskeletal Diseases in SLE**

**Facilitator**
Eun Young Lee (Seoul Nat’l Univ., Korea)

08:00-09:00
**Breakfast Symposium 12 - Kazar Life Science**

**Zetomipzomib: A Novel Approach in Lupus Nephritis**

**Chair**
Eric Morand (Monash Univ., Australia)

08:00-08:40
Selective immunoproteasome inhibition with Zetomipzomib for the treatment of lupus nephritis
Richard Furst (Northwell Health, USA)

09:00-09:40
**Evolution of therapeutic B cell depletion in lupus**
Stephen Oliver (Novartis AG, Switzerland)

09:45-10:00
**Q&A**

09:00-09:40
**Evolution of therapeutic B cell depletion in lupus**
Stephen Oliver (Novartis AG, Switzerland)

09:45-10:00
**Q&A**

10:30-12:00
**Plenary Session 5**

**Clinical Challenges: Diagnosis and Outcome Measures**

**Chairs**
Andrea Doria (Univ. of Padua, Italy)
Young Ho Lee (Korea Univ., Korea)

10:30-11:00
**Diagnostic challenges in SLE**
David Tansey (Univ. College London, UK)

11:00-11:30
**Challenges in measuring clinical outcomes in SLE**
Eric Morand (Monash Univ., Australia)

LO-031
**Working towards a core minimal dataset for systemic lupus erythematosus studies**
Ian Bruce (The Univ. of Manchester, UK)

LO-032
**Increased IFITM gene-signatures in age-associated B and plasma cells define non-response to mycophenolate mofetil in systemic lupus erythematosus**
Daniele Toro-domínguez (Centre for Genomics and Oncological Research, Spain)

LO-033
**Towards a novel clinical outcome assessment for systemic lupus erythematosus trials - first outcomes of an international consensus process**
Eric Morand (Monash Univ., Australia)
**DA Y 4. - May 20 (Sat)**

**The Session with the icon provides English-Korean translation**

**Grand Ballroom 104**

### 10:30-12:00 [International Symposium 6]

**The Evolution of Fibromyalgia, its Concepts, and Treatment**

**Chairs**

- Geun-Tae Kim (Koan Uni., Korea)
- Hyung-In Yang (Kyeong Hae Uni., Korea)

**10:30-11:00**

- Fibromyalgia, how stress becomes neuropathic pain
  - Manuel Martinez-Lean (Istt Institute of Cardiology Mexico, Mexico)

**11:00-11:30**

- What role for neuroinflammation and small fiber neuropathy in fibromyalgia?
  - Jae-young Oh (Konkuk Univ., Korea)

**11:30-12:00**

- New insights into the pathophysiology of fibromyalgia
  - Jeung-Hwang (Gungjuunhu Uni., Korea)

---

### 10:30-12:00 [Free Paper Session 7]

**Basic and Translational Research**

**Chairs**

- Saung-Ki Kwak (The Catholic Univ., of Korea)
- Yong-Wook Park (Chonnam Natl. Univ., Korea)

**KO-038**

- A novel therapeutic target for arthritis pain
  - Kevin Lee (Uni. of Melbourne, Australia)

**KO-039**

- AMP-activated protein kinase modulates the migration of fibroblast-like synoviocytes via SLC11A1-NOX4-ROS signaling in patients with rheumatoid arthritis
  - Hee-Bum Lee (Chungnam Nat’l Uni., Korea)

**KO-040**

- Exosome-based delivery of super-repressor IκB ameliorates inflammation in rheumatoid arthritis
  - Hae-in Lee (Chonnam Nat’l Uni., Korea)

**KO-041**

- Low-dose radiotherapy attenuates experimental autoimmune arthritis by inducing lymphocyte apoptosis
  - Bo-Gyu Kim (Gyeongsang Nat’l Uni., Korea)

**KO-042**

- Identification of three novel susceptibility loci for rheumatoid arthritis in a large-scale genome-wide association study in the Korean population
  - Ayeong Kwon (Kyung Hee Univ., Korea)

**KO-043**

- The effect of treatment with TIP-1 and MIF-2 through blocking TLRs in adult-onset Still’s disease animal model
  - In-Myung Ahn (Apin Uni., Korea)

**KO-046**

- Multi-tissue adaptive regeneration of musculoskeletal tissues by novel human musculoskeletal stem cells induced from hPSCs
  - Sung-Ji Lee (Spayunggu Nat’l Uni., Korea)

---

**Grand Ballroom 103**

### 10:30-12:00 [International Symposium 6]

**The Evolution of Fibromyalgia, its Concepts, and Treatment**

**Chairs**

- Geun-Tae Kim (Koan Uni., Korea)
- Hyung-In Yang (Kyeong Hae Uni., Korea)

**10:30-11:00**

- Fibromyalgia, how stress becomes neuropathic pain
  - Manuel Martinez-Lean (Istt Institute of Cardiology Mexico, Mexico)

**11:00-11:30**

- What role for neuroinflammation and small fiber neuropathy in fibromyalgia?
  - Jae-young Oh (Konkuk Univ., Korea)

**11:30-12:00**

- New insights into the pathophysiology of fibromyalgia
  - Jeung-Hwang (Gungjuunhu Uni., Korea)

---

### 10:30-12:00 [Free Paper Session 8]

**Miscellaneous rheumatic disease and inflammatory disease**

**Chairs**

- Won Park (Yta Uni., Korea)
- Seong-Ho Kim (Yta Uni., Korea)

**KO-044**

- Use of Infliximab in 90 children with Kawasaki Disease
  : Experience from a tertiary care centre in North-West India
  - Prabal Barman (Post Graduate Institute of Medical Education and Research Chandigarh, India)

**KO-045**

- A comparative study of pattern of paediatric uveitis in different subtypes of juvenile idiopathic arthritis
  : Experience from a tertiary care centre in North-West India
  - Prabal Barman (Post Graduate Institute of Medical Education and Research Chandigarh, India)

**KO-046**

- Educational project for rheumatology through a self-paced online learning platform
  : 6 year update of applied rheumatology on the go
  - Lia Tabacco (St Luke’s Medical Center, Philippines)

**KO-047**

- Prediction of osteoporosis in patients with rheumatoid arthritis using machine learning
  - Ki Won Moon (Kangwon Nat’l Uni., Korea)

**KO-048**

- Artificial intelligence for detection of inflammatory sacroiliitis in magnetic resonance imaging in patients with axial spondyloarthritis
  - Saulees Lee (Sungchuncheon Uni., Korea)

**KO-049**

- Clinical factors associated with pneumocystis pneumonia despite its primary prophylaxis
  : A case-control study
  - Ju Yeon Kim (Seoul Nat’l Uni., Korea)

**KO-050**

- Germium telluride-polyvinylpyrrolidone nanosheets ameliorate inflammatory response in inflammatory disease model
  - Jeun Han (Yongju Uni., Korea)

---

**Grand Ballroom 101+102**

### 12:00-13:00 [Luncheon Symposium 9 - Janssen]

**Considerations in Patients with Systemic Lupus Erythematosus: Pulmonary Arterial Hypertension**

**Chair**

- Jae-Bum Jun (Hanyang Uni., Korea)

**12:00-12:40**

- Identification of risk factors of pulmonary arterial hypertension in patients with SLE & updates of 2022 ESC/ERS PH Guidelines
  - Yeon-Ah Lee (Yonga His Lh, Korea)

---

**Grand Ballroom 103**

### 12:00-13:00 [Luncheon Symposium 10 - Pfizer]

**Role of the Tofacitinib in Rheumatology**

**Chair**

- Eun Bong Lee (Sexu Nat’l Uni., Korea)

**12:00-12:40**

- Review the clinical trial data for XELJANZ across RA, PsA, AS
  - Uta Kiltz (Rheumazentrum Ruhrgebiet, Germany)
The Session with the icon provides English-Korean translation.
통역 아이콘의 표시된 세션은 한-영 동시통역을 제공합니다.

12:00-13:00 [Luncheon Symposium 11 - Celltrion]
The First High-concentration Adalimumab Biosimilar
Grand Ballroom 104

Chair
Geun-Tae Kim (Konkuk Univ., Korea)

12:00-13:00
CT-P17 (Yuflyma) clinical trial review based on efficacy and safety
Hyon-Suk Kim (Sohnhunyang Univ., Korea)

12:00-13:00 [Luncheon Symposium 12 - Otsuka]
Practical approach of G1 in Rheumatology
Grand Ballroom 105

Chair
Jun-Ki Min (The Catholic Univ. of Korea, Korea)

12:00-12:40
Practical approach of Mucosta SR in rheumatology: Optimal GI medication & additional benefit
Hyon-Suk Kim (Sohnhunyang Univ., Korea)

13:00-14:30 [Concurrent Session 9]
Targeting Organs
Auditorium

Chairs
John Esdaile (Arthritis Research Canada, The Univ. of British Columbia, Canada)
Hae-Rim Kim (Konkuk Univ., Korea)

13:00-13:20
The skin manifestation of lupus: From genotype to phenotype
Yong Cui (China-Japan Friendship Hosp., China)

13:20-13:40
Decoding neurocognitive dysfunction in SLE with advanced functional neuroimaging
Anselm Mak (Natl. Univ. of Singapore, Singapore)

13:40-14:00
Performance of combining eye sign and functional magnetic resonance imaging in diagnosing patients with neuropsychiatric systemic lupus erythematosus
Jerry Lin-Hong Shi (The Chinese Univ. of Hong Kong, China)

13:40-14:00
The effects and molecular mechanisms of TRAF5 on pulmonary artery endothelial cells in patients with systemic lupus erythematosus associated pulmonary arterial hypertension
Xiaoyue Deng (Peking Union Medical College Hosp., China)

13:40-14:00
Inhibition of transcobalamin2 overexpression ameliorated renal injury in systemic lupus erythema via reducing pathogenic Tfh and B cell infiltration
Baoyi Liu (China-Japan Friendship Hosp., China)

13:00-14:30 [Concurrent Session 10]
Immune Cells
Grand Ballroom 101

Chairs
Nan Shen (Jiao Tong Univ., China)
Yoontae Lee (Pohang Univ. of Science and Technology, Korea)

13:00-13:20
Myeloid-derived suppressor cells in SLE
Seungki Yeo (The Catholic Univ. of Korea, Korea)

13:20-13:40
Effector B cell responses in SLE
Ignacio Sanz (Emory Univ., USA)

13:40-14:00
Role neutrophils in SLE pathogenesis
Marinae Kaplan (Ref Institute of Arthritis and Musculoskeletal and Skin Disorders, USA)

LO-038
ETV5 promotes follicular helper T cell differentiation and lupus pathogenesis
Jiro Park (POSTECH, Korea)

LO-039
Vitamin D3 mitigates immune system alterations caused by activation of myeloid dendritic cells in SLE
Mingfeng Li (The Third Affiliated Hosp. of Guangzhou Medical Univ., China)

LO-037
Altered peripheral non-classic monocyte and NKT counts and CD8+ TCR diversity of systemic lupus erythematosus identified via integrated high-dimensional flow cytometry, CyTOF, metabolic profiling and TCR clonality analyses
Anselm Mak (Natl. Univ. of Singapore, Singapore)

13:00-14:30 [Concurrent Session 11]
Antiphospholipid Syndrome
Grand Ballroom 102

Chairs
Munther Khamashta (Kings College London, UK)
Eun Young Lee (Seoul Nat’l Univ., Korea)

13:00-13:20
Antiphospholipid syndrome: 40 years on and counting!
Munther Khamashta (Kings College London, UK)

13:20-13:40
Management of obstetric antiphospholipid syndrome
Michelle Petri (Johns Hopkins Univ., USA)

13:40-14:00
Catastrophic antiphospholipid syndrome
Nathalee Costedoat-Chalumeau (Cochin Hosp., France)

LO-040
The efficacy of tacrolimus in antiphospholipid antibodies associated thrombocytopenia: A prospective cohort study
Yu Sh (Peking Union Medical College, China)

LO-041
Severe thrombocytopenia is associated with adverse pregnancy outcomes in obstetric antiphospholipid syndrome
Chun Li (Peking Univ. People’s Hosp., China)
13:00-14:30 [International Symposium 7] Grand Ballroom 103

Chondrocyte Metabolism and Osteoarthritis

Chairs
Hyun Ah Kim (Hallym Univ., Korea)
Gunwoo Kim (Daegu Fatima Hosp., Korea)

13:00-13:30 The role of metabolism in the pathogenesis of osteoarthritis
Ali Mobasheri (Univ. of Oulu, Finland)

13:30-14:00 Chondrocyte metabolism, ROS and inflammation
Seungwoo Han (Kyungpook Nat’l Univ., Korea)

KIO-011 Enhancing oxidative phosphorylation through inhibition of PDK2 alleviates cartilage degradation in a surgical model of osteoarthritis
Jin Han (Kyungpook Nat’l Univ., Korea)

KIO-012 Genetic knockout of CKCR7 in articular chondrocyte has potential protective effect on advanced knee osteoarthritis in mouse model
Jungyong Park (Dong-A Univ., Korea)

KIO-013 Effect of intra-articular injection of stigmastanol loaded nanoparticles in osteoarthritis rat model
Jae Hyun Jung (Korea Univ., Korea)

KO-051 Enhancing oxidative phosphorylation through inhibition of PDK2 alleviates cartilage degradation in a surgical model of osteoarthritis
Jin Han (Kyungpook Nat’l Univ., Korea)

KO-052 Genetic knockout of CKCR7 in articular chondrocyte has potential protective effect on advanced knee osteoarthritis in mouse model
Jungyong Park (Dong-A Univ., Korea)

KO-053 Effect of intra-articular injection of stigmastanol loaded nanoparticles in osteoarthritis rat model
Jae Hyun Jung (Korea Univ., Korea)

KO-054 Longitudinal analysis and treatment response of pathogenic B cells in Sjögren’s syndrome
Joanne Reed (Westmead Institute for Medical Research, Australia)

KO-055 Binding of CXCL13 with heparan sulfate of syndecan-1 plays an important role in pathogenesis of Sjögren’s syndrome
Jae Lee (Daegu Fatima Hosp., Korea)

KO-056 High dimensional cartography of lymphocytes using single-cell mass cytometry differentiates systemic lupus erythematosus and primary Sjögren’s syndrome
Franziska Szelinski (Charité, Germany)

KO-057 Risk of incident psoriasis in patients with systemic sclerosis: A nationwide cohort study
Oh Chan Kwon (Inje Univ., Korea)

KO-058 All-cause mortality and risk factors for death in a large multi-center prospective registry cohort of idiopathic inflammatory myositis in China
Yang Peng (Peking Union Medical College Hosp., China)

KO-059 Serial imaging changes in skeletal muscle composition and their association with clinical outcomes in idiopathic inflammatory myopathies (IM)
Maniketa Gorajhaly (Jawaharlal Institute of Postgraduate Medical Education and Research, India)

KO-060 The expression and regulation of Nox4 in damaged myoblasts in inflammatory myopathy
Hae Rim Kang (Seoul Nat’l Univ., Korea)

KO-061 The expression and regulation of Nox4 in damaged myoblasts in inflammatory myopathy
Hae Rim Kang (Seoul Nat’l Univ., Korea)

KO-062 The expression and regulation of Nox4 in damaged myoblasts in inflammatory myopathy
Hae Rim Kang (Seoul Nat’l Univ., Korea)

KO-063 The expression and regulation of Nox4 in damaged myoblasts in inflammatory myopathy
Hae Rim Kang (Seoul Nat’l Univ., Korea)

KO-064 The expression and regulation of Nox4 in damaged myoblasts in inflammatory myopathy
Hae Rim Kang (Seoul Nat’l Univ., Korea)

KO-065 The expression and regulation of Nox4 in damaged myoblasts in inflammatory myopathy
Hae Rim Kang (Seoul Nat’l Univ., Korea)

KO-066 The expression and regulation of Nox4 in damaged myoblasts in inflammatory myopathy
Hae Rim Kang (Seoul Nat’l Univ., Korea)

KO-067 The expression and regulation of Nox4 in damaged myoblasts in inflammatory myopathy
Hae Rim Kang (Seoul Nat’l Univ., Korea)

KO-068 The expression and regulation of Nox4 in damaged myoblasts in inflammatory myopathy
Hae Rim Kang (Seoul Nat’l Univ., Korea)
**LUPUS & KCR 2023**
**DAY 4. - May 20 (Sat)**

**14:30-15:30**
**[Short Oral Presentation]**
**Conference Room 206 A+B**

**LUPUS**
**SLE Comorbidities**

**Chair**
Sang Youn Jung (Chonnam Nat’l Univ., Korea)

**LSO-070**
CHADS2-VASc score for prediction of ischemic stroke in patients with systemic lupus erythematosus without atrial fibrillation: RISK of risk scores in the era of artificial intelligence
We Yiun Hu (China Medical Univ Hosp., Taiwan)

**LSO-071**
Correlation of traditional and SLE related risk factors with carotid intima media thickness as early MACES predictor in SLE patients: A systematic review and meta-analysis
Sandra Suryawati (North Lombok Regional Hosp., Indonesia)

**LSO-073**
Improvements and challenges of systemic lupus erythematosus associated pulmonary arterial hypertension: A 10-year multicenter cohort study
Xingbei Dong (Peking Union Medical College Hosp., China)

**LSO-074**
All-cause mortality and the incidence of cancer in patients with moderate-to-severe SLE: Results from the British Isles Lupus Assessment Group Biologies Registry (BILAG-BR)
Ian Bruce (The Univ. of Manchester, UK)

**LSO-075**
Performance of conventional cardiovascular risk scores in identifying subclinical atherosclerosis in systemic lupus erythematosus
Gayatri Mis (Jawaharlal Institute of Postgraduate Medical Education and Research, India)

**LSO-076**
Risk factors associated with the development of cardiovascular events in a multiethnic Asian systemic lupus erythematosus cohort
Ho Kw Seow Hwee (Tan Tock Seng Hosp., Singapore)

**LSO-077**
Association of hypertension with higher chronicity index scores among patients with lupus nephritis
Peter Paulo Deleon (Univ. of Santo Tomas Hosp., Philippines)

**14:30-15:30**
**[Short Oral Presentation]**
**Auditorium Meeting Room A**

**LUPUS**
**SLE Precision Medicine**

**Chair**
So-Young Bang (Panyang Univ., Korea)

**LSO-076**
Understanding the genetic architecture of SLE from the perspective of associations from 14 other autoimmune diseases
Wending Yang (Univ. of Hong Kong, Hong Kong)

**LSO-077**
Identification of an interferon 5-gene signature score as a pharmacodynamic and potential predictive biomarker for deucravacitinib treatment in a phase 2 trial in patients with systemic lupus erythematosus
Chun Wu (Bristol Myers Squibb, USA)

**LSO-078**
Clinical characteristics and genetic variants in a large cohort of monogenic lupus patients: Emerging or fading frontiers?
Sukeyesun Al moyayi (King Faisal Specialist Hosp & Research Center, Saudi Arabia)

**LSO-079**
Dynamic changes of immune cells in systemic lupus erythematosus with nephritis using longitudinal peripheral blood single-cell RNA-seq
Seung-Jun Park (Asics Univ., Korea)

**LSO-080**
Machine-learning approach on lupus low disease activity prediction
Nick Fadner (Univ. of the Philippines, Philippines)

**LSO-081**
Genomic prediction model using machine learning techniques that can distinguish autoimmune diseases (RA or SLE) from healthy controls
Hyuk-Soon Lee (Panyang Univ., Korea)

**14:30-15:30**
**[Short Oral Presentation]**
**Conference Room 205A**

**LUPUS**
**SLE Pregnancy and Reproductive Health**

**Chair**
Sung Hae Chang (Soonchunhyang Univ., Korea)

**LSO-082**
Withdrawn

**LSO-083**
“Systemic lupus erythematosus Women with lupus nephritis in pregnancy: Therapeutic Challenge (SWITCH)”: The systemic lupus international collaborating clinics experience
Joo-Young (Esther) Lee (Research Institute of McGill Univ. Health Centre, Canada)

**LSO-084**
Pregnancy outcomes in patients with systemic lupus erythematosus (SLE), anti-phospholipid antibody syndrome (APL), scleroderma (SSc) and Rheumatoid arthritis (RA) at the Kenyatta national hospital, Nairobi, Kenya.
Paul Etau Ekwom (KNH, Kenya)

**LSO-085**
National patterns and factors associated with adverse pregnancy outcomes in women with systemic lupus erythematosus
Yu Seun Jung (Chung-Ang Univ., Korea)

**LSO-086**
Pregnancy outcomes in systemic lupus erythematosus: Data from a multiethnic, multinational latin american cohort
Guilherme Pira-Estal (Centro Regional de Enfermedades Autoinmunes y Reumáticas, Argentina)

**14:30-15:30**
**[Short Oral Presentation]**
**Conference Room 205 B**

**LUPUS**
**SLE Treatment 2**

**Chair**
Dong-Jin Park (Chonnam Nat’l Univ., Korea)

**LSO-087**
Sub-optimal use of anti-malarial therapy for SLE in the Asia Pacific Region; Observations from the Asia Pacific lupus cohort
Rangiro Manaka-Kumar (Monash Univ., Australia)

**LSO-088**
Le-IL2 synthesis with belimumab in the treatment of systemic lupus erythematosus patients
Riding Peng (Peking Univ. People’s Hosp, China)

**LSO-089**
Effectiveness of belimumab in systemic lupus erythematosus patients of a multicenter Spanish cohort.
Irene Altabás-gonzález (Complejo Hospitalario universitario de Vigo, Spain)

**LSO-090**
A placebo-controlled phase 1 study in healthy adult volunteers of the safety, tolerability, pharmacokinetics, and pharmacodynamics of povetacicept, a potent dual BAFF/APRIL antagonist, for the treatment of systemic lupus erythematosus
Stacey Ullman (Alpine Immune Sciences, USA)

**LSO-091**
Study design of ENERGY: A phase 2/3 trial to assess the efficacy and safety of nipocalimab in warm autoimmune hemolytic anemia
Youngja Lee (Univ. of Santo Tomas, Philippines)

**LSO-092**
Safety, efficacy and pharmacodynamics of cenerimod in patients with systemic lupus erythematosus: Two randomised, double-blind phase 2 clinical trials
Sandra Navarra (Univ. of Hawaii, Honolulu, Hawaii)
14:30-15:30 [Short Oral Presentation]
Auditorium Meeting Room B

Miscellaneous Conditions Associated with SLE

Chair: Seonghoon Park (Daegu Catholic Univ., Korea)

LSO-093 Gut microbiota analysis in Korean patients with systemic lupus erythematosus
Ji-Won Kim (Aju Univ., Korea)

LSO-094 Analysis of microbiota in patients with systemic lupus erythematosus
Toshino Nari (Toho Univ., Japan)

LSO-095 Withdrawn

LSO-096 Analyzing the shared and specific genetic signals among 15 autoimmune diseases shed new light on the underlying causal genes and molecular mechanisms
Xiao Dang (The Univ. of Hong Kong, Hong Kong)

LSO-097 Captopril preventing blood brain barrier breach by Anti-Smith Antibody
Yoshiyuki Arima (Koseiho Univ., Japan)

LSO-108 Ambulatory blood pressure in patients with systemic lupus erythematosus
Borjadal Pfoegar-Chwarzen (Medical Univ. of Székesfehérvár, Poland)

LSO-109 Characteristics associated with poor COVID-19 outcomes in people with rheumatic disease: Data from one single center from China
Nahong Yoo (Pusan Univ., People’s Hosp., China)

LSO-072 Comparison of COVID-19 vaccination with Influenza vaccination in Korean patients with systemic lupus erythematosus: Perception, adverse events, and flares from the CIVIL study
Seonghoon Park (Daegu Catholic Univ., Korea)

15:30-17:00 [International Symposium 8]
Managing Spondyloarthritis: Where are We Now

Chairs: Seong R. Kwon (Inha Univ., Korea) Min-Chan Park (Pusan Univer., Korea)

15:30-16:00 ASAS health index and spondyloarthritis treatment
Utka Kitz (Rheumazentrum Ruhrgebiet, Germany)

16:00-16:30 The epidemiology and treatment of ankylosing spondylitis in Korea
Seong R. Kwon (Inha Univ., Korea)

KIO-014 Time-dependent csDMARDs use and inflammatory burden can predict cardiovascular risk in patients with ankylosing spondylitis: A population-based study
Jenny Lin-Hong Shu (The Chinese Univ. of Hong Kong, China)

KIO-015 Risk of cardiovascular disease associated with long-term use of non-steroidal anti-inflammatory drugs in ankylosing spondylitis
Ji-Won Kim (Daegu Catholic Univ., Korea)

15:30-17:00 [Workshop]
Editorial Committee Workshop

Chairs: Seong-Kyu Kim (Daegu Catholic Univ., Korea) Joong Kyong Ahn (Sungkyunkwan Univ., Korea)

15:30-16:00 How to write effective peer review comments
Yunhee Whang (Compec Inc., Korea)

16:00-16:30 Creating effective scientific figures for publication
Hyunjeo Kang (MEDAWT, Korea)

16:30 - 17:00 Appropriateness of study design in biomedical journal
Changsoo Kim (Yonsei Univ., Korea)

15:30-17:00 [Symposium]
Coding and Insurance Guideline in Rheumatic Disease

Chairs: Seung-Jae Hong (Kyung Hee Univ., Korea) Sung-Soo Kim (Univ. of Ulsan, Korea)

15:30-16:00 Functional responsibility of insurance and policy committee
Bong-Seog Kim (Innovative Drug Research Center, Boryung Co. LTD., Korea)

16:00 - 16:30 Practical tips from HIRA
Eunmi Koh (Sungkyunkwan Univ., Korea)

16:30 - 17:00 Rheumatic diseases and Korean version of International Classification of Diseases (ICD)-11
Bo Young Yoon (Inje Univ., Korea)
Short Oral Presentation
### May 18 (Thu) 14:30 – 15:30 Auditorium Meeting Room A

**SLE Etiology & Pathogenesis 1**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Yoontae Lee (Pohang Univ. of Science and Technology, Korea)</th>
</tr>
</thead>
</table>
| **LSO-001** | Modulating T-bet-promoted energy metabolism in pathogenic age/autoimmune-associated B cells ameliorates lupus autoimmunity  
Dai Dai (Shanghai Jiaotong Univ., China) |
| **LSO-002** | The transcriptional factor Pbx1 adjusts peripheral B cell homeostasis to constrain lupus autoimmunity  
Dai Dai (Shanghai Jiaotong Univ. School of Medicine, China) |
| **LSO-003** | Effects of progesterone-induced blocking factor 1 on the alleviation of lupus nephritis in MRL/lpr mice  
Young Eun Kim (Univ. of Ulsan, Korea) |
| **LSO-004** | cGAS deficiency enhances inflammasome activation in macrophages and inflammatory pathology in pristane-induced lupus  
Santisya Kumpanya (Center of Excellence in Systems Biology, Thailand) |
| **LSO-005** | Type I interferon affects Th23 cell differentiation participated in the pathogenesis of lupus nephritis  
Haqie Xu (Peking Union Medical College Hosp., China) |
| **LSO-006** | Targeting pathogenic auto-reactive VH4-34 B cells with a rationally developed and highly specific anti-VH4-34 antibody offers a new therapeutic approach for VH4-34 autoimmune disorders  
Jerome Boyd-Kirkup (Hummingbird Bioscience, Singapore) |
| **LSO-007** | TrimERIC oligonucleotides ameliorate disease in a mouse model of CLE-like inflammatory skin disease  
Mary Spear (Hudson Institute of Medical Research, Australia) |
| **LSO-008** | Decreased Natural Killer T-like Cells Correlated To Disease Activity In Systemic Lupus Erythematosus  
Yingni Li (Peking Univ. people’s Hosp., China) |

---

### May 18 (Thu) 14:30 – 15:30 Auditorium Meeting Room B

**Antiphospholipid Syndrome**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Hae-Rim Kim (Konkuk Univ., Korea)</th>
</tr>
</thead>
</table>
| **LSO-008** | Precipitating Factors Of Catastrophic Antiphospholipid Syndrome: The Role Of Anticoagulant Treatment In A Series Of 112 Patients  
Romain Stammerer (Cochin Hosp., France) |
| **LSO-009** | The impact of high-risk antiphospholipid antibodies profile on major organ damage progression in systemic lupus erythematosus: CSTAR multiple prospective cohort study.  
Yufang Ding (Peking Union Medical College Hosp., China) |
| **LSO-010** | Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibodies associated adverse pregnancy outcomes: a based on a 13-year longitudinal cohort study  
Ying Long (Peking Union Medical College Hosp., China) |
| **LSO-011** | Withdrawn |
| **LSO-012** | Withdrawn |
| **LSO-013** | Metabolomics analysis identifies biomarkers for APS and suggests potential new pathway for APS pathogenesis  
Yongjing Luo (Peking Univ. People’s Hosp., China) |

---

### May 18 (Thu) 14:30 – 15:30 Conference Room 206 A+B

**SLE Biomarkers 1**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Jason Jungskil Song (Yonsei Univ., Korea)</th>
</tr>
</thead>
</table>
| **LSO-014** | Clinico-pathological association of serum CD44 level in lupus nephritis patients  
Suan Yung (The Univ. of Hong Kong, Hong Kong) |
| **LSO-015** | Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 PAISLEY study  
Ian M. Catlett (Bristol Myers Squibb, USA) |
| **LSO-016** | Activated leukocyte cell adhesion molecule, hemopexin, and peroxiredoxin 6 as a potential urine biomarker for Korean patients with systemic lupus erythematosus  
Ji-Won Kim (Ajou Univ., Korea) |
| **LSO-017** | Anti-TCP1 antibody is the potential biomarker of systemic lupus erythematosus (SLE)  
Sang-Won Lee (Ajou Univ., Korea) |
| **LSO-018** | iC3b/C3 ratios more strongly correlate with SLE disease activity in African- Americans compared with Whites  
Alfred Kim (Washington Univ., USA) |
| **LSO-019** | The neutrophil-to-C3 ratio (NC3R) was an inflammatory marker in the assessment of lupus nephritis and ocular vessel density in systemic lupus erythematosus patients  
Shuilian Yu (The Second Affiliated Hosp. of Guangzhou Medical Univ., China) |
The effect of air pollutant exposure on disease activity of systemic lupus erythematosus: A prospective longitudinal study from Korea

Ji-Hyun Kang (Chonnam National Univ., Korea)

LSO-019

Intervention to improve medication adherence among patients with systemic lupus erythematosus

Ke Sun (Duke Univ., USA)

LSO-020

Epidemiology and survival of SLE in the last decade: data from a large population-based study in northeastern Italy

Margherita Zen (Univ. of Padua, Italy)

LSO-021

Adverse childhood experiences and disease activity: The role of trauma in the black women’s experiences living with lupus (bwell) study

Kyla W. Chung (Tufts School of Public Health and Tropical Medicine, USA)

LSO-022

Clinical characteristics of SARS-CoV-2 infection in patients with systemic lupus erythematosus in Argentina: Data from the SAR-COVID national registry

Guillermo Pons-Estel (Centro Regional de Enfermedades Autoinmunes y Reumáticas, Argentina)

LSO-023

Comparison of clinical characteristics and outcomes in patients with systemic lupus erythematosus: A cross-national study

Sung Sam Lim (Emory Univ., USA)

LSO-024

Comparison between add-on pulse methylprednisolone versus medium to high dose glucocorticoids alone in Thai patients with proliferative lupus nephritis receiving monthly pulse intravenous cyclophosphamide

Porntip Intapiboon (Prince of Songkla Univ., Thailand)

LSO-025

Stroblus versus mycophenolate mofetil for the treatment of lupus nephritis: Results from a real-world CSTAR cohort

Wei Fan (Peking Union Medical College Hosp., China)

LSO-026

Predictors of long-term renal survival and mortality in patients with biopsy-proven lupus nephritis: A prospective cohort study

Jung-Min Shin (Eulji Univ., Korea)

LSO-027

Predictors of de novo renal flares in systemic lupus erythematosus – time to revisit belimumab dose for extra-renal disease? Results from five phase III clinical trials of belimumab

Isaara Pandis (Karolinska Institute, Sweden)

LSO-028

Predictors of renal relapse in Korean patients with lupus nephritis: Over a 35-year period at a single center

Hoowon Jeon (Seoul Natl Univ., Korea)

LSO-029

Predictors of renal flares in systemic lupus erythematosus: A post-Hoc analysis of four phase III clinical trials of belimumab

Akaro Gemsu (Karolinska Institute, Sweden)

LSO-030

Does early complete remission preclude adverse outcomes in lupus nephritis?

Dafna Gladman (Univ. of Toronto, Canada)

LSO-100

Association of serologic and clinical low disease activity states with outcomes in a large multi-national lupus cohort

Yanjie Hao (The Univ. of Melbourne, Australia)

LSO-031

Predictors of first hospitalizations due to disease activity and infections in systemic lupus erythematosus patients

Bernardo A. Pons-Estel (Regional Center for Autoimmune and Rheumatic Diseases, Argentina)

LSO-032

Comparison of the systemic lupus international collaborating clinics frailty index (SLICC-FI) and the FRAIL scale for identifying frailty among individuals with systemic lupus erythematosus

Alexandru Loga (Cluj University, Romania)

LSO-033

Association of latent tuberculosis infection with clinical and serological parameters in systemic lupus erythematosus - a prospective observational study

Gayatri Nis (Jawaharlal Institute of Postgraduate Medical Education and Research, India)

LSO-034

Cluster analysis and subphenotype stratification in lupus erythematosus based on data from the Asia Pacific Lupus Collaboration cohort (APLC-CASTLE)

Shirley Chu Wei Chen (Univ. of Hong Kong, Hong Kong)

LSO-035

LSO-036

Comparison of the systemic lupus international collaborating clinics frailty index (SLICC-FI) and the FRAIL scale for identifying frailty among individuals with systemic lupus erythematosus

May 18 (Thu) 14:30 – 15:30 Grand Ball Room 101

Lupus Nephritis

Chair Seung-Geun Lee (Pusan Nat’l Univ., Korea)

LSO-025: Comparison between add-on pulse methylprednisolone versus medium to high dose glucocorticoids alone in Thai patients with proliferative lupus nephritis receiving monthly pulse intravenous cyclophosphamide

Porntip Intapiboon (Prince of Songkla Univ., Thailand)

LSO-026: Stroblus versus mycophenolate mofetil for the treatment of lupus nephritis: Results from a real-world CSTAR cohort

Wei Fan (Peking Union Medical College Hosp., China)

LSO-027: Predictors of long-term renal survival and mortality in patients with biopsy-proven lupus nephritis: A prospective cohort study

Jung-Min Shin (Eulji Univ., Korea)

LSO-028: Predictors of de novo renal flares in systemic lupus erythematosus – time to revisit belimumab dose for extra-renal disease? Results from five phase III clinical trials of belimumab

Isaara Pandis (Karolinska Institute, Sweden)

LSO-029: Predictors of renal relapse in Korean patients with lupus nephritis: Over a 35-year period at a single center

Hoowon Jeon (Seoul Natl Univ., Korea)


Akaro Gemsu (Karolinska Institute, Sweden)

LSO-100: Does early complete remission preclude adverse outcomes in lupus nephritis?

Dafna Gladman (Univ. of Toronto, Canada)

LSO-031: Association of serologic and clinical low disease activity states with outcomes in a large multi-national lupus cohort

Yanjie Hao (The Univ. of Melbourne, Australia)

LSO-032: Predictors of first hospitalizations due to disease activity and infections in systemic lupus erythematosus patients

Bernardo A. Pons-Estel (Regional Center for Autoimmune and Rheumatic Diseases, Argentina)

LSO-033: Comparison of the systemic lupus international collaborating clinics frailty index (SLICC-FI) and the FRAIL scale for identifying frailty among individuals with systemic lupus erythematosus

Alexandru Loga (Cluj University, Romania)

LSO-034: Association of latent tuberculosis infection with clinical and serological parameters in systemic lupus erythematosus - a prospective observational study

Gayatri Nis (Jawaharlal Institute of Postgraduate Medical Education and Research, India)

LSO-035: Cluster analysis and subphenotype stratification in lupus erythematosus based on data from the Asia Pacific Lupus Collaboration cohort (APLC-CASTLE)

Shirley Chu Wei Chen (Univ. of Hong Kong, Hong Kong)

LSO-036

May 18 (Thu) 14:30 – 15:30 Grand Ball Room 102

SLE Diagnosis and Manifestations

Chair Chang-Nam Son (Sulji Univ., Korea)

LSO-037: STING/TMEM173 mutation in systemic lupus erythematosus: From animal model to intrinsic human genetics

Preeprom Pritikun (Mahidol Univ., Thailand)

LSO-038: Nlrp12 deficiency mice present severer lupus nephritis in lupus prone model and pristane-induced lupus like model

Yen Po Tao (Taipei Veterans General Hosp., Taiwan)

LSO-039: Proteomic analysis of cutaneous lupus erythematosus and dermatomyositis dermal infiltrate reveals differentially expressed canonical pathways

Alisa Häyry (Karolinska Institute, Sweden)

LSO-040: Mitochondria promotes autoimmune plasmablasts generation in lupus

Sung Hoon Jang (Seoul Nat’l Univ., Korea)

LSO-041: Loss-of-function NADPH oxidase variants promote lupus pathogenesis by modulating B cell-intrinsic TLR signals

Shaun Jackson (Seattle Children’s Research Institute, USA)

LSO-042: The treatment effect of STING inhibitor (SSID-017) on lupus phenotypes in the Fcgr2b-deficient mice

Isaara Alee (Chulalongkorn Univ., Thailand)

LSO-010: A spatially-resolved single cell resolution atlas of pediatric lupus nephritis uncovers complex interactions between stromal and infiltrating immune cells.

Shaun Jackson (Seattle Children’s Research Institute, USA)

LSO-101

May 19 (Fri) 14:30 – 15:30 Auditorium Meeting Room A

SLE Etiology & Pathogenesis 2

Chair Youn-soo Choi (Seoul Nat’l Univ., Korea)

LSO-037

LSO-038

LSO-039

LSO-040

LSO-041

LSO-042

LSO-101

LSO-043: Mitochondria promotes autoimmune plasmablasts generation in lupus

Sung Hoon Jang (Seoul Nat’l Univ., Korea)

LSO-040

LSO-041: Loss-of-function NADPH oxidase variants promote lupus pathogenesis by modulating B cell-intrinsic TLR signals

Shaun Jackson (Seattle Children’s Research Institute, USA)

LSO-042: The treatment effect of STING inhibitor (SSID-017) on lupus phenotypes in the Fcgr2b-deficient mice

Isaara Alee (Chulalongkorn Univ., Thailand)

LSO-010: A spatially-resolved single cell resolution atlas of pediatric lupus nephritis uncovers complex interactions between stromal and infiltrating immune cells.

Shaun Jackson (Seattle Children’s Research Institute, USA)

LSO-101

LSO-043
May 19 (Fri) 14:30 – 15:30 Conference Room 206 A+B

**SLE Biomarkers 2**

**Chair**
Seokchan Hong (Univ. of Ulsan, Korea)

**LSO-043** Urinary neutrophil gelatinase-associated lipocalin (NGAL) as a mediator of the association between particulate matter exposure and disease activity in systemic lupus erythematosus
Ji-Hyun Kang (Chonnam Nat’l Univ., Korea)

**LSO-044** Sphingolipids are potential diagnostic biomarkers for Korean patients with systemic lupus erythematosus
Yeon-Ah Lee (Kyung Hee Univ., Korea)

**LSO-045** Multiple molecular biomarkers that predict response to treatment in lupus nephritis
Dae Jin Park (Yonsei Univ., Korea)

**LSO-046** Metabolomic analysis for the unique profile and novel biomarkers of neuropsychiatric systemic lupus erythematosus
Xiaolin Sun (Peking Univ. People’s Hosp., China)

**LSO-047** Utility of autoantibody against an UCH-L1 epitope as a serum diagnostic marker for neuropsychiatric systemic lupus erythematosus
Xiaolin Sun (Peking Univ. People’s Hosp., China)

**LSO-102** The correlation between interleukin-6 (IL-6) and the development of systemic lupus erythematosus (SLE) in Universiti Sains Malaysia (USM)
Mohamed Shafi Mohd Hashim (Universiti Sains Malaysia, Malaysia)

---

May 19 (Fri) 14:30 – 15:30 Auditorium Meeting Room B

**SLE Genetics & Omics**

**Chair**
Kwangwoo Kim (Kyung Hee Univ., Korea)

**LSO-053** Elevated expression of sa_circ_0000479 in neutrophils correlates with features of systemic lupus erythematosus
Ranran Yao (Peking Univ. People’s Hosp., China)

**LSO-054** Genetic fine mapping of independent variants in MHC region associated with predisposition and clinical feature of systemic lupus erythematosus in Han Chinese population
Ke Xue (China Japan Friendship Hosp., China)

**LSO-055** Genetic contributions to neuropsychiatric systemic lupus erythematosus
Soojin Cha (Hanyang Univ., Korea)

**LSO-056** Impaired function of neutrophil cytosolic factor 2 (NCF2) may participate in lupus from multiple pathways
Ang J.L. (Peking Union Medical College and Chinese Academy of Medical Sciences, China)

**LSO-057** Association between TNFSF13B gene polymorphism and serum BAFF Levels with disease activity in SLE patients
Nadia Gita Ghassemi (Universitas Padjadjaran, Indonesia)

---

May 19 (Fri) 14:30 – 15:30 Conference Room 205 A

**SLE Outcomes and Prognosis**

**Chair**
Seung Min Jung (The Catholic Univ. of Korea, Korea)

Young Eun Jo (Yonsei Univ., Korea)

**LSO-059** Systemic lupus erythematosus (SLE) patients in Auckland: Epidemiology and attainment of Lupus Low Disease Activity State (LLDAS)
Nadine Weather (Te Whatu Ora Aotearoa, New Zealand)

**LSO-060** Self-efficacy is associated with a lower probability of damage accrual in patients with systemic lupus erythematosus.
Manuel Ugarte-gil (Universidad Cientifica del Sur, Peru)

**LSO-061** Withdrawn

**LSO-062** Worse outcomes linked to ethnicity for the early treatment of refractory SLE: Results from the BILAG-BR
Ian Bruce (The Univ. of Manchester, UK)

**LSO-063** Prediction of mortality using clusters based on clinical and lab parameters: Data from 2072 patients from INSPIRE cohort
Changappa Kasiviswanatha (AMRIN, India)

**LSO-064** Impact of time to remission, flares and exposure to immunosuppressives on the development of advanced chronic kidney disease (stage IV or worse) in lupus nephritis
Dafna Gladman (Univ. of Toronto, Canada)

---
### May 19 (Fri) 14:30 – 15:30 Conference Room 205B

#### SLE Treatment 1

**Chair** Su-Jin Moon (Chonnam National University of Korea, Korea)

1. **LSO-064**
   - Disease-modifying effect and long-term safety data of belimumab in patients with SLE: A single centre retrospective analysis
   - Takafumi Nakao (St Luke’s Heart Hosp, Japan)

2. **LSO-065**
   - Belimumab in combination with antiinflammatory agents prevent renal flares in patients with systemic lupus erythematosus and moderate-to-high extra-renal activity: Results from four randomised clinical trials
   - Alkero Goma (Karolinska Institutet, Sweden)

3. **LSO-066**
   - Spanish national registry of belimumab in patients with systemic lupus erythematosus
   - Vicente-Aldavero (Hospital Universitario de Navarra, Spain)

4. **LSO-067**
   - Withdrawn

5. **LSO-068**
   - Association between organ-specific safety of estrogens in lupus erythematosus national assessment-systemic lupus erythematosus (SELENA-SLEDAI) disease activity index (SELENA-SLEDAI) response to belimumab and SF-36v2 and FACIT-Fatigue scores in patients with SLE
   - Wen-Yung Chen (GSK, UK)

6. **LSO-069**
   - Satisfaction and effectiveness of switching from intravenous to subcutaneous belimumab treatment in daily clinical practice
   - Betsa Sofia (Hosp Clin of Barcelona, Spain)

7. **LSO-105**
   - D-ALW nanoparticles ameliorate lupus nephritis in MRL/lpr mice
   - Yuem-Ma (The Second Affiliated Hosp of Xiamen Univ, China)

### May 20 (Sat) 14:30 – 15:30 Conference Room 206 A+B

#### SLE Comorbidities

**Chair** Sang Youn Jung (CHU, Univ, Korea)

1. **LSO-070**
   - CHA2DS2-VASc score for prediction of ischemic stroke in patients with systemic lupus erythematosus without atrial fibrillation-RISK of risk scores in the era of artificial intelligence
   - Wei Yuan Hu (China Medical Univ Hosp, Taiwan)

2. **LSO-071**
   - Correlation of traditional and SLE related risk factors with carotid intima media thickness as early MACs predictors in SLE patients: A systematic review and meta-analysis
   - Sandra Surya Rini (North Lombok Regional Hosp, Indonesia)

3. **LSO-073**
   - Improvements and challenges of systemic lupus erythematosus associated pulmonary arterial hypertension: A 10-year multicenter cohort study
   - Xingbei Dong (Peking Union Medical College Hosp, China)

4. **LSO-074**
   - All-cause mortality and the incidence of cancer in patients with moderate-to-severe SLE: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)
   - Ian Bruce (The Univ of Manchester, UK)

5. **LSO-075**
   - Performance of conventional cardiovascular risk scores in identifying subclinical atherosclerosis in systemic lupus erythematosus
   - Gayatri M (Jawaharlal Institute of Postgraduate Medical Education and Research, India)

6. **LSO-106**
   - Risk factors associated with the development of cardiovascular events in a multiethnic Asian systemic lupus erythematosus cohort
   - Hwee Siew Howe (Tan Tock Seng Hosp, Singapore)

7. **LSO-107**
   - Association of hypertension with higher chronicity index scores among patients with lupus nephritis
   - Peter Paolo Daleon (Univ of Santo Tomas Hosp, Philippines)

### May 20 (Sat) 14:30 – 15:30 Auditorium Meeting Room A

#### SLE Precision Medicine

**Chair** So-Young Bang (Pusan Nat’l Univ, Korea)

1. **LSO-076**
   - Understanding the genetic architecture of SLE from the perspective of associations from 14 other autoimmune diseases
   - Wenbing Yang (Univ of Hong Kong, Hong Kong)

2. **LSO-077**
   - Identification of an interferon 5-gene signature score as a pharmacodynamic and potential predictive biomarker for deucravacitinib treatment in a phase 2 trial in patients with systemic lupus erythematosus
   - Chun Wu (Bristol Myers Squibb, USA)

3. **LSO-078**
   - Clinical characteristics and genetic variants in a large cohort of monogenic lupus patients: Emerging or fading frontiers?
   - Sulaiman Al-Murajj (King Fahad Specialist Hosp & Research Centre, Saudi Arabia)

4. **LSO-079**
   - Dynamic changes of immune cells in systemic lupus erythematosus with nephritis using longitudinal peripheral blood single-cell RNA-seq
   - Seung-Jun Park (Ajou Univ, Korea)

5. **LSO-080**
   - Machine-learning approach on lupus low disease activity prediction
   - Nick Faelnar (Univ. of the Philippines, Philippines)

6. **LSO-081**
   - Genomic prediction model using machine Learning techniques that can distinguish autoimmune diseases (RA or SLE) from healthy controls
   - Young Bin Joo (Pusan Nat’l Univ, Korea)

### May 20 (Sat) 14:30 – 15:30 Conference Room 205A

#### SLE Pregnancy and Reproductive Health

**Chair** Sung Hae Chang (Soonchunhyang Univ, Korea)

1. **LSO-082**
   - Withdrawn

2. **LSO-083**
   - “Systemic lupus erythematosus Women with lupus nephritis In pregnancy Therapeutic CHallenge (SWITCH)” : The systemic lupus international collaborating clinics experience
   - Joo-Young (Esther) Lee (Research Institute of McGill Univ Health Centre, Canada)

3. **LSO-084**
   - Pregnancy outcomes in patients with systemic lupus erythematosus (SLE), anti-phospholipid antibody syndrome (APS), scleroderma (SSc) and rheumatoid arthritis (RA) at the Kenyatta national hospital, Nairobi, Kenya.
   - Paul Etau Ekwom (KNH, Kenya)

4. **LSO-085**
   - Nationwide patterns and factors associated with adverse pregnancy outcomes in women with systemic lupus erythematosus
   - Yu-Seon Jung (Chung-Ang Univ, Korea)

5. **LSO-086**
   - Pregnancy outcomes in systemic lupus erythematosus: Data from a multiethnic, multinational Latin American cohort
   - Guillermo Porcayo (Centro Regional de Enfermedades Autoinmunes y Reumáticas, Argentina)
# SLE Treatment 2

### Chair: Dong-Jin Park (Chonnam Nat’l Univ., Korea)

<table>
<thead>
<tr>
<th>Session No.</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>LSO-087</td>
<td>Sub-optimal use of anti-malarial therapy for SLE in the Asia Pacific Region: Observations from the Asia Pacific lupus cohort</td>
<td>Rangi Kandane-Rathnayake (Monash Univ., Australia)</td>
</tr>
<tr>
<td>LSO-088</td>
<td>Ld-IL2 synthesis with belimumab in the treatment of systemic lupus erythematosus patients</td>
<td>Ruiling Feng (Peking Univ. People’s Hosp., China)</td>
</tr>
<tr>
<td>LSO-089</td>
<td>Effectiveness of belimumab in systemic lupus erythematosus patients of a multicenter Spanish cohort</td>
<td>Irene Altabás-gonzález (Complejo Hospitalario Universitario de Vigo, Spain)</td>
</tr>
<tr>
<td>LSO-090</td>
<td>A placebo-controlled phase 1 study in healthy adult volunteers of the safety, tolerability, pharmacokinetics, and pharmacodynamics of povetaxcept, a potent dual BAFF/APRIL antagonist, for the treatment of systemic lupus erythematosus</td>
<td>Stacey Dillon (Alpine Immune Sciences, USA)</td>
</tr>
<tr>
<td>LSO-091</td>
<td>Study design of ENERGY: A phase 2/3 trial to assess the efficacy and safety of nopalimab in warm autoimmune hemolytic anemia</td>
<td>Youngja Lee (Jeonbuk-Asia Pacific, Korea)</td>
</tr>
<tr>
<td>LSO-092</td>
<td>Safety, efficacy and pharmacodynamics of cenerimod in patients with systemic lupus erythematosus: Two randomised, double-blind phase 2 clinical trials</td>
<td>Sandra Navarra (Univ. of Santo Tomas, Philippines)</td>
</tr>
</tbody>
</table>

---

# Miscellaneous Conditions Associated with SLE

### Chair: Seonghoon Park (Daegu Catholic Univ., Korea)

<table>
<thead>
<tr>
<th>Session No.</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>LSO-093</td>
<td>Gut microbiota analysis in Korean patients with systemic lupus erythematosus</td>
<td>Ji-Won Kim (Ajou Univ., Korea)</td>
</tr>
<tr>
<td>LSO-094</td>
<td>Analysis of microbiota in patients with systemic lupus erythematosus</td>
<td>Toshikiro Nanei (Tokyo Univ., Japan)</td>
</tr>
<tr>
<td>LSO-095</td>
<td>Withdrawn</td>
<td></td>
</tr>
<tr>
<td>LSO-096</td>
<td>Analyzing the shared and specific genetic signals among 15 autoimmune diseases shed new light on the underlying causal genes and molecular mechanisms</td>
<td>Xiao Dang (The Univ. of Hong Kong, Hong Kong)</td>
</tr>
<tr>
<td>LSO-097</td>
<td>Captopril preventing blood brain barrier breach by anti-smith antibody</td>
<td>Yoshiyuki Amuru (Kitasato Univ., Japan)</td>
</tr>
<tr>
<td>LSO-108</td>
<td>Ambulatory blood pressure in patients with systemic lupus erythematosus</td>
<td>Brygida Proyeasa-Chowsawin (Medical Univ. of Silesia, Poland)</td>
</tr>
<tr>
<td>LSO-109</td>
<td>Characteristics associated with poor COVID-19 outcomes in people with rheumatic disease</td>
<td>Haihong Yao (Peking Univ. People’s Hosp., China)</td>
</tr>
<tr>
<td>LSO-072</td>
<td>Comparison of COVID-19 vaccination with influenza vaccination in Korean patients with systemic lupus erythematosus</td>
<td>Seonghoon Park (Daegu Catholic Univ., Korea)</td>
</tr>
</tbody>
</table>
E-poster Presentation

LUPUS & KCR 2023
# Antiphospholipid syndrome

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>LP-001</td>
<td>Antiphospholipid syndrome in Juvenile systemic lupus erythematosus</td>
<td>La Rein Sangarin (Sejong Hosp., Malaysia)</td>
</tr>
<tr>
<td>LP-002</td>
<td>Immunomagnetic anti-cardiolipin antibody sorption in SLE-associated APS using magnetic polyacrylamide carrier</td>
<td>Maria Murusov (Research Institute of Clinical and Experimental Rheumatology, Russian Federation)</td>
</tr>
<tr>
<td>LP-003</td>
<td>Antiphospholipid antibodies and recurrent thrombosis in primary antiphospholipid syndrome</td>
<td>Tatiana Reshetnyak (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)</td>
</tr>
<tr>
<td>LP-004</td>
<td>Serum calprotectin could be a novel marker of microangiopathy in antiphospholipid syndrome patients</td>
<td>Yuan Zhao (Peking Union Medical College Hosp., China)</td>
</tr>
<tr>
<td>LP-005</td>
<td>Withdrawn</td>
<td></td>
</tr>
<tr>
<td>LP-006</td>
<td>Hemorrhage complications in obstetric antiphospholipid syndrome - Risk factors and the association with adverse pregnancy outcomes</td>
<td>Yangjing Luo (Peking Univ. People’s Hosp., China)</td>
</tr>
<tr>
<td>LP-007</td>
<td>Cytokine profiles in antiphospholipid syndrome</td>
<td>Xiangjun Liu (Peking Univ. People’s Hosp., China)</td>
</tr>
</tbody>
</table>

# SLE Biomarkers

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>LP-008</td>
<td>Genetic analysis auto-antigen biomarkers for lupus</td>
<td>Ramtah Rambah (Universitas Sulawesi Barat, Indonesia)</td>
</tr>
<tr>
<td>LP-009</td>
<td>Immunoglobulin Gamma-3 subclass is a potential biomarker in serums, saliva, and urine of patients with systemic lupus erythematosus</td>
<td>Ji-Won Kim (Ajou Univ., Korea)</td>
</tr>
<tr>
<td>LP-010</td>
<td>Analytical performance of improved Anti-β2GPI ELISA test for SLE diagnostics</td>
<td>Maria Murusov (Research Institute of Clinical and Experimental Rheumatology, Russian Federation)</td>
</tr>
<tr>
<td>LP-011</td>
<td>Role of naive and memory CD8 T cells in predicting the risk of pneumonia among systemic lupus erythematosus patients</td>
<td>Mina Zaka Pratama (Universitait Brawijaya, Indonesia)</td>
</tr>
<tr>
<td>LP-012</td>
<td>Patients with systemic lupus erythematosus and hyperproduction of antibodies to anti-URNP</td>
<td>Rushana Shyakhmetova (Research Institute of Rheumatology, Russian Federation)</td>
</tr>
<tr>
<td>LP-013</td>
<td>Autoantibody trajectories associate with classification and treatment response in lupus nephritis</td>
<td>Andras Fekete (Johns Hopkins Univ., USA)</td>
</tr>
<tr>
<td>LP-014</td>
<td>Gas and liquid chromatography-based urine metabolomics reveals a distinctive signature in patients with lupus nephritis</td>
<td>Lisandro Pacheco (Universidad Simon Bolivar, Colombia)</td>
</tr>
<tr>
<td>LP-015</td>
<td>Exploring the Lupus Risk Index (LRI) as a biomarker in patients with lupus nephritis</td>
<td>Cynthia Aranow ( Feinstein Institutes for Medical Research, USA)</td>
</tr>
<tr>
<td>LP-016</td>
<td>Anti-histone and anti-nucleosome antibodies, rather than anti-dsDNA antibodies are associated with interferon-induced biomarkers in Sudanese and Swedish SLE patients</td>
<td>Johan Ronnfeld (Uppsala Univ., Sweden)</td>
</tr>
<tr>
<td>LP-017</td>
<td>Double-stranded DNA breaks are a marker of the inflammatory activity of systemic lupus erythematosus</td>
<td>Anastasia Andreeva (V.A. Nasonova Research Institute of Rheumatology, Russia)</td>
</tr>
<tr>
<td>LP-018</td>
<td>The new markers of systemic lupus erythematosus activity: focus on interleukin (IL)-1β and soluble IL-2 receptor</td>
<td>Tatiana Popkova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)</td>
</tr>
</tbody>
</table>

# SLE Comorbidities

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>LP-018</td>
<td>Risk factors for moderate to severe COVID-19 infection in systemic lupus erythematosus</td>
<td>Wendell Oliver Espahola (UST Hosp., Philippines)</td>
</tr>
<tr>
<td>LP-019</td>
<td>Social maladjustment and anxiety-depressive spectrum disorders in systemic lupus erythematosus and primary antiphospholipid syndrome patients</td>
<td>Tatiana Reshetnyak (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)</td>
</tr>
<tr>
<td>LP-020</td>
<td>Retrospective analysis of low-dose interleukin-2 therapy on chronic autoimmune thyroid disease complicated with systematic lupus erythematosus</td>
<td>Nadi Wang (Peking Univ. People’s Hosp., China)</td>
</tr>
<tr>
<td>LP-021</td>
<td>Problem in management of systemic lupus erythematosus in pregnancy with antiphospholipid syndrome and congenital heart block as comorbidities</td>
<td>Gede Arya Destaprayana (Universitas Udayana, Indonesia)</td>
</tr>
<tr>
<td>LP-023</td>
<td>Systemic lupus erythematosus concomitant with atopic dermatitis, A case series report</td>
<td>Seun Young Song (Hanyang Univ., Korea)</td>
</tr>
<tr>
<td>LP-024</td>
<td>Colorectal duplication cyst with recto-vesica fistule in systemic lupus erythematosus patient</td>
<td>Gede Pardana Putera (RSUP Dr. Sangaji, Indonesia)</td>
</tr>
<tr>
<td>LP-025</td>
<td>Lipid spectrum and cholesterol content in circulating immune complexes in the blood of SLE patients</td>
<td>Tatiana Popkova (V.A. Nasonova Research Institute of Rheumatology, Russia)</td>
</tr>
<tr>
<td>LP-026</td>
<td>Obesity, hyperleptinemia and insulin resistance in women with systemic lupus erythematosus and rheumatoid arthritis</td>
<td>Tatiana Popkova (V.A. Nasonova Research Institute of Rheumatology, Russia)</td>
</tr>
<tr>
<td>LP-027</td>
<td>Overweight and obesity phenotypes based on body mass index and insulin resistance in women with systemic lupus erythematosus</td>
<td>Tatiana Popkova (V.A. Nasonova Research Institute of Rheumatology, Russia)</td>
</tr>
<tr>
<td>LP-028</td>
<td>Ideal perforation occurring at the beginning of anti-tuberculosis treatment in a 19-year old with disseminated tuberculosis and systemic lupus erythematosus</td>
<td>Bryan Leonard Dizon (Nat’l Kidney and Transplant Institute, Philippines)</td>
</tr>
</tbody>
</table>
### SLE Diagnosis and Manifestations

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>LP-029</td>
<td>Pediatric lupus erythematosus-an interdisciplinary challenge</td>
<td>Rodica Chisaru (Balenia Clinical Hosp, Romania)</td>
</tr>
<tr>
<td>LP-030</td>
<td>Diffuse alveolar hemorrhage: A rare fatal complication of systemic lupus erythematosus (a report of two cases)</td>
<td>Kendra Donee Moromito (Univ of the Philippines, Philippines)</td>
</tr>
<tr>
<td>LP-031</td>
<td>Autoimmune hepatitis in a 28-year-old female with lupus nephritis: A case report</td>
<td>Renald Ramirez (Valencia Medical Center, Philippines)</td>
</tr>
<tr>
<td>LP-032</td>
<td>Protein losing enteropathy as a manifestation of lupus in a 19-year-old Filipino female: A case report</td>
<td>Alyssa Nalle Borpus (Baguio General Hosp. and Medical Center, Philippines)</td>
</tr>
<tr>
<td>LP-033</td>
<td>A study of treatment satisfaction in the patients with rheumatoid arthritis and systemic lupus erythematosus</td>
<td>Hyun-Ji Choi (Seochon Univ GY Medical Center)</td>
</tr>
<tr>
<td>LP-034</td>
<td>Factors associated with health-related quality of life in lupus nephritis</td>
<td>Hyeok Ellasses (CHU/Muhannad H, Morocco)</td>
</tr>
<tr>
<td>LP-037</td>
<td>A case of systemic lupus erythematosus after SARS-CoV-2 vaccination and review of literatures</td>
<td>Eri Renala Guevara (Univ of Santo Tomas Hosp, Philippines)</td>
</tr>
<tr>
<td>LP-038</td>
<td>Long-term outcome related with initial clinical parameters in juvenile systemic lupus erythematosus: Retrospective study</td>
<td>Mu-Ying Li (Peking Union Medical College Hosp, China)</td>
</tr>
<tr>
<td>LP-040</td>
<td>Comparison of clinical and serological features in juvenile and adult-onset systemic lupus erythematosus in a tertiary care center in pakistan</td>
<td>Amna Khan (Faiz Foundation Hosp. Rawalpindi, Pakistan)</td>
</tr>
<tr>
<td>LP-041</td>
<td>Successful management of myasthenia gravis in crisis as an initial presentation of systemic lupus erythematosus: A case report</td>
<td>Gesa Alden Damus (Zamboanga City Medical Center, Philippines)</td>
</tr>
<tr>
<td>LP-042</td>
<td>Cardiac tamponades: Uncommon manifestation in systemic lupus erythematosus</td>
<td>Eli Noi (Andalas Univ, Indonesia)</td>
</tr>
<tr>
<td>LP-043</td>
<td>Gastrointestinal manifestations in systemic lupus erythematosus are associated with high disease activity and mortality: A nationwide cohort study from India</td>
<td>Parvati Matha (King Garghar Medical Univ, India)</td>
</tr>
<tr>
<td>LP-044</td>
<td>A comparative study on the effect of high-dose dexamethasone pulse therapy versus methylprednisolone pulse therapy in systemic lupus erythematosus patients admitted at Bicol Medical Center</td>
<td>Aiken Bilomen (Bicol Medical Center, Philippines)</td>
</tr>
<tr>
<td>LP-045</td>
<td>Refractory immune thrombocytopenia in a patient with lupus nephritis and anti-phospholipid syndrome on treatment for disseminated tuberculosis</td>
<td>Eri Renala Guevara (Univ of Santo Tomas Hosp, Philippines)</td>
</tr>
<tr>
<td>LP-047</td>
<td>Bilateral pallidal lesions in a patient with neuropsychiatric lupus patient: A case report</td>
<td>Chan-Sheng Hu (Far Eastern Memorial Hosp, Taiwan)</td>
</tr>
<tr>
<td>LP-048</td>
<td>Characteristics and clinical outcome of incomplete systemic lupus erythematosus</td>
<td>Tatiana Popkovs (Ukrainian Research Institute of Rheumatology, Russian Federation)</td>
</tr>
<tr>
<td>LP-049</td>
<td>Influence of activity and clinical features of systemic lupus erythematosus on serum anti-vasil antibody levels</td>
<td>Maria Mamus (Research Institute of Clinical and Experimental Rheumatology, Russian Federation)</td>
</tr>
<tr>
<td>LP-050</td>
<td>Recurrent seizures as a wake-up call for SLE diagnosis in a limited resource setting</td>
<td>Radjiahian Marthiay (RSUP Fatmawati, Indonesia)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>LP-051</td>
<td>Sleep quality of patients with systemic lupus erythematosus at East avenue medical center</td>
<td>Ramar John Bangayan (East Avenue Medical Center, Philippines)</td>
</tr>
<tr>
<td>LP-052</td>
<td>A rare case of chronic tophaceous gout and systemic lupus erythematosus in a female Filipino patient</td>
<td>Ramar John Bangayan (East Avenue Medical Center, Philippines)</td>
</tr>
<tr>
<td>LP-053</td>
<td>Dietary and lifestyle habits of patients with gastrointestinal involvement of systemic lupus erythematosus</td>
<td>Hanja Xu (Peking Union Medical College Hosp, China)</td>
</tr>
<tr>
<td>LP-054</td>
<td>Serious infections among Thai patients with systemic lupus erythematosus: Data from the LUCRA cohort</td>
<td>Reatta Pakinsonorn (Phramongkutklao College of Medicine, Thailand)</td>
</tr>
<tr>
<td>LP-055</td>
<td>The effect of different remission definitions in patients with systemic lupus erythematosus on damage accrual: Data from the LUCRA cohort</td>
<td>Reatta Pakinsonorn (Phramongkutklao College of Medicine, Thailand)</td>
</tr>
<tr>
<td>LP-056</td>
<td>Pseudo-pseudo Maligna Syndrome or Tjalma Syndrome - An initial presentation in a young female with systemic lupus erythematosus</td>
<td>Chad Klein Fernandez (Davao Regional Medical Center, Philippines)</td>
</tr>
<tr>
<td>LP-057</td>
<td>Psychological problems of women with systemic lupus erythematosus</td>
<td>Andrea IgBarret (Alumna Universitas Gadjah Mada, Indonesia)</td>
</tr>
<tr>
<td>LP-058</td>
<td>The involvement of scalp and nails in cutaneous lupus erythematosus patients: A retrospective study</td>
<td>Ji-Hyun Kang (Kyungpook Univ, Korea)</td>
</tr>
<tr>
<td>LP-059</td>
<td>Association of seasonal vitamin D levels and disease activity in patients with systemic lupus erythematosus</td>
<td>Minako Momohara (Nagoya Univ, Japan)</td>
</tr>
<tr>
<td>LP-060</td>
<td>Extracellular vesicular proteins in plasma from patients with cutaneous lupus correlate with disease activity</td>
<td>Galvaminio Peres Estrada (Centro Regional de Enfermedades Autoinmunes y Reumaticas, Argentina)</td>
</tr>
<tr>
<td>LP-061</td>
<td>Male sex and disease activity at diagnosis are predictors of severe hemolytic anemia in patients with systemic lupus erythematosus: A data from a multiethnic Latin American cohort study</td>
<td>Yousuke Hikuma (Kagawa Univ, Japan)</td>
</tr>
<tr>
<td>LP-062</td>
<td>Two-year outcomes by belimumab additive on standard of care in patients with systemic lupus erythematosus: A single center retrospective cohort study</td>
<td>Eunsong Kang (Seoul Medical Center, Korea)</td>
</tr>
<tr>
<td>LP-063</td>
<td>Effect of osteoporosis on major adverse cardiovascular events (MACEs) in systemic lupus erythematosus: A longitudinal study</td>
<td>Chi-Chiu Mok (Tsuen Mun Hosp., Hong Kong)</td>
</tr>
<tr>
<td>LP-064</td>
<td>Prevalence and risk factors of fragility fractures in systemic lupus erythematosus: A longitudinal study over 12 years</td>
<td>Chi-Chiu Mok (Tsuen Mun Hosp., Hong Kong)</td>
</tr>
<tr>
<td>LP-065</td>
<td>Severe systemic lupus erythematosus with manifestation of lupus nephritis and pericardial effusion: A case report</td>
<td>Arif Nuruddin (Sepeda Medel Univ, Indonesia)</td>
</tr>
<tr>
<td>LP-066</td>
<td>Analysis of hospital length of stay in systemic lupus erythematosus patients hospitalised with infection</td>
<td>Alberta Ho (Monash Health, Australia)</td>
</tr>
<tr>
<td>LP-067</td>
<td>Withdraw</td>
<td></td>
</tr>
<tr>
<td>LP-068</td>
<td>Withdraw</td>
<td></td>
</tr>
<tr>
<td>LP-072</td>
<td>Withdraw</td>
<td></td>
</tr>
</tbody>
</table>
### SLE Epidemiology and Public Health

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>LP-068</td>
<td>The challenges in the management of systemic lupus erythematosus during the 3rd wave of COVID19 pandemic in Sri Lanka: A single-centre experience</td>
<td>Chathurika Dandeniya (Univ. of Peradeniya, Sri Lanka)</td>
</tr>
<tr>
<td>LP-069</td>
<td>Update of the epidemiology and mortality of juvenile onset SLE and pediatric SLE in Italy</td>
<td>Margherita Zen (Univ. of Padua, Italy)</td>
</tr>
<tr>
<td>LP-070</td>
<td>Medication compliance in systemic lupus erythematosus: Community-based study in surakarta, Indonesia</td>
<td>Indayana Sunarso (Sebelas Maret Univ., Indonesia)</td>
</tr>
<tr>
<td>LP-071</td>
<td>Accuracy of disease-specific ICD-10 code for incident systemic lupus erythematosus: Results from a population-based cohort study set in Norway</td>
<td>Sigrid Røge (Røge Univ Hosp, Norway)</td>
</tr>
<tr>
<td>LP-072</td>
<td>Validity of a claim-based algorithm for SLE disease severity to clinical SLE Disease Activity Index in Korean patients with SLE</td>
<td>Hyungyoung Kim (Hanyang Univ, Korea)</td>
</tr>
<tr>
<td>LP-073</td>
<td>Identification of systemic lupus erythematosus classification criteria attributes in a regional medical record data network</td>
<td>Rosalind Ramsey-goldman (Northeastern Univ., USA)</td>
</tr>
<tr>
<td>LP-074</td>
<td>Cost-of-illness changes before and after diagnosis of systemic lupus erythematosus: A nationwide population-based cohort study in Korea</td>
<td>Hyungyoung Kim (Hanyang Univ, Korea)</td>
</tr>
<tr>
<td>LP-075</td>
<td>The effect of religiosity and spirituality on quality of life among moslem patients with systemic lupus erythematosus in Indonesia: A qualitative study</td>
<td>Annuity Amanda Damayanti (Islamic Univ of Indonesia, Indonesia)</td>
</tr>
<tr>
<td>LP-076</td>
<td>The correlation between sociodemographic factors and health-related quality of life (HRQOL) among patients with systemic lupus erythematosus (SLE) in Indonesia</td>
<td>Norma Nabila (Universit di Medan Indonesia, Indonesia)</td>
</tr>
<tr>
<td>LP-077</td>
<td>The role of social support on mood improvement and remission of systemic lupus erythematosus (SLE) patients: A case study in Bandung</td>
<td>Nadia Sefira (Universitas Islam Indonesia, Indonesia)</td>
</tr>
<tr>
<td>LP-078</td>
<td>Characterization of a cohort of patients with a diagnosis of systemic lupus erythematosus followed-up in the city of Cali, Colombia</td>
<td>Carlos Toro (Centro de Referencia en Osteoporosis, Colombia)</td>
</tr>
</tbody>
</table>

### SLE Etiology & Pathogenesis

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>LP-079</td>
<td>Lactobacillus paracasei GMNL-32 exerts a therapeutic effect on cardiac abnormalities in NZB/W F1 mice</td>
<td>Wei Sun Hu (China Med Univ Univ Hosp, Taiwan)</td>
</tr>
<tr>
<td>LP-080</td>
<td>Transplantation of mesenchymal stem cells increases expression of antioxidant proteins and ameliorates GP91/ROS/antiinflammation signaling in lupus cardiomyopathy</td>
<td>Wei Sun Hu (China Med Univ Univ Hosp, Taiwan)</td>
</tr>
<tr>
<td>LP-081</td>
<td>TRIM21 as a regulator of UBV-driven IFN responses in lupus</td>
<td>Richard More (Cedars-Sinai, USA)</td>
</tr>
<tr>
<td>LP-082</td>
<td>Effects of roussavatrin for the treatment in lupus-prone mice</td>
<td>Wooyoung Baek (Ajou Univ, Korea)</td>
</tr>
<tr>
<td>LP-083</td>
<td>Phorbol ester activates human mesenchymal stem cells to inhibit B cells and ameliorate lupus symptoms in MRL Faspr mice</td>
<td>Hong Kyoung Lee (Researching Institute, Corestem Inc., Korea)</td>
</tr>
<tr>
<td>LP-084</td>
<td>Single cell genomics of self-reactive B cells in systemic lupus erythematosus</td>
<td>Joanne Read (Westermed for Medical Research, Australia)</td>
</tr>
<tr>
<td>LP-085</td>
<td>Investigating the therapeutic potential of achatina fulica snail mucus on pristane-induced lupus nephritis in mice</td>
<td>Arif Nuruddin (Sebelas Maret Univ., Indonesia)</td>
</tr>
<tr>
<td>LP-086</td>
<td>Desamethasone-incorporated immunomodulatory POMAEMA-PGLA nanoparticles potentially induced tolerogenic dendritic cells and ameliorated lupus disease by mediating antigen-specific immune tolerance</td>
<td>Prateep Kriwaeprasop (Graduate Program in Medical Microbiology, Thailand)</td>
</tr>
<tr>
<td>LP-087</td>
<td>LILRA3 plays a protective role in MAS-like disease</td>
<td>Yundi Tang (Peking Univ People’s Hosp, China)</td>
</tr>
<tr>
<td>LP-088</td>
<td>IL-21 regulating age-associated b cells (ABCs) drive autoimmune disease phenotype in aged mice</td>
<td>Jiew Oh (Seoul Nat’l Univ, Korea)</td>
</tr>
<tr>
<td>LP-089</td>
<td>Role of inflammatory cytokines, IL-6 and the correlation with ratio of IL-6 and IL-17 serum cytokines in active systemic lupus erythematosus patients.</td>
<td>Dwiaty Elora (Universitas Airlangga, Indonesia)</td>
</tr>
<tr>
<td>LP-090</td>
<td>Correlation between serum interleukin-1 with glomerular filtration rate in systemic lupus erythematosus</td>
<td>Gede Arya Dewiyana (Universitas Udayana, Indonesia)</td>
</tr>
<tr>
<td>LP-091</td>
<td>Neutrophil extracellular traps in APS and SLE</td>
<td>Tetsuya Ishikawa (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)</td>
</tr>
<tr>
<td>LP-092</td>
<td>Interferon stimulated genes in CD4 T cells are associated with pyroptosis pathways in patients with lupus</td>
<td>Sang Jin Lee (Kyungpook Nat’l Univ, Korea)</td>
</tr>
<tr>
<td>LP-093</td>
<td>Role of Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3) in the pathogenesis of lupus-like disease</td>
<td>Yundi Tang (Peking Univ People’s Hosp, China)</td>
</tr>
<tr>
<td>LP-094</td>
<td>Repression of id3 aggravates lupus phenotypes in murine models via aberrant B cell differentiation</td>
<td>Youngjae Park (The Catholic Univ of Korea)</td>
</tr>
<tr>
<td>LP-095</td>
<td>Macrophage activation in untreated patients with systemic lupus erythematosus (preliminary data)</td>
<td>Tatiana Reshetnyak (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)</td>
</tr>
<tr>
<td>LP-096</td>
<td>Plasmablast-like antigen-experienced CCR10+ CD19low B cells are expanded in systemic lupus erythematosus</td>
<td>Francesca Sosnicki (Charite-Universitaets Medicine Berlin, Germany)</td>
</tr>
<tr>
<td>LP-097</td>
<td>Degranulating PR3+ myeloid cells characterize proliferative lupus nephritis</td>
<td>Andreas Faiss (Johns Hopkins Univ, USA)</td>
</tr>
<tr>
<td>LP-098</td>
<td>Proteomic analysis of histological lesions in lupus nephritis identifies an inflammatory signature of fibrous crescents</td>
<td>Andreas Faiss (Johns Hopkins Univ, USA)</td>
</tr>
<tr>
<td>LP-210</td>
<td>Peripheral blood B-cell subsets in patients with systemic lupus erythematosus</td>
<td>Tatjana Popkova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)</td>
</tr>
</tbody>
</table>
## SLE Genetics & Omics

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>LP-099</td>
<td>High genetic risk loads increase the risk of lupus nephritis in Koreans</td>
<td>So-Young Bang (Hanyang Univ., Korea)</td>
</tr>
<tr>
<td>LP-100</td>
<td>Association of the TNFo rs1800629 and STAT4 rs7574865 polymorphisms with systemic lupus erythematosus susceptibility</td>
<td>Mohammad Selimul Islam (National Science and Technology Univ., Bangladesh)</td>
</tr>
<tr>
<td>LP-101</td>
<td>LINCO1420 inhibit inflammation through MAPK pathway in systemic lupus erythematosus</td>
<td>Kako Li (Hunan Children’s Hosp., China)</td>
</tr>
<tr>
<td>LP-102</td>
<td>Understanding human disease mutations through gene editing and genome-wide next generation investigations</td>
<td>Hye Kyung Lee (Nat’l Institutes of Health, USA)</td>
</tr>
<tr>
<td>LP-103</td>
<td>Annotation of cell-type specific differences in the function of the SLE-associated gene IKZF2, using ChIP-Seq</td>
<td>Deborah Cunningham Graham (King’s College London, UK)</td>
</tr>
<tr>
<td>LP-104</td>
<td>The Association between CD40 rs1883832 polymorphism and susceptibility of systemic lupus erythematosus : Systematic review and meta analysis</td>
<td>Ratul Febriawan (Univ. of Indonesia, Indonesia)</td>
</tr>
<tr>
<td>LP-105</td>
<td>Synergistic effect of extra X chromosomes in the development of systemic lupus erythematosus in Klinefelter syndrome karyotype 47, XXY and karyotype 47, XXX females</td>
<td>Irene J. Tan (Emirates Medical Center Philadelphia, USA)</td>
</tr>
<tr>
<td>LP-106</td>
<td>Multi-omics integrated analysis characterizing DAS1 variant in systemic lupus erythematosus</td>
<td>Jingxia Xu (China-Japan Friendship Hosp., China)</td>
</tr>
<tr>
<td>LP-107</td>
<td>A meta-analytic approach to explore the association between complement gene polymorphisms and systemic lupus erythematosus</td>
<td>MutAdbulahak Al-Merif (ThamHing Kong Politechnic Univ., Hong Kong)</td>
</tr>
<tr>
<td>LP-108</td>
<td>The distribution of gene variants in Yakut children with SLE</td>
<td>Mikhail Kotok (Saint Petersburg State Pediatric Medical Univ., Russian Federation)</td>
</tr>
<tr>
<td>LP-109</td>
<td>Genetic study of children with familial lupus: Preliminary results</td>
<td>Rinal Raycop (Saint Petersburg State Pediatric Medical Univ., Russian Federation)</td>
</tr>
<tr>
<td>LP-110</td>
<td>Development of GSTA1, CYP2C19, and CYP2B6 gene polymorphism detection methods on the response of cyclophosphamide therapy for lupus nephritis patients</td>
<td>Yen Yen An Indrawijaya (Institut Teknologi Bandung, Indonesia)</td>
</tr>
</tbody>
</table>

## Miscellaneous Conditions Associated with SLE

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>LP-111</td>
<td>Autoimmune hepatitis with SLE on a 28 year old female presenting as liver cirrhosis : A case report</td>
<td>Rica Kezia King (St. Lukes Medical Center, Philippines)</td>
</tr>
<tr>
<td>LP-112</td>
<td>A case of macrophage activation syndrome in neonatal lupus</td>
<td>Jung Wooy Rhim (The Catholic Univ. of Korea, Korea)</td>
</tr>
<tr>
<td>LP-113</td>
<td>Systemic lupus erythematosus induced by experimental therapy with a combination of monoclonal antibodies against the SARS-CoV-2 surface s-protein</td>
<td>Tatiana Popkova, (U.K. National Research Institute of Rheumatology, Russian Federation)</td>
</tr>
<tr>
<td>LP-114</td>
<td>Lupus and multiple sclerosis may share an initiating pathogenesis : The anti-EBNA1 heuristic conjecture</td>
<td>John St. Harley (Cincinnati Education and Research Foundation for Veterans, USA)</td>
</tr>
<tr>
<td>LP-115</td>
<td>Mask and vaccinated. New-onset systemic lupus erythematosus after mRNA SARS-COV-2 vaccination</td>
<td>Fajrene Patricia Lim (San Pedro Hosp., Philippines)</td>
</tr>
<tr>
<td>LP-116</td>
<td>To get, or not to get. Risk and benefit of COVID-19 vaccine in Korean patients with systemic lupus erythematosus</td>
<td>Seonghun Park (Seoul Catholic Univ., Korea)</td>
</tr>
<tr>
<td>LP-117</td>
<td>A case report of a 22 year old Filipino male diagnosed SLE who was infected with HIV-AIDS and COVID 19 moderate disease</td>
<td>Patricia Abadranen (Mindanao State Univ. Medical Center, Philippines)</td>
</tr>
<tr>
<td>LP-118</td>
<td>Assessment of systemic lupus erythematosus activity and remission: SLEDAI-2k or SLE-DAS – which to choose?</td>
<td>Tatiana Reshetnyak (U.K. National Research Institute of Rheumatology, Russian Federation)</td>
</tr>
<tr>
<td>LP-119</td>
<td>Thalassemia traits in systemic lupus erythematosus patients with anemia</td>
<td>Lantake Hamityo (Univ. Padjadjaran, Indonesia)</td>
</tr>
<tr>
<td>LP-120</td>
<td>Antioxidant COVID-19 vaccine in 4 patients with new-onset severe lupus nephritis : Possible causality?</td>
<td>Vincent Lucario (Univ. of Santo Tomás Hosp., Philippines)</td>
</tr>
<tr>
<td>LP-121</td>
<td>Disseminated tuberculosis with associated vitamin D deficiency in a male patient with systemic lupus erythematosus</td>
<td>Etica Tan Gernosso (Makati Medical Center, Philippines)</td>
</tr>
</tbody>
</table>
E-Poster Presentation: LUPUS

SLE Genetics & Omics

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>LP-122</td>
<td>Lupus nephritis presenting as a renal hematoma in a Filipino female patient: A case report</td>
<td>Ronald Ramirez (Valenzuela Medical Center, Philippines)</td>
</tr>
<tr>
<td>LP-123</td>
<td>Calcinurin inhibitors as induction treatment for proliferative lupus nephritis: A systematic review and meta-analysis</td>
<td>Wendell Oliver Escardilla (UST Hosp., Philippines)</td>
</tr>
<tr>
<td>LP-124</td>
<td>Childhood-onset lupus nephritis: Real-world long-term outcome data from a single center</td>
<td>Jeon Jung (Asan Medical Center Children’s Hosp, Korea)</td>
</tr>
<tr>
<td>LP-125</td>
<td>Glomerulonephritis in systemic lupus erythematosus: “Not everything is Lupus” a case series</td>
<td>Diana Michelle Pare Gohino (Guatemalan Social Security Institute, Guatemala)</td>
</tr>
<tr>
<td>LP-126</td>
<td>The infectious complication in multitarget therapy of class v lupus nephritis: A case report</td>
<td>Tatiana Prikopka (V/A Nansenos Research Institute of Rheumatology, Russian Federation)</td>
</tr>
<tr>
<td>LP-127</td>
<td>Tacrolimus is effective treatment in patients with refractory lupus nephritis</td>
<td>Ji-Won Kim (Ajou Univ., Korea)</td>
</tr>
<tr>
<td>LP-128</td>
<td>Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and azathioprine as maintenance therapies for lupus nephritis: A network meta-analysis</td>
<td>Yong Ho Lee (Korea Univ. Medicine, Korea)</td>
</tr>
<tr>
<td>LP-129</td>
<td>Lupus line disease activity state as an attainable and complementary target for lupus nephritis</td>
<td>Chaik Kee-Chung (Queen Mary Hosp. and the Univ. of Hong Kong, Hong Kong)</td>
</tr>
<tr>
<td>LP-130</td>
<td>Effect of renin-angiotensin system inhibitors on renal remission in lupus nephritis: A real-world single-center study</td>
<td>Xuehu Zhang (Peking Univ. First Hosp., China)</td>
</tr>
<tr>
<td>LP-131</td>
<td>Serum uric acid and the risk of renal involvement in premenopausal female systemic lupus erythematosus patients</td>
<td>Su Jin Choi (Ulsan Univ., Korea)</td>
</tr>
<tr>
<td>LP-132</td>
<td>Comparison in efficacy and safety of mycophenolate mofetil and cyclophosphamide in lupus nephritis: Evidence from a real-world study</td>
<td>Xuehu Zhang (Peking Univ. First Hosp., China)</td>
</tr>
<tr>
<td>LP-133</td>
<td>Baseline clinical characteristics of SLE patients compared to those with Lupus nephritis and on renal replacement treatment (RRT) including Kidney transplantation</td>
<td>Rajeev Narmes (Cleveland Clinic Abu Dhabi, United Arab Emirates)</td>
</tr>
<tr>
<td>LP-134</td>
<td>Withdrawn</td>
<td></td>
</tr>
<tr>
<td>LP-207</td>
<td>Impact of time to remission, flares and time on immunosuppressives on the estimated glomerular filtration rate in lupus nephritis</td>
<td>Delphi Sladram (Univ. of Toronto, Canada)</td>
</tr>
<tr>
<td>LP-208</td>
<td>Mesangial lupus nephritis: Long term outcomes</td>
<td>Delphi Sladram (Univ. of Toronto, Canada)</td>
</tr>
</tbody>
</table>

SLE Outcomes and Prognosis

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>LP-135</td>
<td>High neutrophil-to-lymphocyte ratio is a risk factor for chronic kidney disease in patients with lupus nephritis</td>
<td>Dong-Jin Park (Chonnam Nat’l Univ., Korea)</td>
</tr>
<tr>
<td>LP-136</td>
<td>A 52 year old female with abdominal pain and diagnosed with chronic inflammatory dermopathy/polychondritis and probable systemic lupus erythematosus: A case report</td>
<td>Kemiyori Yu (Far Eastern Univ. – Mano Research Medical Foundation, Japan)</td>
</tr>
<tr>
<td>LP-137</td>
<td>Benefits of ARA screening for NPSLE in patients admitted to the department of psychiatry</td>
<td>Yee-Jin Lee (Asan Medical Center, Korea)</td>
</tr>
<tr>
<td>LP-138</td>
<td>Predictors for future development of systemic lupus erythematosus in Korean Sjögren’s syndrome patients</td>
<td>Bong-Woo Lee (The Catholic Univ. of Korea, Korea)</td>
</tr>
<tr>
<td>LP-139</td>
<td>Baseline characteristics of a longitudinal, multinational, multicentric study of lupus patients, with or without lupus nephritis</td>
<td>Guillermo Pons-estel (Centro Regional de Enfermedades Autoinmunes y Reumatologicas, Argentina)</td>
</tr>
<tr>
<td>LP-140</td>
<td>Application of supervised machine learning algorithms in classification of systemic lupus erythematosus versus other autoimmune positive autoantibody positive autoimmune rheumatic diseases</td>
<td>Prathis Krishna Manjap (Aranya Institute of Medical Sciences, India)</td>
</tr>
<tr>
<td>LP-141</td>
<td>Delay to diagnosis of systemic lupus erythematosus and its impact on cumulative damage and mortality: Data from a Multicentric Latin American Cohort</td>
<td>Guillermo Pons-estel (Centro Regional de Enfermedades Autoinmunes y Reumatologicas, Argentina)</td>
</tr>
<tr>
<td>LP-142</td>
<td>The use of childhood LLDBS: First results in a real-life longitudinal childhood lupus cohort shows good feasibility but difficult attainment</td>
<td>Sandy Bergkamp (AmsterdamUMC, Emma Children’s Hosp, Netherlands)</td>
</tr>
<tr>
<td>LP-143</td>
<td>A case of systemic lupus erythematosus in a male patient presenting with mouth bleeding and cutaneous manifestation</td>
<td>Maruan-Amanda Kostansz Kostansz (Prof. Dr. W.J., Johan Kapsang General Hosp, Indonesia)</td>
</tr>
<tr>
<td>LP-144</td>
<td>Cytosolic localization of antibodies in monocytes is positively associated with disease activity of the patients with systemic lupus erythematosus</td>
<td>Min-Jay Kim (Ajou Univ., Korea)</td>
</tr>
<tr>
<td>LP-145</td>
<td>Case report: A 4:3-year-old Filipino with lupus myocarditis as initial presentation of systemic lupus erythematosus</td>
<td>Mark Leja Georros (FEU-NRMF, Philippines)</td>
</tr>
<tr>
<td>LP-146</td>
<td>Thrombotic thrombocytopenic purpura as initial presentation of systemic lupus erythematosus: A case report</td>
<td>Norry Marie Garcia-pedro (Makati Medical Center, Philippines)</td>
</tr>
<tr>
<td>LP-147</td>
<td>Multiple opportunistic infection in a male with systemic lupus erythematosus and concomitant human immunodeficiency virus infection</td>
<td>Joseph Peter T. Lim (Makati Medical Center, Philippines)</td>
</tr>
<tr>
<td>LP-148</td>
<td>Acute myocarditis: A rare manifestation of systemic lupus erythematosus</td>
<td>Norry Marie Garcia-pedro (Makati Medical Center, Philippines)</td>
</tr>
<tr>
<td>LP-149</td>
<td>Latin-American systemic lupus erythematosus clusters</td>
<td>Guillermo Pons-estel (Centro Regional de Enfermedades Autoinmunes y Reumatologicas, Argentina)</td>
</tr>
<tr>
<td>LP-150</td>
<td>Outcomes of serologically active clinically quiescent (SACO) versus serologically and clinically quiescent (SQCQ) statuses in patients with systemic lupus erythematosus</td>
<td>Raislop Pakcharoem (Phramongkutklao College of Medical Sciences, Thailand)</td>
</tr>
<tr>
<td>LP-151</td>
<td>Cluster analysis of serious infections in SLE predicts subsets susceptible to recurrent intracutaneous and bacterial infections.</td>
<td>Rutverdeal Chatterjee (Jagat Gopa Postgraduate Institute of Medical Sciences, India)</td>
</tr>
<tr>
<td>LP-152</td>
<td>Sinus node dysfunction (Bradycardia-bradycardia syndrome) and acute transversion myeltis as initial presentation of systemic lupus erythematosus in a 55-year female: A case report</td>
<td>Ria May Laines (Chong Hua Hosp, Philippines)</td>
</tr>
<tr>
<td>LP-153</td>
<td>The potential role of serum cytokeratin-associated protein 4 as a novel biomarker to monitor disease activity in systemic lupus erythematosus</td>
<td>Yuki Kudo (Hokkaido Univ., Japan)</td>
</tr>
<tr>
<td>LP-154</td>
<td>Peripheral gangrene in systemic lupus erythematosus – a rare case report</td>
<td>Nural Fadilah (Nusantara Univ., Indonesia)</td>
</tr>
<tr>
<td>LP-155</td>
<td>Psychosis as an early manifestation of neuropsychiatric systemic lupus erythematosus – a case report</td>
<td>Widya Rinastra Dinar (Nusantara Univ., Indonesia)</td>
</tr>
<tr>
<td>LP-156</td>
<td>OPTIMISE - Validation of the SLEDAI-P self-questionnaire completed by the patient to measure the activity of the systemic lupus</td>
<td>Marc Scherling (Centre Hospitalier Universitaire de Strasbourg, France)</td>
</tr>
<tr>
<td>LP-157</td>
<td>Progressive discoid lupus related severe vasculitis - A rare case report</td>
<td>Ira SaputriBurukshuk (Nusantara Univ., Indonesia)</td>
</tr>
<tr>
<td>LP-158</td>
<td>Macrophage activation syndrome in 10 children with systemic lupus erythematosus - The retrospective cohort observation study</td>
<td>Mikhail Kostik (Saint Petersburg State Pediatric Medical University, Russian Federation)</td>
</tr>
<tr>
<td>LP-159</td>
<td>Studying the disease activity and the degree of internal organ damage in systemic lupus erythematosus patients in the Kazakh population</td>
<td>Guban Alibekov (NISC, Astana Medical Centers, Kazakhstan)</td>
</tr>
<tr>
<td>LP-160</td>
<td>Characteristics of patients with seronegative lupus erythematosus</td>
<td>Janci Caperanara Baron (Fundacion Universitaria de ciencia de la salud [FUCS] Hosp. San Jose, Colombia)</td>
</tr>
<tr>
<td>LP-161</td>
<td>Tjulma syndrome (Pseudo-pseudo Neiens Syndrome): Polynoritis with increased CA-125 in patients with systemic lupus erythematosus</td>
<td>Drew Fancy paulin (Faisalabad Univ., India)</td>
</tr>
<tr>
<td>LP-162</td>
<td>Prognostic factors for the chronic thrombocytopenia in systemic lupus erythematosus</td>
<td>Soo Min Ahn (Univ of Ulsan, Korea)</td>
</tr>
<tr>
<td>LP-163</td>
<td>The correlation between depression and fatigue in patient with systemic lupus erythematosus (SLE) in Indonesia</td>
<td>Zewa Putri Saibabia (Universitas Alau Indonesia, Indonesia)</td>
</tr>
<tr>
<td>LP-164</td>
<td>Urinary N-acetyl-beta-D-glucosaminidase, a marker of lupus nephritis activity</td>
<td>A M J Jajakar Hal (Lab-Aid Specialist Hosp, Bangladesh)</td>
</tr>
</tbody>
</table>
SLE Pregnancy and Reproductive Health

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>LP-177</td>
<td>Intravenous immunoglobulin in pregnant women with severe active lupus: A case series</td>
<td>Jari Caparranas-Barrion (Fundacion Universitaria de Ciencias de la Salud (FUCS) Hosp San Jose, Colombia)</td>
</tr>
<tr>
<td>LP-178</td>
<td>Association between systemic lupus erythematosus (SLE) and abnormal uterine bleeding (AUB) among reproductive-age women</td>
<td>Zublena Rahimb (Universitas Islam Indonesia, Indonesia)</td>
</tr>
<tr>
<td>LP-200</td>
<td>Relapsing polychondritis and systemic lupus erythematosus overlap in a 26 year old G2P1 pregnant mother with successful pregnancy outcome</td>
<td>Adel Tanjut (Zambonga City Medical Center, Philippines)</td>
</tr>
</tbody>
</table>

SLE Treatment

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>LP-179</td>
<td>Design of 2 phase 3, double-blind, placebo-controlled, global trials of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active systemic lupus erythematosus</td>
<td>Cristiano Armes (Oklahoma Medical Research Foundation, USA)</td>
</tr>
<tr>
<td>LP-180</td>
<td>Design of a phase 2, double-blind, placebo-controlled, global trial of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active discoid and/or subacute cutaneous lupus erythematosus</td>
<td>Victoria R. Wherly (Shriners Hospital for Children, USA)</td>
</tr>
</tbody>
</table>
Systemic sclerosis and Raynaud’s phenomenon

No. | Title | Presenter
--- | --- | ---
KP-050 | The clinical characteristics, management, and immunological features in patients with mixed connective tissue disease | Aneu Kim
(KP-051) | Mortality and prognostic factors in connective tissue disease associated pulmonary arterial hypertension patients complicated with right heart failure | Xueyue Deng
(KP-052) | Anti-fibrotic effect of Ginkgo biloba extract on skin fibrosis in bleomycin-induced systemic sclerosis mouse model | Kang Qian Liu
(KP-053) | The comorbidity burden in interstitial lung disease associated with systemic sclerosis | Ruchana Shapkakhteva
(KP-054) | Body composition in women with systemic sclerosis | Ruchana Shapkakhteva
(KP-055) | Osteoporosis in premenopausal women with systemic sclerosis | Ruchana Shapkakhteva
(KP-056) | Systemic sclerosis in men: Focus on osteoporosis | Ruchana Shapkakhteva
(KP-057) | Changes of acute-phase reactants in systemic sclerosis during rituximab therapy | Ruchana Shapkakhteva
(KP-058) | Cardiac involvement in systemic sclerosis and impact of rituximab therapy | Ruchana Shapkakhteva
(KP-059) | Impact of systemic sclerosis subset on the efficacy of rituximab therapy | Ruchana Shapkakhteva
(KP-060) | Association immunological parameters and pulmonary function parameters in patients with SSc and ILD over 5 year follow up study | Ruchana Shapkakhteva
(KP-061) | The predictive intervals for patients with systemic sclerosis and interstitial lung disease using discriminant analysis | Ruchana Shapkakhteva
(KP-062) | Evaluation of the clinical significance of the main radiological signs of interstitial lung disease in systemic sclerosis | Olga Kureeva
(KP-063) | To study the influence of a variety of clinical, laboratory and instrumental parameters on the results of treatment of patients with systemic sclerosis and interstitial lung disease | Olga Kureeva
(KP-064) | Study of the traditional basic drugs and anti-B-cell therapy effect on systemic sclerosis skin and pulmonaryological manifestations | Olga Kureeva
(KP-065) | Rituximab in the treatment of patients with systemic sclerosis: influence of the renal function | Maria Stavreva
(KP-066) | Vascular manifestations of systemic sclerosis in patients with pulmonary arterial hypertension | Natalia Yudina
(KP-067) | Clinical characteristics of overlap-syndrome systemic sclerosis-systemic lupus erythematosus | Olena Sazonova
(KP-068) | Model for the detection of systemic sclerosis in patients with pulmonary arterial hypertension | Natalia Yudina
(KP-069) | Bifidobacterium longum RAPO ameliorates dermal and pulmonary fibrosis through the modulation of gut microbiota and immune response in bleomycin-induced systemic sclerosis in mice | Suhye Kim
(KP-040) | Dynamics of traditional modifiable risk factors, and structural changes of carotid arteries in patients with rheumatoid arthritis on long-term interleukin-6 receptor antagonist treatment | Tatsana Popkova
(KP-041) | Tofacitinib in halting radiographic progression—evidence from 2 cases | Naga Prithu
(KP-198) | How the caregiver status could increase the quality of life among rheumatoid arthritis elderly with dementia status? | Rosenta HERMÁN-PÉREZ Fuentes
(KP-199) | How religiosity have positive association with mental health and derive prolonged survival in rheumatoid arthritis patients: A systematic review | Lintong Nettaya Sukosol
(KP-200) | Differential drug retention rates between tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis subgroups defined by simple laboratory tests | Jung Sun Kim
(KP-042) | Withdrawn | 
(KP-043) | Quantitative analysis of efficacy and associated factors of platelet rich plasma treatment for osteoarthritis | Ying Cao
(KP-044) | Quantitative analysis of efficacy and associated factors of therapeutic exercise and education on symptoms in osteoarthritis | Zhuhua Zhu
(KP-045) | Efficacy of metformin and ibuprofen joint treatment in patients with knee osteoarthritis and metabolic syndrome | Jaroslav Uskova
(KP-046) | Circulating exosomal microrna expression in patients with knee osteoarthritis and metabolic syndrome | Zurnnaa Uskova
(KP-047) | Influence of metabolic syndrome components in patients with hip osteoarthritis | Jaroslav Uskova
(KP-048) | Factorial validity of the PHQ-9 in individuals with osteoarthritis. Results from the 2020 Korea National Health and Nutrition Examination Survey (KNHANES) | Patrick Brzoska
(KP-049) | The effect of nerve growth factor on in vitro chondrogenesis using induced pluripotent stem cells | Jung Siun
(KP-201) | Therapeutic role of Wharton’s jelly mesenchymal stem cells (WM-MSCs) to the MIA-induced osteoarthritis model | Ernaldy Damar
Idiopathic inflammatory myopathy

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>KP-070</td>
<td>High fatigue scores in patients with idiopathic inflammatory myopathies: A multipurpose comparative study from the COVID-19 e-survey</td>
<td>Lisa Tabiosco (University of the Philippines, Philippines)</td>
</tr>
<tr>
<td>KP-071</td>
<td>Performance of cut-offs adjusted with positive control band intensity in line-blot assays for myositis-specific antibodies</td>
<td>Sa Bin Choi (Seoul National University, Korea)</td>
</tr>
<tr>
<td>KP-072</td>
<td>Anti-HMGCR positive necrotizing myopathy after statin use in a 77 year old male: A case report</td>
<td>Rica Kaeu King (St. Lukes, Philippines)</td>
</tr>
<tr>
<td>KP-073</td>
<td>Challenging treatment of anti-synthetase syndrome complicated by severe immunodeficiency</td>
<td>Suzy Marie (Universitas Indonesia, Indonesia)</td>
</tr>
<tr>
<td>KP-074</td>
<td>Flares after COVID-19 infection in patients with idiopathic inflammatory myopathies: Results from the COVID study</td>
<td>Chou Luan Tan (Hosp. Putrajaya, Malaysia)</td>
</tr>
<tr>
<td>KP-075</td>
<td>Complete remission of severe anti-MDA5 dermatomyositis with combination sequential immunosuppressive and antioxidant therapy</td>
<td>Yeon-Kam Hon (El Shaddai Arthritis &amp; Rheumatoid Specialist Medical Centre, Singapore)</td>
</tr>
<tr>
<td>KP-076</td>
<td>Anti-hydroxy-3-methylglutaryl-coenzyme a reductase myopathy with new onset diabetes: A case report</td>
<td>Maricel Bolente (Univ of Santo Tomas Hosp, Philippines)</td>
</tr>
</tbody>
</table>

Sjögren's syndrome

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>KP-077</td>
<td>Chronic sclerosing sialadenitis, is it a Sjögren’s syndrome or not?</td>
<td>Eui-Jang Kwon (The Catholic Univ. of Korea, Korea)</td>
</tr>
<tr>
<td>KP-078</td>
<td>EULAR Sjögren’s syndrome patient index (ESSPRI) and other patient-reported outcomes in assessment of glandular dysfunction in Sjögren’s syndrome</td>
<td>Minul Yadaa Ture (Kyungpook National Univ., Korea)</td>
</tr>
<tr>
<td>KP-079</td>
<td>The clinical characteristics of Korean primary Sjögren’s syndrome (pSS) patients with positive anti-double-stranded DNA (anti-dsDNA) antibody by the Farr method</td>
<td>Bong-Woo Lee (The Catholic Univ. of Korea, Korea)</td>
</tr>
<tr>
<td>KP-080</td>
<td>Design of a phase 2, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy and safety of niocondazole in adults with primary Sjögren’s syndrome</td>
<td>Yeong-Ju Lee (Asia University), Korea</td>
</tr>
<tr>
<td>KP-081</td>
<td>Deep learning based assessment of salivary gland ultrasonography images for supporting the diagnosis of Primary Sjögren’s syndrome</td>
<td>Yan Geng (Peking University First Hospital, China)</td>
</tr>
<tr>
<td>KP-082</td>
<td>A study of clinical characteristics and autoantibody clustering of Hypokalemic periodic polyhydramnios (HPP) in primary Sjögren syndrome (PSS) from India</td>
<td>Ritikman Baliga (Assistant Professor, India)</td>
</tr>
<tr>
<td>KP-083</td>
<td>Withdrawn</td>
<td></td>
</tr>
</tbody>
</table>

Spondyloarthropathies and psoriatic arthritis

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>KP-082</td>
<td>Risk of cancer, tuberculosis, and serious infections in patients with ankylosing spondylitis, psoriatic arthritis, and psoriasis treated with IL-17 and TNF-a inhibitors: A nationwide nested case-control analysis</td>
<td>Sung Soo Ahn (Yonsei University, Korea)</td>
</tr>
<tr>
<td>KP-083</td>
<td>Proposal of simplified CT syndesmophyte score (aCTSS) and comparison with CTSS in patients with ankylosing spondylitis</td>
<td>Hong Ki Min (Korea University, Korea)</td>
</tr>
<tr>
<td>KP-084</td>
<td>The relationship between long-term use of nonsteroidal anti-inflammatory drugs and kidney function in patients with ankylosing spondylitis</td>
<td>Bon San Koo (Yonsei University, Korea)</td>
</tr>
<tr>
<td>KP-085</td>
<td>Prevalence of fall risk factors in patients followed for spondylarthropathy</td>
<td>Raja Rezadi (University of Minnesota, USA)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>KP-086</td>
<td>A case of difficult to treat psoriatic arthritis: Is there a hope with switching biologics?</td>
<td>Satheeshkumar Udayan (Rheumatology and Rehabilitation Hosp, Ramagya, Srilanka)</td>
</tr>
<tr>
<td>KP-087</td>
<td>Risks of cancers in patients with ankylosing spondylitis</td>
<td>Jhyoun Kim (Chungbuk Nat’l Univ., Korea)</td>
</tr>
<tr>
<td>KP-088</td>
<td>The development of axial spondyloarthritis after a COVID-19 infection</td>
<td>Emilena Agafonova (U.4. Research Institute of Rheumatology, Russian Federation)</td>
</tr>
<tr>
<td>KP-089</td>
<td>Relationship of x-ray progression and MRI changes in the hip joints in patients with axial spondyloarthritis</td>
<td>Emilena Agafonova (U.4. Research Institute of Rheumatology, Russian Federation)</td>
</tr>
<tr>
<td>KP-090</td>
<td>The difference in disease activity score and treatment response according to gender in patients with axial spondyloarthritis</td>
<td>Seung Eun Lee (Sungkyunkwan University, Korea)</td>
</tr>
<tr>
<td>KP-091</td>
<td>Association between triglyceride-glucose index and carotid atherosclerosis in patients with psoriatic arthritis: A cross-sectional study</td>
<td>Wonhu Heo (Peking University First Hospital, China)</td>
</tr>
<tr>
<td>KP-092</td>
<td>Complete remission of severe erythrodermic psoriasis with combination isokizumab and abrocitinib therapy</td>
<td>Yeon-Kam Hon (El Shaddai Arthritis &amp; Rheumatoid Specialist Medical Centre, Singapore)</td>
</tr>
<tr>
<td>KP-093</td>
<td>Effects of TNF inhibitors on lipid profile in ankylosing spondylitis patients</td>
<td>Hee-jae Kim (Narayang University, Korea)</td>
</tr>
<tr>
<td>KP-094</td>
<td>Mortality in patients with psoriatic arthritis: A systematic review and meta-analysis</td>
<td>Hong Huang (Peking University First Hospital, China)</td>
</tr>
<tr>
<td>KP-095</td>
<td>Value of low-dose computed tomography for examination of sacroiliac joints in axial spondyloarthritis</td>
<td>In Woo Baek (E.J. Bokman, Korea)</td>
</tr>
<tr>
<td>KP-096</td>
<td>Renal safety of long term NSAD use in patients with ankylosing spondylitis</td>
<td>Young-Eun Kim (UNIST, Korea)</td>
</tr>
<tr>
<td>KP-097</td>
<td>Subchondral insufficiency fracture of the Femoral head in a Patient with Ankylosing spondylitis: Case report and literature review</td>
<td>Yee-Jin Lee (Asan Medical Center, Korea)</td>
</tr>
<tr>
<td>KP-098</td>
<td>Oral administration with DPP4 inhibitor ameliorates pathological bone formation in cedran-injected SKG mice</td>
<td>Sungjin Jo (Narayang University, Korea)</td>
</tr>
<tr>
<td>KP-099</td>
<td>Withdrawn</td>
<td></td>
</tr>
<tr>
<td>KP-100</td>
<td>Usefulness of MRI in patients without findings of sacroiliitis on X-rays</td>
<td>Yee-Jin Lee (Asan Medical Center, Korea)</td>
</tr>
<tr>
<td>KP-101</td>
<td>Factors associated with cause-specific discontinuation of the first line anti-tumor necrosis factor agent in ankylosing spondylitis</td>
<td>Bora Nam (Pusan National University, Korea)</td>
</tr>
<tr>
<td>KP-102</td>
<td>Knowledge of disease among Filipino patients with spondyloarthritis</td>
<td>Kelvie Demata Monsanto (Univ of the Philippines, Philippines)</td>
</tr>
<tr>
<td>KP-103</td>
<td>Impact of disease activity on functional impairment in patients with spondyloarthritis is different according to the degree of radiographic progression: Result from SMHU-AS cohort</td>
<td>Jee Jung (Seoul National University, Korea)</td>
</tr>
<tr>
<td>KP-104</td>
<td>A case of IgA nephropathy developed during seinkumab treatment in a patient with ankylosing spondylitis</td>
<td>Seung-Bin Nam (Wonju Severance Christian Hosp, Korea)</td>
</tr>
<tr>
<td>KP-105</td>
<td>HIV Induced Spondyloarthropathy (SpA): An autoimmune disease in immunodeficiency state</td>
<td>inte Darmanik (V.A. Nasonova Research Institute of Rheumatology, Russia)</td>
</tr>
<tr>
<td>KP-204</td>
<td>Long-term safety of isokizumab in adult patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis</td>
<td>Young In Eom (Ewha Womans University, Korea)</td>
</tr>
</tbody>
</table>
Poly medication and risk of falling

Correlation between vitamin D and falling: About 425 Moroccan patients

Genetic association between mild osteogenesis imperfecta (OI) and postmenopausal osteoporosis in women

An analysis of hospital discharge coding for Giant Cell Arteritis shows high proportion of patients meeting the ACR criteria, but one-third do not have GCA

IgA vasculitis as an initial presentation of HIV in a young Filipino male: A case report

Thoracic endovascular aneurysm repair in a patient with Behçet's disease and thoracic aortic aneurysm: A case report

Association between interleukin-1 gene polymorphisms and behcet’s disease susceptibility: Systematic review and meta-analysis

Behçet’s disease: Demographic, social, clinical manifestations and ongoing therapy in Kazakhstan

Clinical characteristics and courses of Korean patients with giant cell arteritis: A multi-center retrospective study

Polyarteritis nodosa: A Rare cause of severe abdominal pain in an elderly filipina

Systemic immune-inflammation index in Behçet’s disease

Neutrophil activity in Behçet’s disease

Inflammatory markers in Behçet’s disease activity

Neutrophil extracellular traps (NETs) in Behçet’s disease

Haemostatic abnormalities in patients with Behçet’s disease and antiphospholipid syndrome before anti-coagulants treatment

Eosinophil granulomatosis with polyangiitis (EGPA) presenting as superior vena cava (SVC) syndrome-like in a Filipino female patient: A case report

Thoracic endovascular aneurysm repair in a patient with Behçet’s disease and thoricacic aneurysm: A case report

Association between interleukin-1 gene polymorphisms and behcet’s disease susceptibility: Systematic review and meta-analysis

Behçet’s disease: Demographic, social, clinical manifestations and ongoing therapy in Kazakhstan

Clinical characteristics and courses of Korean patients with giant cell arteritis: A multi-center retrospective study

Polyarteritis nodosa: A Rare cause of severe abdominal pain in an elderly filipina

Systemic immune-inflammation index in Behçet’s disease

Neutrophil activity in Behçet’s disease

Inflammatory markers in Behçet’s disease activity

Neutrophil extracellular traps (NETs) in Behçet’s disease

Haemostatic abnormalities in patients with Behçet’s disease and antiphospholipid syndrome before anti-coagulants treatment

Eosinophil granulomatosis with polyangiitis in a 56-year-old female presenting with hoarseness: A case report

Eosinophilic granulomatosis with polyangiitis in a patient with discoid lupus

Indian data on patients with Behçet’s disease: A multi centre study

An analysis of hospital discharge coding for Giant Cell Arteritis shows high proportion of patients meeting the ACR criteria, but one-third do not have GCA

Acute transverse myelitis and leptomeningitis in an adolescent female: A dramatical presentation leading to neurobehcet’s disease diagnosis

Fibromyalgia and cataract: Friend or foe

Acute transverse myelitis and leptomeningitis in an adolescent female: A dramatical presentation leading to neurobehcet’s disease diagnosis

Fibromyalgia and cataract: Friend or foe

The impact of personality trait on the comorbidity of fibromyalgia in patients with rheumatoid arthritis

Withdrawn

No. | Title | Presenter
--- | --- | ---
KP-106 | IgA vasculitis as an initial presentation of HIV in a young Filipino male: A case report | Antonio Lorenzo Quambao (East Avenue Medical Center, Philippines)
KP-107 | Eosinophilic granulomatous polyangiitis (EGPA) presenting as superior vena cava (SVC) syndrome-like in a Filipino female patient: A case report | Ronald Ramirez (Valenzuela Medical Center, Philippines)
KP-108 | Thoracic endovascular aneurysm repair in a patient with Behçet’s disease and thoracic aneurysm: A case report | Ronald Ramirez (Valenzuela Medical Center, Philippines)
KP-109 | Association between interleukin-1 gene polymorphisms and behcet’s disease susceptibility: Systematic review and meta-analysis | Steven Irving (Universitas Sediane Memb, Indonesia)
KP-110 | Behçet’s disease: Demographic, social, clinical manifestations and ongoing therapy in Kazakhstan | Almas Arip (Almaty City Rheumatology, Kazakhstan)
KP-111 | Clinical characteristics and courses of Korean patients with giant cell arteritis: A multi-center retrospective study | Jeon Lee (Seoul Nat’l Univ., Korea)
KP-112 | Polyarteritis nodosa: A Rare cause of severe abdominal pain in an elderly filipina | Golden Meri Rason (VSMMC, Philippines)
KP-113 | Systemic immune-inflammation index in Behçet’s disease | Tatiana Reshetnyak (Nasonova Research Institute of Rheumatology, Russian Federation)
KP-114 | Neutrophil activity in Behçet’s disease | Tatiana Reshetnyak (Nasonova Research Institute of Rheumatology, Russian Federation)
KP-115 | Inflammatory markers in Behçet’s disease activity | Tatiana Reshetnyak (Nasonova Research Institute of Rheumatology, Russian Federation)
KP-116 | Neutrophil extracellular traps (NETs) in Behçet’s disease | Tatiana Reshetnyak (Nasonova Research Institute of Rheumatology, Russian Federation)
KP-117 | Haemostatic abnormalities in patients with Behçet’s disease and antiphospholipid syndrome before anti-coagulants treatment | Nataliya Seredavkina (Scientific Research Institute of Rheumatology named after V.A. Nasonov, Russian Federation)
KP-118 | Eosinophilic granulomatosis with polyangiitis in a 56-year-old female presenting with hoarseness: A case report | Lendojo Jose Dado (St. Luke’s Medical Center, Philippines)
KP-119 | Eosinophilic granulomatosis with polyangiitis in a patient with discoid lupus | Chayawany Vangde-Dua (St. Luke’s Medical Center, Philippines)
KP-120 | Indian data on patients with Behçet’s disease: Single centre experience | Sehat Roop Kaur (ARDS, India)
KP-121 | An analysis of hospital discharge coding for Giant Cell Arteritis shows high proportion of patients meeting the ACR criteria, but one-third do not have GCA | Andrew Dershaman (Royal North Hops, Australia)
KP-205 | Acute transverse myelitis and leptomeningitis in an adolescent female: A dramatical presentation leading to neurobehcet’s disease diagnosis | Rachid Small (Universitary Hosp. of Tangier, France)
KP-122 | Association and correlation between bone mineral density and osteoporosis with blood pressure indices, hypertension and body mass index | Javed Meherar (Natl Taipei Univ. of Nursing and Health Sciences, Taiwan)
KP-123 | Bisphosphonates therapy for osteoporosis in women with breast cancer: A 3-year follow up | Rajaa Assadi (Marrakech Univ., Morocco)
KP-124 | Poly medication and risk of falling | Rajaa Assadi (Marrakech Univ., Morocco)
KP-125 | Correlation between vitamin D and falling: About 425 Moroccan patients | Rajaa Assadi (Marrakech Univ., Morocco)
KP-126 | Falling and vitamin D status in osteoporotic patients | Rajaa Assadi (Marrakech Univ., Morocco)
KP-127 | Biochemical evaluation of plant based diet and its preventive effects against osteoporosis and other bone related disorder | Muhammad Sajid Arshad (Government College Univ. Faisalaba, Pakistan)
KP-128 | Variations in free vitamin D and vitamin D binding protein in patients with acute and chronic upper limb injuries | Li Sup Hoang (Seoul Nat’l Univ., Korea)
KP-129 | Case reports: Primary hypertrophic osteoarthropathy identified by gene mutation of skduc1 in Vietnam | Trang Do Thi Huong (Hanoi Medical Univ. Hosp, Vietnam)
KP-130 | Genetic association between mild osteogenesis imperfecta (OI) and postmenopausal osteoporosis | Eman Shahrour (Tishreen Univ., Syria)
KP-131 | Coccydynia - A Covid era pain alment and role of vitamin D | Sumit Ghoswati (Medan Mohan Medical and Counselling Centre, India)
KP-132 | Osteogenesis imperfecta, osteoporosis and rheumatoid arthritis in the era of biologic therapies: Do we have the right solutions? | Bogdan Ion Gavrila (Univ. of Medicine and Pharmacy “Carol Davila”, Romania)
KP-206 | Withdrawn |
## LUPUS & KCR 2023 Steering Committee

### LUPUS

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>University</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Sang-Cheol Bae</td>
<td>Hanyang University</td>
</tr>
<tr>
<td>Secretary General</td>
<td>Seung-Cheol Shim</td>
<td>Chungnam National University</td>
</tr>
<tr>
<td>Deputy Secretary General</td>
<td>Chan-Bum Choi</td>
<td>Hanyang University</td>
</tr>
<tr>
<td>Scientific Committee Chair</td>
<td>Jisoo Lee</td>
<td>Ewha Womans University</td>
</tr>
<tr>
<td>Scientific Committee Vice Chair</td>
<td>Chang-Hee Suh</td>
<td>Ajou University</td>
</tr>
</tbody>
</table>

### KCR

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>University</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Sang-Cheol Bae</td>
<td>Hanyang University</td>
</tr>
<tr>
<td>Chairman of the Board</td>
<td>Shin-Seok Lee</td>
<td>Chonnam National University</td>
</tr>
<tr>
<td>Director of Planning</td>
<td>Hoon-Suk Cha</td>
<td>Sungkyunkwan University</td>
</tr>
<tr>
<td>Director of General Affairs</td>
<td>Seung-Ki Kwok</td>
<td>The Catholic University of Korea</td>
</tr>
<tr>
<td>Director of Finance</td>
<td>Yong-Beom Park</td>
<td>Yonsei University</td>
</tr>
<tr>
<td>Director of Academic Affairs</td>
<td>Yoon-Kyoung Sung</td>
<td>Hanyang University</td>
</tr>
</tbody>
</table>

## Local Organizing Committee

### President

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>University</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Sang-Cheol Bae</td>
<td>Hanyang University</td>
</tr>
<tr>
<td>Secretary General</td>
<td>Seung-Cheol Shim</td>
<td>Chungnam National University</td>
</tr>
<tr>
<td>Deputy Secretary General</td>
<td>Chan-Bum Choi</td>
<td>Hanyang University</td>
</tr>
<tr>
<td>Scientific Committee Chair</td>
<td>Jisoo Lee</td>
<td>Ewha Womans University</td>
</tr>
</tbody>
</table>

### Scientific Committee Vice Chair

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>University</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member</td>
<td>Shin-Seok Lee</td>
<td>Chonnam National University</td>
</tr>
<tr>
<td>Yeonseok Chung</td>
<td>(Seoul National University)</td>
<td></td>
</tr>
<tr>
<td>Seung Hyeok Han</td>
<td>(Yonsei University)</td>
<td></td>
</tr>
<tr>
<td>Seung-ki Kwok</td>
<td>(The Catholic University of Korea)</td>
<td></td>
</tr>
<tr>
<td>Chang-Keun Lee</td>
<td>(University of Ulsan)</td>
<td></td>
</tr>
<tr>
<td>Hye-Soon Lee</td>
<td>(Hanyang University)</td>
<td></td>
</tr>
</tbody>
</table>

## Scientific Committee

### Basic

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>University</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soyoung Bang</td>
<td>(Hanyang University)</td>
<td></td>
</tr>
<tr>
<td>Seokchan Hong</td>
<td>(University of Ulsan)</td>
<td></td>
</tr>
<tr>
<td>Ki-Jo Kim</td>
<td>(The Catholic University of Korea)</td>
<td></td>
</tr>
<tr>
<td>Kwangwoo Kim</td>
<td>(Kyung Hee University)</td>
<td></td>
</tr>
<tr>
<td>Seungki Kwok</td>
<td>(The Catholic University of Korea)</td>
<td></td>
</tr>
<tr>
<td>Youn-soo Choi</td>
<td>(Seoul National University)</td>
<td></td>
</tr>
<tr>
<td>Yoonrae Lee</td>
<td>(POSTECH)</td>
<td></td>
</tr>
<tr>
<td>Su-Jin Moon</td>
<td>(The Catholic University of Korea)</td>
<td></td>
</tr>
<tr>
<td>Yong-wook Park</td>
<td>(Chonnam National University)</td>
<td></td>
</tr>
</tbody>
</table>

### Clinical

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>University</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sung Hae Chang</td>
<td>(Soonchunhyang University)</td>
<td></td>
</tr>
<tr>
<td>Sangtae Choi</td>
<td>(Chung-Ang University)</td>
<td></td>
</tr>
<tr>
<td>Eun Ha Kang</td>
<td>(Seoul National University)</td>
<td></td>
</tr>
<tr>
<td>Geun-Tae Kim</td>
<td>(Kosin University)</td>
<td></td>
</tr>
<tr>
<td>Hae-Rim Kim</td>
<td>(Konkuk University)</td>
<td></td>
</tr>
<tr>
<td>Yong-Gil Kim</td>
<td>(University of Ulsan)</td>
<td></td>
</tr>
<tr>
<td>Jin Kyun Park</td>
<td>(Seoul National University)</td>
<td></td>
</tr>
<tr>
<td>Seonghoon Park</td>
<td>(Daegu Catholic University)</td>
<td></td>
</tr>
<tr>
<td>Yoon-Kyoung Sung</td>
<td>(Hanyang University)</td>
<td></td>
</tr>
</tbody>
</table>
### LUPUS Organizing Committee

#### International Organizing Committee

<table>
<thead>
<tr>
<th>No.</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olufemi Adelowo</td>
<td>Lagos State University Teaching Hospital, Nigeria</td>
</tr>
<tr>
<td>Tatsuya Atsumi</td>
<td>Hokkaido University, Japan</td>
</tr>
<tr>
<td>Sasha Bernatsky</td>
<td>Research Institute of the McGill University Health Centre, Canada</td>
</tr>
<tr>
<td>Marina Botto</td>
<td>Imperial College London, UK</td>
</tr>
<tr>
<td>Ian Bruce</td>
<td>The University of Manchester, UK</td>
</tr>
<tr>
<td>Tak Mao Chan</td>
<td>University of Hong Kong, Hong Kong</td>
</tr>
<tr>
<td>Nathalie Costedoat-Chalumeau</td>
<td>Cochin Hospital, France</td>
</tr>
<tr>
<td>Joe Craft</td>
<td>Yale University, USA</td>
</tr>
<tr>
<td>Lindsay Criswell</td>
<td>National Institutes of Health, USA</td>
</tr>
<tr>
<td>Mary Crow</td>
<td>Hospital for Special Surgery, USA</td>
</tr>
<tr>
<td>Yong Cui</td>
<td>China - Japan Friendship Hospital, China</td>
</tr>
<tr>
<td>Betty Diamond</td>
<td>The Feinstein Institutes for Medical Research, USA</td>
</tr>
<tr>
<td>Andrea Doria</td>
<td>University of Padua, Italy</td>
</tr>
<tr>
<td>Thomas Dörner</td>
<td>Charite Universitätsmedizin Berlin, Germany</td>
</tr>
<tr>
<td>John Eddale</td>
<td>Arthritis Research Canada, The University of British Columbia, Canada</td>
</tr>
<tr>
<td>Paul Fortin</td>
<td>Université Laval, Canada</td>
</tr>
<tr>
<td>Richard Furie</td>
<td>Northwell Health, USA</td>
</tr>
<tr>
<td>Dafna Gilsman</td>
<td>University of Toronto, Canada</td>
</tr>
<tr>
<td>Lanyiati Hamjaya</td>
<td>University of Padjadjaran, Indonesia</td>
</tr>
<tr>
<td>Masayoshi Horiguchi</td>
<td>Tokyo Women’s Medical University, Japan</td>
</tr>
<tr>
<td>John Harley</td>
<td>Cincinnati Education and Research for Veterans Foundation, USA</td>
</tr>
<tr>
<td>Lüthi Herrmannhauser</td>
<td>National Institutes of Health, USA</td>
</tr>
<tr>
<td>Wan-Nan Huang</td>
<td>Taichung Veterans General Hospital, Taiwan</td>
</tr>
<tr>
<td>David Isenberg</td>
<td>University College London, UK</td>
</tr>
<tr>
<td>Rangi Kandane-Rathnayake</td>
<td>Monash University, Australia</td>
</tr>
<tr>
<td>Mariana Kaplan</td>
<td>National Institute of Arthritis and Musculoskeletal and Skin Diseases/AIH, USA</td>
</tr>
<tr>
<td>Munther Khameil</td>
<td>Kings College London, UK</td>
</tr>
<tr>
<td>Uta Klitz</td>
<td>Rheumazentrum Ruhrgebiet, Germany</td>
</tr>
<tr>
<td>Chak-Sing Lau</td>
<td>University of Hong Kong, Hong Kong</td>
</tr>
<tr>
<td>Arnaud Laurent</td>
<td>Strasbourg University, France</td>
</tr>
<tr>
<td>Alexandra Legge</td>
<td>Dalhousie University, Canada</td>
</tr>
<tr>
<td>Menglan Li</td>
<td>Peking Union Medical College Hospital, China</td>
</tr>
<tr>
<td>Matthew H Liang</td>
<td>Harvard Medical School, USA</td>
</tr>
<tr>
<td>Sung Sam Lim</td>
<td>Emory University, USA</td>
</tr>
<tr>
<td>Peter E. Lipsky</td>
<td>AMPERE Biosolutions, USA</td>
</tr>
</tbody>
</table>

### LUPUS Organizing Committee

#### International Organizing Committee

<table>
<thead>
<tr>
<th>No.</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anselm Mak</td>
<td>National University of Singapore, Singapore</td>
</tr>
<tr>
<td>David McCann</td>
<td>Harvard University, USA</td>
</tr>
<tr>
<td>Joan Merrill</td>
<td>Oklahoma Medical Research Foundation, USA</td>
</tr>
<tr>
<td>Chandra Mohan</td>
<td>University of Houston, USA</td>
</tr>
<tr>
<td>Chi-Chiu Moi</td>
<td>Tan Tock-Seng Hospital, Singapore</td>
</tr>
<tr>
<td>Eric Morand</td>
<td>Monash University, Australia</td>
</tr>
<tr>
<td>Sandra Nawar</td>
<td>University of Santo Tomas, Philippines</td>
</tr>
<tr>
<td>Mandarita Nilipour</td>
<td>The University of Melbourne, Australia</td>
</tr>
<tr>
<td>Kenji Oku</td>
<td>Keio University, Japan</td>
</tr>
<tr>
<td>Michelle Pietri</td>
<td>Johns Hopkins University, USA</td>
</tr>
<tr>
<td>Barnardo A. Pons-Estel</td>
<td>Centro Regional de Enfermedades Autoinmunes y Reumatologicas, Argentina</td>
</tr>
<tr>
<td>Guillermo Pons-Estel</td>
<td>Centro Regional de Enfermedades Autoinmunes y Reumatologicas, Argentina</td>
</tr>
<tr>
<td>Rosalind Ramsey-Goldman</td>
<td>Northwestern University, USA</td>
</tr>
<tr>
<td>Angela Rawlin</td>
<td>IRECS Istituto Giannina Gaslini, Italy</td>
</tr>
<tr>
<td>Boris Reiss</td>
<td>NYU Grossman School of Medicine, USA</td>
</tr>
<tr>
<td>Brad Rovin</td>
<td>The Ohio State University, USA</td>
</tr>
<tr>
<td>Ignacio Sanz</td>
<td>Emory University, USA</td>
</tr>
<tr>
<td>Matthias Schneider</td>
<td>Heinrich-Heine-Universität Düsseldorf, Germany</td>
</tr>
<tr>
<td>Nan Shen</td>
<td>Jiaotong University, China</td>
</tr>
<tr>
<td>Yahuda Shoenfeld</td>
<td>Zab Judowitz Center for Autoimmunity, Shaba Medical Center, Israel, Israel</td>
</tr>
<tr>
<td>Koshibo Sonamoto</td>
<td>University of Occupational and Environmental Health, Japan</td>
</tr>
<tr>
<td>Tedora Steva</td>
<td>Lupus Research Alliance, USA</td>
</tr>
<tr>
<td>Elisabet Stenungsson</td>
<td>Karolinska institutet and Karolinska Univ. Hosp., Sweden</td>
</tr>
<tr>
<td>Tadomu Takeuchi</td>
<td>Keio University, Japan</td>
</tr>
<tr>
<td>Lai Shan Tam</td>
<td>The Chinese University of Hong Kong, Hong Kong</td>
</tr>
<tr>
<td>Yoshiya Tanaka</td>
<td>University of Occupational and Environmental Health, Japan</td>
</tr>
<tr>
<td>Xiping Tian</td>
<td>Peking Union Medical College, China</td>
</tr>
<tr>
<td>Angela Tinarni</td>
<td>ASST-Spedali Civili and University of Brescia, Italy</td>
</tr>
<tr>
<td>George Tsokos</td>
<td>Harvard Medical School, USA</td>
</tr>
<tr>
<td>Ronald Van Vollenhoven</td>
<td>Amsterdam UMC, Netherlands</td>
</tr>
<tr>
<td>Eveline Vinat</td>
<td>McGill University Health Centre, Canada</td>
</tr>
<tr>
<td>Tim Vyse</td>
<td>King’s College London, UK</td>
</tr>
<tr>
<td>Victoria Warth</td>
<td>University of Pennsylvania, USA</td>
</tr>
<tr>
<td>Pingping Yang</td>
<td>China Medical University, China</td>
</tr>
<tr>
<td>Xiaofeng Zeng</td>
<td>Peking Union Medical College, China</td>
</tr>
<tr>
<td>Juliang Zhao</td>
<td>Peking Union Medical College, China</td>
</tr>
</tbody>
</table>
**LUPUS Organizing Committee**

<table>
<thead>
<tr>
<th>Advisory Committee of Past Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1st</strong></td>
</tr>
<tr>
<td>Marvin J. Fritzler</td>
</tr>
<tr>
<td>Eng M. Tan</td>
</tr>
<tr>
<td><strong>2nd</strong></td>
</tr>
<tr>
<td>Pao-Hsii Feng †</td>
</tr>
<tr>
<td><strong>3rd</strong></td>
</tr>
<tr>
<td>Graham R.V. Hughes</td>
</tr>
<tr>
<td><strong>4th</strong></td>
</tr>
<tr>
<td>Yehuda Shoenfeld</td>
</tr>
<tr>
<td><strong>5th</strong></td>
</tr>
<tr>
<td>Donato Alarcon-Segovia †</td>
</tr>
<tr>
<td><strong>6th</strong></td>
</tr>
<tr>
<td>Munther A. Khamashita</td>
</tr>
<tr>
<td><strong>7th</strong></td>
</tr>
<tr>
<td>Robert G. Lahita</td>
</tr>
<tr>
<td><strong>8th</strong></td>
</tr>
<tr>
<td>Shunle Chen †</td>
</tr>
<tr>
<td><strong>9th</strong></td>
</tr>
<tr>
<td>John M. Esdaile</td>
</tr>
<tr>
<td><strong>10th</strong></td>
</tr>
<tr>
<td>Bernardo A. Pons-Estel</td>
</tr>
<tr>
<td>Mary Carmen Amigo</td>
</tr>
<tr>
<td><strong>11th</strong></td>
</tr>
<tr>
<td>Josef S. Smolen</td>
</tr>
<tr>
<td><strong>12th</strong></td>
</tr>
<tr>
<td>Eric F. Morand</td>
</tr>
<tr>
<td><strong>13th</strong></td>
</tr>
<tr>
<td>Lindsey A. Criswell</td>
</tr>
<tr>
<td><strong>14th</strong></td>
</tr>
<tr>
<td>Andrea Doria</td>
</tr>
</tbody>
</table>

† Honorary member

**KCR Organizing Committee**

<table>
<thead>
<tr>
<th>Organizing Committee</th>
<th>Academic Affairs Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>President</strong></td>
<td><strong>Director</strong></td>
</tr>
<tr>
<td>Sang-Cheol Bae</td>
<td>Yoon-Kyoung Sung</td>
</tr>
<tr>
<td>(Hanyang University)</td>
<td>(Hanyang University)</td>
</tr>
<tr>
<td><strong>Chairman of the Board of Directors</strong></td>
<td></td>
</tr>
<tr>
<td>Shin-Seok Lee</td>
<td>(Chonnam National University)</td>
</tr>
<tr>
<td><strong>Director of Planning</strong></td>
<td></td>
</tr>
<tr>
<td>Wan-Uk Kim</td>
<td>Seung-Ki Kwak</td>
</tr>
<tr>
<td>(The Catholic University of Korea)</td>
<td>(The Catholic University of Korea)</td>
</tr>
<tr>
<td>Hoon-Suk Cha</td>
<td><strong>Editor-in-Chief</strong></td>
</tr>
<tr>
<td>(Sungkyunkwan University)</td>
<td>Seong-Kyu Kim (Daegu Catholic University)</td>
</tr>
<tr>
<td><strong>Director of Finance</strong></td>
<td></td>
</tr>
<tr>
<td>Yong-Beom Park</td>
<td><strong>Director of Education &amp; Training</strong></td>
</tr>
<tr>
<td>(Yonsei University)</td>
<td>Bo Young Yoon (Inje University)</td>
</tr>
<tr>
<td><strong>Director of International Affairs</strong></td>
<td></td>
</tr>
<tr>
<td>Kichul Shin</td>
<td>Seung-Jae Hong (Kyung Hee University)</td>
</tr>
<tr>
<td>(Seoul National University)</td>
<td><strong>Director of Health Insurance</strong></td>
</tr>
<tr>
<td><strong>Director of Public Relations</strong></td>
<td></td>
</tr>
<tr>
<td>Myeung Su Lee</td>
<td>Bo Young Yoon (Inje University)</td>
</tr>
<tr>
<td>(Wonkwang University)</td>
<td><strong>Director of Health Information</strong></td>
</tr>
<tr>
<td><strong>Director of Research</strong></td>
<td></td>
</tr>
<tr>
<td>Yong-Gil Kim</td>
<td>Chan-Bum Choi (Hanyang University)</td>
</tr>
<tr>
<td>(University of Ulsan)</td>
<td><strong>Director of Legislation &amp; Ethics</strong></td>
</tr>
<tr>
<td><strong>Director of Health Policy</strong></td>
<td></td>
</tr>
<tr>
<td>Chong-Hyeon Yoon</td>
<td>Seung-Hyon Kim (Kernyung University)</td>
</tr>
<tr>
<td>(The Catholic University of Korea)</td>
<td><strong>Director of Clinical Practice Guideline</strong></td>
</tr>
<tr>
<td>Eun Bong Lee</td>
<td></td>
</tr>
<tr>
<td>(Seoul National University)</td>
<td></td>
</tr>
<tr>
<td><strong>Executive Secretary</strong></td>
<td></td>
</tr>
<tr>
<td>Ki-Jo Kim</td>
<td>(The Catholic University of Korea)</td>
</tr>
<tr>
<td><strong>Member</strong></td>
<td></td>
</tr>
<tr>
<td>Joong Kyong Ahn</td>
<td>Seung-Geun Lee (Pusan National University)</td>
</tr>
<tr>
<td>(Sungkyunkwan University)</td>
<td>Yeon-Ah Lee (Kyung Hee University)</td>
</tr>
<tr>
<td>Soo-Kyung Cho</td>
<td>Hong Ki Min (Konkuk University)</td>
</tr>
<tr>
<td>(Hanyang University)</td>
<td>Dong-Jin Park (Chonnam National University)</td>
</tr>
<tr>
<td>Hyun Sik Gong</td>
<td>Jin Kyun Park (Seoul National University)</td>
</tr>
<tr>
<td>(Seoul National University)</td>
<td>Jung-Woo Rhee (The Catholic University of Korea)</td>
</tr>
<tr>
<td>Chan Hong Jeon</td>
<td>Chang-Nam Son (Eulji University)</td>
</tr>
<tr>
<td>(Seoul National University)</td>
<td></td>
</tr>
<tr>
<td>Hyoun-Ah Kim</td>
<td></td>
</tr>
<tr>
<td>(Ajou University)</td>
<td></td>
</tr>
<tr>
<td>Jinhyun Kim</td>
<td></td>
</tr>
<tr>
<td>(Chungnam National University)</td>
<td></td>
</tr>
<tr>
<td>Yong-Gil Kim</td>
<td></td>
</tr>
<tr>
<td>(University of Ulsan)</td>
<td></td>
</tr>
<tr>
<td>Oh Chan Kwon</td>
<td></td>
</tr>
<tr>
<td>(Yonsei University)</td>
<td></td>
</tr>
</tbody>
</table>
LUPUS & KCR 2023
The 15th International Congress on Systemic Lupus Erythematosus and
The 43rd KCR Annual Scientific Meeting & 17th International Symposium

Stairway to the End of the War

May 17 (Wed) - 20 (Sat), 2023 | Coex, Seoul, Korea
Please contact the Secretariat of LUPUS & KCR 2023 if you have any further inquiry. Please address all correspondence to:

**Secretariat of LUPUS & KCR 2023**

8F Geumcheok Tower, 460 Bongeuna-ro, Gangnam-gu, Seoul, Korea
T. +82-2-576-9945 | E. secretariat@lupus-kcr2023.org | info@kcr2023.com

**Korean College of Rheumatology**

Raemian Yongsan A Building 1917, 95 Hangang-daero, Yongsan-gu, Seoul, 04378, Korea
T. +82-2-794-2630 | F. +82-2-794-2631
E. webmaster@rheum.or.kr